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Abstract 
The world covers more than 190 countries in which at the moment in most of them 
pharmaceutical legislations and regulatory requirements are established and implemented, 
e.g. to describe the marketing authorization (MA) procedure for medicinal products. 
To be able to submit a marketing authorization application (MAA) in all these countries, it is 
important to know exactly the pharmaceutical legislations (regulations, directives and 
guidelines) and the regulatory requirements in each of the country in advance.  
The objective of the pharmaceutical companies is to identify ways and factors that impede 
the efficient registration of new medicinal products and their timely access to patients. Due to 
the fact that the European Union (EU) and the United States (US) are the biggest and most 
potential markets for medicinal products in the world, global working companies focus and 
analyze the EU and US pharmaceutical legislations and regulatory requirements very 
detailed in advance and include these requirements from EU and US normally in their 
development concept of a new medicinal product and consequently in their global regulatory 
strategy for MAA of this product. But the industry recognized in the last few years also that 
the other regions of the world – Japan (JP), Latin America (LA), Middle East (ME)/Africa 
(AFR) and South East Asia (SEA), and are becoming increasingly important to 
pharmaceutical companies in their global marketing strategies. Therefore companies with 
global approach realize that it is not sufficient anymore to develop their global regulatory 
strategy based on the regulatory requirements in EU and US but also to take into 
consideration the other regions of the world. 
 
Therefore within this dissertation a scientific evaluation and recommendation for the 
development of a new compound (new biological entity (NBE) or new chemical entity (NCE)) 
is provided. Based on these recommendations for a global development for a new 
compound, a regulatory strategy for an NBE on the example of a monoclonal antibody (mAb) 
is provided. 
 
First, the different pharmaceutical legislations and regulatory requirements for a new MAA of 
an NBE and NCE based on the examples of EU, United States of America (USA), 
Collaboration Agreement of Drug Regulatory Authorities in European Union Associated 
Countries (CADREAC) (example: Croatia), LA (Brazil) and SEA ((Association of South-East 
Asian Nations (ASEAN): example Singapore) and China) are discussed and analyzed in 
detail. The analyses are made especially concerning the aspects required and accepted 
dossier format, dossier requirements (documents required for an MAA) and different 
regulatory procedures for MAAs. Also the aspects concerning confidentiality of the 
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documentation submitted to the different authorities, the IP (intellectual property) rights and 
patent issues are covered shortly. 
Afterwards the comparison between the different pharmaceutical and regulatory legislations 
in these countries and the comparison between MAAs for NBEs and NCEs follows. 
Based on this comparison the general aspects of a global development for a new compound 
(NBE or NCE) are discussed. The differences in global development between an NBE and 
an NCE are also covered within this dissertation. Based on this general strategy for global 
development of new compounds a global regulatory strategy for an NBE on the example of a 
mAb is developed.  
As the pharmaceutical legislations and requirements are permanently changing it is of utmost 
importance that pharmaceutical companies check the current legislations and requirements 
before starting a global development of a new compound. Also during the development of a 
new compound the changes in pharmaceutical legislations and regulations have to be 
checked and have to be incorporated in the global strategy in order to submit a MA dossier 
according to current requirements. This will ensure that the authorities accept the MA 
because of following regulations or guidelines. In case a regulation or guideline is not 
followed the applicant has to be present a justification for doing this approach and it cannot 
be guaranteed that authorities will accept this. Therefore it is strongly recommended to check 
the requirements and fulfill all requirements to be able to get an approval for the MA dossier 
of the newly developed compound. 
The requirements to get a medicinal product approved increase constantly and it can be 
anticipated that they will increase further. During the last years the tendency can be 
observed that more patient tailored drugs are requested by authorities compared to products 
approved in very broad indications. This might be not so beneficial from a company 
perspective as the number of patients which can be treated with one medicinal product which 
is patient tailored might be smaller. Nevertheless, this is the direction agencies might follow 
in future. Therefore topics like biomarkers or other specific markers to identify patient tailored 
drugs will become more and more of importance in future. It is advisable for companies to 
include biomarkers or other specific markers in their development program of a new 
compound as otherwise authorities might not grant the submitted MA.  
In addition to the increasing requirements by authorities to get a new medicinal product 
registered, the pharmaceutical environment will change due to greater influences of 
governments and changing health care systems. It has to be awaited how governments will 
build up the health care systems in future and how requirements will change. It is most likely 
that the prices for new medicines will be limited by governments to relieve the health care 
systems and that requirements to get medicinal products reimbursed will also increase in 
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future. Studies to proof a positive cost benefit ratio might be required for each new medicinal 
product as a prerequisite to get the product reimbursed. 
In conclusion the requirements to get a drug registered and reimbursed will increase and 
consequently the development costs for companies will increase, too.  
One possible solution to deal with the increased costs for development and the increasing 
requirements might be that pharmaceutical companies will merge and will develop new 
innovative medicinal products together and share the development costs. This will be 
especially attractive for small and medium-sized companies. Also companies might think 
about the location of their development centers in order optimize the development. It is 
recommended that companies will have only one or two global development centers where 
the global development for all new compounds is done.  
Pharmaceutical companies should be in closed contact with authorities in order to be able to 
fulfill all requirements needed to get a new medicinal product approved and marketed. 
Companies should be also in close contacts with governments especially regarding health 
care systems in order to fulfill their requirements and in order to be able to influence them 
with regard to decisions on health care systems.  
Besides all increasing barriers for getting new products approved and marketed, it is of 
utmost importance that the development of new innovative medicinal products will be 
continued to offer patients best medicinal supply. 
Therefore it seems to be logical that pharmaceutical companies, authorities and 
governments have to work together and find solutions that the development of new 
innovative drugs will be attractive and efficient for all sites in future. 
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1 0BIntroduction 
Today, the regulatory requirements in the various countries of the world are still quite 
different. Therefore it is very difficult - especially for companies with global activities - to 
develop one single regulatory approach for a marketing authorization application (MAA) for a 
new medicinal product on the basis of one dossier submitted simultaneously to various 
countries in the world. 
On this background it is very important to know in detail the regulatory requirements in each 
concerned country where an MAA should be submitted to establish a suitable regulatory 
strategy before the submission in order to avoid any major difficulties and unexpected 
surprises. 
The dissertation topic “Comparison of a global submission of new biological entity and a new 
chemical entity – strategic decisions and criteria for implementation” as a first focus includes 
the development of a global regulatory strategy for the submission of an MAA of a new 
compound (new biological entity (NBE) or new chemical entity (NCE)). For this strategy 
which is based on my personal professional experiences in pharmaceutical industry a 
detailed analysis of the pharmaceutical legislations and regulatory requirements in the 
different regions (International Conference of Harmonization (ICH) countries (which are 
European Union (EU), Japan (JP) and United States of America (USA)) and non-ICH-
countries) and countries over the world is made. The analysis is focused especially to identify 
and discuss the commonness and the main differences. Based on the result of the analysis 
of the pharmaceutical legislation and regulatory requirements for NBEs and NCEs worldwide, 
a general strategy for the development of a new compound (NBE or NCE) is provided. The 
general strategy for the development of a new compound results then into the development 
of a global regulatory strategy for the submission of a new MAA of an NBE on the example of 
a monoclonal antibody (mAb). 
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2 1BStatus as of Today 
The United Nations cover 192 countries in which at the moment in most of them 
pharmaceutical legislations and regulatory requirements are established and implemented, 
e.g. to describe the marketing authorization (MA) procedure for medicinal products. 
To be able to submit an MAA in all the major markets, it is important to know exactly the 
pharmaceutical legislations (regulations, directives, and guidelines) and the regulatory 
requirements in each of the country in advance. Differences in the pharmaceutical 
legislations and regulatory requirements can be found for example in the requirement for 
administrative data (e.g. type of documents which are requested, legalization necessary, 
etc.), in the pharmaceutical data (e.g. in the requirements for stability data (ICH versus 
ASEAN) and also in the clinical data (e.g. placebo-controlled studies or comparative studies). 
Therefore, it is very important to analyze and discuss especially the differences and 
commonness between the pharmaceutical legislations and regulatory requirements in the 
different countries of the world. 
Due to the fact that the EU and United States (US) are the biggest and most potential 
markets for medicinal products in the world, globally working companies focus and analyze 
the EU and US pharmaceutical legislations and regulatory requirements very detailed in 
advance and include these requirements from EU and US normally in their development 
concept of a new medicinal product and consequently in their global regulatory strategy for 
the MAA of this product. 
In the last few years pharmaceutical companies recognized that other regions of the world –
Japan (JP), Latin America (LA), South Eastern Europe (SEE), Middle East/Africa (ME/AFR) 
and South East Asia and Western Pacific (SEA), and are becoming increasingly important for 
pharmaceutical companies in their global marketing strategies. The objective of the 
companies is to identify ways and factors that impede the efficient registration of new 
medicinal products and their timely access to patients. 
Therefore companies with global approach realize that it is not sufficient anymore to develop 
their global regulatory strategy based on the regulatory requirements in EU and US but also 
to take into consideration the other regions of the world. 
Consequently, a detailed analysis of the pharmaceutical legislations and regulatory 
requirements in Eastern Europe (EE), LA and SEA are necessary - in addition to the detailed 
analysis of the pharmaceutical legislations and regulatory requirements in EU and USA - to 
be finally able to develop a global regulatory strategy for an MAA of a new compound (NBE 
or NCE). The third country of ICH – JP - is not covered by this thesis. 
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The pharmaceutical legislations and regulatory requirements in the world were established 
during the last 100 years, often as results of some tragedies. 1937, in the USA 100 people 
died after consumption of a children’s syrup (Diethylene glycol poisoning) and based on this 
in 1938 the first Food Drug and Cosmetic Act was implemented. The resulting Food Drug 
and Cosmetic Act of 1938 required that proof, in the form of a New Drug Application 
(commonly called an NDA) has to be submitted to a new department called the US Food and 
Drug Administration (FDA). Anyone wishing to market a "New Drug" has to show safety for 
intended use in the form of an NDA. 
In Germany, the first Drug Law was established in 1961 and was implemented soon 
afterwards the thalidomide tragedy in Europe, which happened in the early sixties. Also in 
Japan the first drug law was established in 1961. In EU the first drug law was established in 
1965 with the Directive 65/65. 
The aim of all the regulatory legislations (drug laws) and all drug regulatory authorities 
(DRAs) is to provide patients with safe medicinal products as fast as possible based on the 
proof of quality, safety and efficacy which has to be shown by a submission of an MAA. 
The changing regulatory requirement and legislations have an impact on the regulatory 
strategy during drug development. 
Consequently, due to the fact that the pharmaceutical legislation in EU was changed some 
years ago accordingly to the “EU Review 2004”, a detailed analysis of the changes in the 
pharmaceutical legislations and regulatory requirements in EU due to the new EU legislation 
is necessary, especially the changes concerning the different regulatory procedures and 
requirements in EU which have an impact on the regulatory strategy. 
The changes in the EU legislation have also an impact on other countries in the world which 
implemented the EU legislations like Serbia or the Collaboration Agreement of Drug 
Regulatory Authorities in European Union Associated Countries (CADREAC) which are 
currently only Croatia because most of its regulation depend on EU legislation. CADREAC 
was renamed to new CADREAC (nCADREAC) after the EU accession of nine of the original 
CADREAC countries in 2004. 
As a result of the review 2004 several regulations and directives have been changed and 
replaced.  
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The Council Regulation 2309/93F1F describes the centralized procedure (CP) in the EU and it 
also has established the European Medicines Agency (EMA) (formerly: The European 
Agency for the Evaluation of Medicinal Products (EMEA)) (also called “Agency”)) and the 
Committee for Medicinal Products for Human Use (CHMP) (formerly: Committee for 
Proprietary Medicinal Products ((CPMP)), the scientific committee - which is responsible for 
the evaluation of new MAAs for medicinal products for human use - under the direction of the 
Agency. 
Due to the review 2004, the Council Regulation 2309/93 X1X was replaced by the new Council 
Regulation 726/2004F2F. This new regulation was adopted on 31st March 2004 and became 
valid on the 20th May 2004. Other parts of the regulation had to be implemented until 20th 
November 2005. 
After the full implementation of the revised community legislation in November 2005 several 
changes was made with regard to the CP. These include an expansion of the scope of the 
procedure, establishment of a procedure for conditional MAs, formalization of an accelerated 
procedure and management of compassionate use programs. In addition, assistance will be 
available for small and medium-sized enterprises. 
 
Next to the Council Regulation 2309/93 X1X also the directive 2001/83F3F - the codification 
directive - was amended by Directive 2004/27F4F and 2004/24 (for herbal drugs)F5F. The two 
Directives 2004/27 and 2004/24 were adopted on 31st March 2004 and had to be 
implemented into national law. Therefore a transition period of 18 months was foreseen. This 
meant that the directives had to be implemented into national law of the EU member states 
(MSs) until November 2005. 
 
                                                
1 Official Journal L 214, 24.08.1993 - Council Regulation (EEC) No 2309/93 of 22 July 1993 laying down 
Community procedures for the authorisation and supervision of medicinal products for human and veterinary use 
and establishing a European Agency for the Evaluation of Medicinal Products – page 1 - 211 
2 Official Journal L 136, 30.04.2004 - Regulation (EC) No 726/2004 of the European Parliament and of the 
Council of 31 March 2004 laying down Community procedures for the authorisation and supervision of medicinal 
products for human and veterinary use and establishing a European Medicines Agency – page 1 ff. 
3 Official Journal L 311, 28.11.2001 - Directive 2001/83/EEC of the European Parliament and of the Council of 6 
November 2001 on the Community code relating to medicinal products for human use – page 67 – 128 
4 Official Journal L 136, 30.04.2004 - Directive 2004/27 EEC of the European Parliament and of the Council of 31 
March 2004 amending Directive 2001/83/EC on the Community code relating to medicinal products for human 
use – page 34 - 57 
5 Official Journal L 136, 30.04.2004 - Directive 2004/24/EC of the European Parliament and of the Council of 31 
March 2004 amending, as regards traditional herbal medicinal products, Directive 2001/83/EC on the Community 
code relating to medicinal products for human use – page 85 - 90 
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The changes in the EU legislation had also a big impact on the CADREAC countries and 
their legislations (F6F,F7F) because the so-called CADREAC procedures are directly linked with 
the EU legislations and depend on the EU legislation and the EU regulatory procedures. 
Another important factor which should be mentioned and discussed in detail is the 
Association of Southern Asian Nations (ASEAN)F8F. ASEAN was established on 8 August 
1967 in Bangkok by the five original member countries Indonesia, Malaysia, Philippines, 
Singapore and Thailand. On 8 January 1984 Brunei Darussalam joined ASEAN, Vietnam on 
28 July 1995, Laos and Myanmar on 23 July 1997, and Cambodia on 30 April 1999. 
In 1999 a harmonization initiative was started among the 10 ASEAN countries. One aim of 
this harmonization should be to harmonize quality guidelines that are valid for all countries 
involved. Another focus lies in the technical co-operation. Therefore the ASEAN Consultative 
Committee on Standards and Quality Pharmaceutical Product Working Group (ACCSQ 
PPWG) was established. The objective of the ACCSQ PPWG is the development of 
“harmonization schemes of pharmaceuticals' regulations of the ASEAN member countries to 
complement and facilitate the objective of ASEAN Free Trade Area (AFTA), particularly, the 
elimination of technical barriers to trade posed by these regulations, without compromising 
on drug quality, safety and efficacy." 8 
ASEAN established the so called ASEAN Common Technical Document (ACTD) and the 
ASEAN Common Technical Requirements (ACTR) to create harmonized requirements and a 
common format for all submissions of dossiers in the ASEAN countries. The ACTD is a 
common format and content acceptable for an application in the ASEAN member countries. 
The ACTR are a set of written requirements or guidelines intended to provide guidance to 
applicants in order to be able to prepare application dossiers in a way that is consistent with 
the expectations of all ASEAN DRAs. 8 
The full implementation of the ASEAN requirements (like ACTD and ACTR) in the ASEAN 
countries is not yet finalized, a prolongation/transition period is possible. There is an interim 
period agreed wherein ACTD and national formats allowed in most of the ASEAN countries, 
whereas in some countries like Singapore ICH CTD is accepted. 
The full implementation of ACTD for new products was expected by 31 December 2008 
whereas the full implementation for currently registered products is expected to be done until 
01 January 2012. According to information received from the ASEAN countries (January 
                                                
6 Procedure on the granting of marketing authorisations by CADREAC Drug Regulatory Authorities for medicinal 
products for human use already authorized in the EU following the centralized procedure and the variation and 
renewal of such marketing authorisations (5th revision of December 21,2001) 
7 Procedure on the granting of marketing authorisations by CADREAC Drug Regulatory Authorities for medicinal 
products for human use already authorized in EU member states following the decentralized procedure (1st 
revision of June 10,2001) 
8 Homepage of ASEAN (Association of Southeast Asian Nationals http://www.aseansec.org/ - dated 27.04.2009 
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2009) some of the ASEAN countries still accept the CTD-format for MAAs of NCEs and 
NBEs whereas for renewals (RENs) and variations (VARs) only the ACTD-format is accepted 
by ASEAN countries. 
As mentioned before, it is important to know exactly the pharmaceutical legislations 
(regulations, directives and guidelines) and the regulatory requirements in each of the 
countries in advance to be able to submit an MAA in all these countries. Based on the result 
of the analyzes of the pharmaceutical legislation and regulatory requirements for NCEs and 
NBEs worldwide, a global regulatory strategy for submission of a new MAA of a new 
compound (NBE or NCE) can be developed and established before the submission in order 
to avoid any major difficulties and unexpected surprises. 
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3 2BAnalysis of the Pharmaceutical Legislation and 
Regulatory Requirements for Applying for a Marketing 
Authorization Application for a New Biological Entity and 
a New Chemical Entity  
3.1 10BICH 
The “International Conference on Harmonization of Technical Requirements for the 
Registration of Pharmaceuticals for Human Use” (ICH) consists of six parties, which 
represents the regulatory bodies and research-based industry in the three main regions - EU, 
JP and the USAF9F. 
ICH was established in 1990 as a joint regulatory authorities/industry project. The purpose of 
this “institution” is to improve the efficiency of the process for developing and registering new 
medicinal products in Europe, Japan and the US because in these regions the majority of 
new medicines are currently developed. This improvement should be achieved through 
harmonization in order to make these products available to patients with a minimum of 
delayX9X. Therefore ICH has developed over 50 guidelines with harmonized requirements in 
order to ensure that the development of medicinal products should be done in the most 
efficient and cost effective way. In addition the harmonized requirements should minimize the 
use of animal testing without compromising safety and efficacy and should avoid unneeded 
duplication of clinical trials in humans. 
During the Fifth International Conference on Harmonization (ICH 5) which took place in San 
Diego in November 2000 the final harmonized Common Technical Document (CTD) was 
released. The Conference followed the recommendations of the ICH Steering Committee 
and Expert Working Groups, which took place some days before the conference and wherein 
the final harmonized Common Technical Document (CTD) was completed. X9 
 
                                                
9 Homepage of ICH (International Conference of Harmonization: 
The Fifth International Conference on Harmonization - ICH5 and Steering Committee Meeting 
"The Common Technical Document Released Putting It All Together 
A Decade of Harmonization" http://www.ich.org/cache/html/454-272-1.html - dated 27.04.2009 
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The CTD consists of five modules (please refer to attached pyramid). The structure of 
Module 2, 3, 4 and 5 is common for all ICH regions (EU, JP and USA). The Module 1 is not 
part of the CTD format and is special for each of the ICH regions.F10 
 
 
The table of contents (ToCs) of Module 2 – 5 of the ICH CTD dossier is enclosed as an 
attachment (see “XAPPENDIX 1 X: CTD table of contents“)F11F. 
 
 
                                                
10 Volume 2B Notice to Applicants (NtA): Medicinal products for human use - Presentation and format of the 
dossier Common Technical Document (CTD) 
http://ec.europa.eu/enterprise/pharmaceuticals/eudralex/vol2_en.htm#2b 
http://ec.europa.eu/enterprise/pharmaceuticals/eudralex/vol-2/b/update_200805/ctd_05-2008.pdf - dated 
27.04.2009 
11 http://en.wikipedia.org/wiki/File:CTD_Pyramid.jpg 
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In addition to the CTD format meanwhile the electronic CTD (eCTD) format was established. 
The eCTD is based on the CTD format and is an interface for pharmaceutical companies to 
transfer regulatory information to DRAs. The dossiers will be submitted electronically in CTD 
format to the authorities. Compared to CTD-dossier the Module 1 is part of the eCTD 
dossier. The eCTD was developed by the ICH Multidisciplinary Group 2 Expert Working 
Group. X9X  
All countries which do not belong to ICH (EU, JP and USA) are covered by the so-called non-
ICH-countries. The non-ICH-countries (in total more than 100 countries) have no obligation 
to establish the ICH-format, nevertheless, some of these countries like Australia (AUS), 
Canada and Switzerland (CH) established the ICH-format. 
 
To sum up, the CTD is only a common format for the preparation of dossiers for submission 
to the regulatory authorities in the three ICH regions of EU, JP and USA and gives no 
information about the content of the dossier. It does not indicate which studies and data are 
required and should be submitted in order to get an approval. The content of a MAA dossier 
is described in the corresponding ICH guidelines (Quality (Q) guidelines, Safety (S) 
guidelines and E (Efficacy guidelines)) and should be identical for all three ICH regions. 
Nevertheless, it might happen that the dossier is not necessarily completely identical for all 
regions, because regional requirements may affect the content of the dossier submitted in 
each region (mainly in the regional section (3.2.R)).F12 
 
The detailed dossier requirements for the ICH regions EU and USA will be described in detail 
in the chapters for EU (chapter X3.2 X) and USA (chapter X3.3 X). As mentioned before the third 
country of ICH – JP - is not covered by this thesis. 
 
                                                
12 VOLUME 2A NtA - Procedures for marketing authorisation CHAPTER 1 Marketing authorisation from 
November 2005 http://ec.europa.eu/enterprise/pharmaceuticals/eudralex/vol-2/a/vol2a_chap1_2005-11.pdf - 
dated 27.04.2009 
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3.2 11BEU 
3.2.1 24BFormat and content of a Marketing Authorization 
Application Dossier – Regulatory Requirements 
In the EU, the regulatory requirements for getting the approval of an MAA are described in 
the Notice to Applicants (NtA) Volume 2B: "Medicinal products for human use - Presentation 
and format of the dossier Common Technical Document (CTD)" X10X: "The CTD gives no 
information about the content of a dossier and does not indicate which studies and data are 
required for a successful approval. Regional requirements may affect the content of the 
dossier submitted in each region, therefore the dossier will not necessarily be identical for all 
regions. 
The CTD indicates an appropriate format for the data that have been required in an 
application. Applicants should not modify the overall organisation of the Common Technical 
Document as outlined in the guideline. However, in the Non-clinical and Clinical Summaries, 
applicants can modify individual formats if needed to provide the best possible tabulated 
presentation of the technical information, in order to facilitate the understanding and NtA, Vol. 
2B-CTD, foreword & introduction, edition June 2006 Page 4 evaluation of the results. The 
new EU-CTD-presentation will be applicable for all types of marketing authorisation 
applications irrespective of the procedure (CP, MRP, DCP or national) and of type of 
application (stand alone, generics etc). The CTD-format will be applicable for all types of 
products (new chemical entities, radiopharmaceuticals, vaccines, herbals etc.) To determine 
the applicability of this format for a particular type of product, applicants should consult with 
the appropriate regulatory authorities.”X10 
The CTD dossier is structured in 5 Modules, whereas Module 2, 3, 4 and 5 are part of the 
CTD. 
For the EU the content of the Module 1 is defined in Volume 2B, NtA, Medicinal products for 
human use, Presentation and format of the dossier- Common Technical Document (CTD): 
“The content of Module 1 for EU was defined by the European Commission in consultation 
with the competent authorities of the Member States, the European Agency for the 
Evaluation of Medicinal Products and interested parties.”X10 
 
The Module 1 in the EU consists of the different documents which are listed in appendix 2 
(“ XAPPENDIX 2 X CTD table of content for EU Module 1“) X10X. 
 
In summary the CTD is only a common format for the preparation of dossiers for submission 
to the regulatory authorities in the three ICH regions of EU, JP and USA and gives no 
information about the content of the dossier. It does not indicate which studies and data are 
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required and should be submitted in order to get an approval. The content of a MAA dossier 
is described in the corresponding ICH guidelines (Quality (Q) guidelines, Safety (S) 
guidelines and E (Efficacy guidelines)) and should be identical for all three ICH regions. 
Nevertheless, it might happen that the dossier is not necessarily identical for all regions, 
because regional requirements may affect the content of the dossier submitted in each 
region. X12 
 
3.2.2 25BDifferent Marketing Authorization Procedures in EU 
In the EU, there are today four possible registration procedures in order to receive an MAA 
for a medicinal product: the national procedure, the Decentralized procedure (DCP), the 
Mutual Recognition Procedure (MRP) and the CP. Depending on the type of the medicinal 
product, the applicant may have no choice between the procedures and is obliged to use the 
CP. According to annex of the Regulation 726/2004X2X the CP is mandatory for the following 
types of medicinal products: 
“1. Medicinal products developed by means of one of the following biotechnological 
processes: 
• recombinant Deoxyribonucleic Acid technology, 
• controlled expression of genes coding for biologically active proteins in prokaryotes 
and eukaryotes including transformed mammalian cells, 
•  hybridoma and monoclonal methods. 
 
2. Medicinal products for veterinary use intended primarily for use as performance enhancers 
in order to promote the growth of treated animals or to increase yields from treated animals. 
3. Medicinal products for human use containing a new active substance which, on the date of 
entry into force of this Regulation, was not authorised in the Community, for which the 
therapeutic indication is the treatment of any of the following diseases: 
• acquired immune deficiency syndrome, 
• cancer, 
•  neurodegenerative disorder 
• diabetes 
and with effect from 20 May 2008 
• auto-immune diseases and other immune dysfunctions, 
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• viral diseases. 
After 20 May 2008, the Commission, having consulted the Agency, may present any 
appropriate proposal modifying this point and the Council shall take a decision on that 
proposal by qualified majority. 
4. Medicinal products that are designated as orphan medicinal products pursuant to 
Regulation (EC) No 141/2000.” 
In addition the CP is compulsory for advanced therapy medicinal products under the 
auspices of Regulation (EC) No 1394/2007 (applied from 30-Dec-2008). 
The CP is optional for getting the MAs for medicinal products referred to in Article 3(2) of 
Regulation (EC) No 726/2004: “relating to medicinal products containing new active 
substances, products which constitute a significant therapeutic, scientific or technical 
innovation or products for which the granting of a Community authorisation would be in the 
interest of patients or animal health at Community level. The applicant has to request 
confirmation that the product is eligible for evaluation through the centralised procedure 
(optional scope) and the EMEA will decide on the matter; and a generic medicinal product of 
a centrally authorised medicinal product if not using the option in Article 3(3) of Regulation 
(EC) No 726/2004.”X12 
The CP is an option for generics and in the future for MAAs which include data to support the 
use of the medicinal product in the pediatric population. 
The detailed activities and timetables for the different EU procedures (national procedure, 
CP, MRP and DCP) are not presented within this dissertation, only general aspects 
regarding the procedures are mentioned. 
Besides the normal registration procedures in EU (national procedure, CP, MRP and DCP) 
there are also some special procedures like Orphan Drug Designation or accelerated 
assessment procedures. The Orphan Drug Designation is applicable for medicinal product 
with orphan drug status and is not described here in more details. 
 
AA ccelerated assessment procedure 
In article 33 of Regulation (EC) 726/2004 X2X it is mentioned that “in order to meet, in particular 
the legitimate expectations of patients and to take account of the increasingly rapid progress 
of science and therapies, accelerated assessment procedures should be set up, reserved for 
medicinal products of major therapeutic interest, and procedures for obtaining temporary 
authorisations subject to certain annually reviewable conditions”.  
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Therefore accelerated assessment procedure can be used for MAAs of medicinal products 
which are of major interest from the viewpoint of public health and in particular from the point 
of view of therapeutic innovation. The applicant can request an accelerated assessment 
procedure and this request shall be duly well-grounded.F13F  
 
Within the request for an accelerated assessment procedure a justification should be 
provided that the medicinal product is expected to be of major public health interest 
particularly from the point of view of therapeutic innovation. X13 
The request for accelerated assessment procedure is submitted to the CHMP. Based on the 
justification of the applicant and the recommendation of the Rapporteur, the CHMP will make 
a decision on the request for accelerated assessment. This decision has no influence on the 
MAA submission. In case the CHMP accepts the request, the time limit for the evaluation of 
the dossier of 210 days to give an opinion shall be reduced to 150 days.  
It is possible that after a request for accelerated assessment procedure has been granted, at 
any time during the MAA, the CHMP may decide to continue the assessment under standard 
CP timelines according to Article 6 (3) of Regulation (EC) 726/2004 X2X . This might happen in 
case the CHMP is the opinion that it is no longer appropriate to conduct an accelerated 
assessment. X13 
The accelerated assessment procedure is not described here in more details. 
 
3.2.2.1 57BNational Procedure 
The national procedure for applying for a MA in EU is today only possible if the medicinal 
product is not yet registered in any other EU MS and if the medicinal product does not fall 
under Regulation 726/2004 X2X for which the CP is mandatory and if a MA is only planned for 
one MS. In such a case it is possible to apply for a MA via national procedure in one specific 
MS. The MAA has to follow the national regulations and should be submitted directly to the 
DRA of this specific MS for evaluation. This national DRA will evaluate the dossier and will 
grant the national MA in case the evaluation of the dossier is positive. As soon as the 
medicinal product should then (after approval in the 1st MS) be registered in a 2nd MS the MR 
procedure has to be used. 
In summary today it is not possible any more to register a product in more than one EU 
member state via national procedure. If the product is intended to be registered in more than 
one EU MS and the CP is not mandatory the applicant can choose between MRP and DCP. 
                                                
13 Guideline on the procedure for accelerated assessment pursuant to articile 14(9) of regulation (EC) No 
726/2004 
http://www.emea.europa.eu/docs/en_GB/document_library/Regulatory_and_procedural_guideline/2009/10/WC50
0004136.pdf - dated 27.04.2009) 
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3.2.2.2 58BCentralized Procedure 
As mentioned above the Regulation 726/2004 X2X and especially the annex of the regulation 
clearly define which types of medicinal products have obligatorily to use the CP. The CP is 
mandatory for new active substances for certain therapeutic areas like acquired immune 
deficiency syndrome (AIDS), cancer or viral diseases and for medicinal products derived 
from biotechnology. The CP is optional for other innovative new medicinal products (e.g. for 
medicinal product containing a new active substance, which was not authorized in the EU at 
the date when the Regulation 726/2004 came into force and for medicinal product for which a 
significant therapeutic, scientific or technical innovation can be demonstrated). The MAAs 
have to be submitted directly to the EMA in London. 
The scientific evaluation of the MAA submitted to EMA is handled by the CHMP within 210 
days. Normally the CHMP gives the assessment of the MAA dossier to two CHMP members 
of two MS, the so-called “Rapporteur” and “Co-Rapporteur”. 
The “Rapporteur and Co-Rapporteur” are members of the CHMP who co-ordinate the 
evaluation of the MAAs. It is possible that the applicant of the MAA indicates in the letter of 
intent - which has to be submitted to announce the intention of an MAA submission to EMA 
via CP - its request for appointment of Rapporteur and Co-Rapporteur. This request for 
appointment of Rapporteur and Co-Rapporteur should be sent at least seven months prior to 
the intended submission date (target dates for submission of the application are published on 
the EMA WebsiteF14F) of MAA to the EMA. The final appointment of the Rapporteur and Co-
Rapporteur takes place six months prior to the intended submission date. The names of the 
Rapporteur and Co-Rapporteur will be communicated to the applicant. 
The “Rapporteur” and “Co-Rapporteur” are the main responsible persons for the scientific 
evaluation of the MA dossier. They issue the preliminary Assessment Report (AR) which is 
distributed to the CHMP members and the applicant. This AR will be discussed during the 
next CHMP meeting and additional comments of other members of the CHMP and the 
outstanding issues which the applicant should address will be identified. A consolidated list of 
questions identifying "major objections" and/or "other concerns" may be adopted. These will 
be sent to the applicant together with the CHMP recommendation and scientific discussion. 
The clock will be stopped at this point. 
On or before day 210 (after answering all open issues), the CHMP adopts its opinion in the 
light of a final recommendation of the Rapporteur and Co-Rapporteur and further evidence 
presented at the oral explanation. 
The draft opinion is prepared by the EMA and then adopted by the CHMP. 
                                                
14 EMA Website (http://www.emea.eu.int/ – Human Medicines - Application procedures - ‘Pre-Submission 
Guidance’) 
http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/general/general_content_000119.jsp&murl=men
us/regulations/regulations.jsp&mid=WC0b01ac0580022974 
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The CHMP opinion, which may be favorable or unfavorable, is, wherever possible, reached 
by scientific consensus and is the conclusion of the scientific evaluation of the CHMP. The 
CHMP opinion is transmitted to the European Commission (EC) within 15 days after of 
adoption of the opinion. Within 15 days the EC will then issue the draft Commission Decision. 
MSs have then 22 days to comment on the draft Commission Decision and afterwards the 
EC is requested to adopt a final commission Decision within 15 days. The Commission 
Decision leads to one single Community MA valid throughout the EU.  
The Community MA confers the same rights and obligations in each of the MS as a MA 
granted by a MS. 
For Norway and Iceland, an identical national MA will be granted subsequent to the 
Commission Decision. 
Details of the procedure including detailed timetables can be found in the NtA VOLUME 2A - 
"Procedures for marketing authorisation - CHAPTER 4 - Centralised Procedure".F15 
3.2.2.3 59BMutual Recognition Procedure 
The legal basis for the MRP is provided in Directive 2001/83 X3X. The directive is supported by 
some guidance documents. Detailed information on the legal basis, the scope, the 
requirements and the procedures are described in VOLUME 2 A NtA "Procedures for 
marketing authorisation CHAPTER 1 Marketing Authorisation" X12X and Volume 2 A of the NtA 
"Procedures for marketing authorisation - CHAPTER 2 - Mutual Recognition".F16F Some more 
information and guidance can be found in the "Best practice guide for decentralized and 
mutual recognition procedures.“F17 
The MRP is applicable for medicinal products which already have a MA in at least one EU 
MS. For medicinal products with no MA in an EU MS the DCP must be used alternatively. 
The MRP can be used for the majority of conventional medicinal products and may also be 
applicable for line extensions under certain circumstances. 
 
The MRP cannot be used for products which have been authorized via CP, but the MRP can 
be used for medicinal products approved under the former ex-concertation procedure and 
medicinal products which have been subject of a Community referral under article 30 or 31 of 
                                                
15 VOLUME 2A NtA - Procedures for marketing authorisation - CHAPTER 4 - Centralised Procedure from April 
2006 http://ec.europa.eu/enterprise/pharmaceuticals/eudralex/vol2/a/chap4rev200604%20.pdf  
16 VOLUME 2A Notice to applicants - Procedures for marketing authorisation - CHAPTER 2 - Mutual Recognition 
from February 2007 
http://ec.europa.eu/enterprise/pharmaceuticals/eudralex/vol-2/a/vol2a_chap2_2007-02.pdf 
Dated 22.07.2009 
17 Best practice guide for decentralised and mutual recognition procedures, October 1996, revision May 2007 
(CMD – Coordination group for mutual recognition procedures and decentralized procedures – human) 
http://www.hma.eu/fileadmin/dateien/Human_Medicines/CMD_h_/procedural_guidance/Application_for_MA/BPG
_MRP_DCP_2007_05_Rev6_Clean.pdf 
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Directive 2001/83 X3X. The MRP can also be used for generic products for which the reference 
product was authorized via CP. 
By using the MRP the applicant intends to have an existing national MA recognized by one 
or more EU MSs selected by the applicant. The applicant submits identical dossiers to all 
relevant MSs, the so-called Concerned Member States (CMSs). 
The applicant can choose one of the EU MS as Reference Member State (RMS) for the 
MRP. To be able to make the decision of the RMS the applicant will consider the factors like 
the processing time taken by each national authority, the reputation of the authority as well 
as the willingness of the authority to co-operate. It is advisable that the applicant discusses 
the proposed MAA with the RMS before submission of the dossier. 
The applicants submit the MAA to the MS, which is intended to act as RMS. It is important to 
inform the MS that the submission will be the basis for other submissions under the MRP. 
Before the MRP will be initiated the applicant has to discuss the content of the Summary 
of Product Characteristics (SPC), package leaflet and labeling with the RMS.  
The initial MA in the RMS has to be granted within a period of 210 days after receipt of valid 
application. It could happen that the time period includes a clock stop in which the applicant 
has to submit additional requested information. The RMS evaluates the MAA dossier and 
prepares an AR. Before starting the MRP the applicant asks the RMS to prepare or update 
the AR within 90 days of receipt of this request. The AR together with the approved SPC), 
labeling and Patient Information Leaflet (PIL) are sent to the CMSs and the applicant by the 
RMS. 
After receipt of the initial MA of the RMS the applicant also submits the MAA dossier to the 
CMSs. This dossier includes a statement that the dossier is identical to the information 
provided in support of the initial MAA as well as the approved SPC, labeling and PIL. Each 
CMS has the obligation to recognize the MA granted by the RMS within a period of 90 days. 
This 90 day period started after CMSs have received the AR of the RMS and have validated 
the application. The RMS sets the starting date of the 90 day period and informs the CMSs 
and the applicant respectively. X3 
If CMSs agrees to the evaluation and the AR of the RMS the procedure will be closed at day 
90. 
If agreement cannot be reached by the MSs, then the following stages occur: 
• Reconciliation phase occurs under the direction of the Coordination group for mutual 
recognition procedures and decentralized procedures – human (CMD(h)) for resolution. 
• If the matter cannot be resolved by the CMD then the CHMP will arbitrate and issue an 
option. 
• CHMP opinion sent to EC. 
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• Commission Decision making process (EC will issue a Commission Decision based on 
the received CHMP opinion). 
At the end of the MRP the AR is updated and national MAs are issued. The national DRAs of 
the CMSs have a 30 day period after finalization of the MRP to adopt the decision and issue 
the MA subject to the receipt of acceptable translations of the PIL. X3 
 
3.2.2.4 60BDecentralized Procedure 
The legal basis for the DCP is provided in Directive 2001/83 X3X. The directive is supported by 
some guidance documents. Detailed information on the legal basis, the scope, the 
requirements and the procedures are described in VOLUME 2 A NtA "Procedures for 
marketing authorisation CHAPTER 1 Marketing Authorisation" X12X and Volume 2 A of the NtA 
"Procedures for marketing authorisation - CHAPTER 2 - Mutual Recognition" X16X .The 
guidelines are issued with respect to the MRP but are currently also applicable for the DCP 
unless specific guidelines exist for the DCP or MRP guidelines cannot be used for, by 
similarity, for the DCP. Some more information and guidance can be also found in the "Best 
practice guide for decentralised and mutual recognition procedures." X17 
The DCP is open for medicinal products, which are not yet approved in any EU MS at the 
time of application. The DCP offers an alternative to the MRP. The DCP cannot be used for 
products, which have to be authorized via CP, but the DCP can be used for duplicate 
applications and extension applications of products originally approved by the MRP. In 
addition it is possible to use the DCP for generic products for which the reference product 
was authorized via CP. 
The main difference between MRP and DCP is the fact that the initial MA is not submitted 
and issued for the RMS alone. Instead of this, the MAA dossier is submitted to the RMS and 
the CMSs (all EU MS where the MA is sought) in parallel. A statement that the identical 
dossier is submitted to RMS and CMSs is submitted together with the MAA dossier. The 
RMS will prepare a draft AR in consultation with the CMSs. This AR is the basis for the RMS 
and CMSs to agree the terms for the MA. 
The applicant can choose one of the EU MS as RMS for the DCP. To be able to make a 
decision on the RMS the applicant will consider the factors like the reputation of the DRA, the 
willingness of the authority to co-operate as well as processing time taken by each national 
DRA. It is advisable that the applicant discusses the proposed MAA with the RMS at least 
two months before submission of the dossier. 
The DCP involves the following stages and takes at maximum 210 days (for more 
information please refer to Volume 2A NtA "Procedures for marketing authorization - Chapter 
2") X16X: 
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• Marketing Authorization Holder (MAH) initiates the procedure. 
• Assessment Step 1:  
• RMS prepares preliminary AR, which is used for discussion between RMS, CMSs and 
the applicant. 
• The procedure may close if mutual consent is achieved. 
• Assessment Step 2: 
• Based on draft AR, further consideration takes places between RMS and CMSs. 
• A break-out session of the MS concerned may be used for facilitation. 
• If consensus cannot be reached by the MS then the following stages take place: 
• Referral to CMD for resolution. 
• If the matter cannot be resolved by the CMD then the CHMP will arbitrate and issue an 
option. 
• CHMP opinion sent to EC. 
• Commission Decision making process (EC will issue a Commission Decision based on 
the received CHMP opinion). 
If agreement can be achieved after assessment step 1 the procedure takes 120 days, if 
assessment step 2 is needed this step will take additional 90 days, so that in total the 
procedure takes 210 days. 
At the end of the procedure, national MAs are issued (same as done in the MRP). 
 
3.3 12BUSA 
3.3.1 26BDossier Format – ICH CTD 
As described already in the section “X3.1 X ICH” the format for submissions in all three ICH 
regions, including USA is the ICH CTD format. 
The ICH CTD format is applicable for Modules 2 – 5, only Module 1 differs from region to 
region (please refer to section "X3.3.2 X. Dossier requirements"). 
3.3.2 27BDossier Requirements 
As mentioned in the section "X3.2.1X. Format and content of a Marketing Authorization 
Application Dossier – Regulatory Requirements" most of the dossier requirements are 
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identical for the three ICH regions. As mentioned before the content from Module 2 – 5 is 
quite similar for all three ICH regions. 
Nevertheless, each region has some special requirements, which are only applicable for one 
region. 
The FDA in USA under federal law regulates the NDA and the biologics license application 
(BLA) process. The FDA Center for Drug Evaluation and Research (CDER) is responsible for 
the review of the NDAs and for parts of the BLAs.F18 
CDER is responsible for the regulatory review and supervision of drug applications and X18X: 
• MAbs for in-vivo use 
• Cytokines, growth factors, enzymes, immunomodulators; and thrombolytics 
• Proteins intended for therapeutic use that are extracted from animals or microorganisms, 
including recombinant versions of these products (except clotting factors) 
• Other non-vaccine therapeutic immunotherapies 
 
The BLA review process is handled by two different divisions of FDA, the Center for Biologics 
Evaluation and Research (CBER) and the CDER. The CBER is responsible for the regulatory 
review and supervision of: X18 
• Viral-vectored gene insertions (i.e., “gene therapy”) 
• Products composed of human or animal cells or from physical parts of those cells 
• Allergen patch tests 
• Allergenics 
• Antitoxins, antivenins, and venoms 
• In vitro diagnostics 
• Vaccines, including therapeutic vaccines 
• Toxoids and toxins intended for immunization 
• Blood, blood components and related products 
NDAs and BLAs can be submitted either as paper submission or electronically to the CDER 
or CBER. 
The NDA contains all data collected during the development of a new drug whereas a BLA 
contains all data assembled during the development of a biological product. The NDA and 
                                                
18 http://www.fda.gov/ 
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BLA contain also all data from preclinical and clinical studies, which were already submitted 
through the Investigational New Drug (IND) process. The content of an NDA and BLA may 
differ based on the nature or class of the drug or the biological product.X18 
 
Three copies of the application are requested for NDAs and Abbreviated New Drug 
Application(s) (ANDA(s)) which differ in their intended purpose and therefore in content: X19X  
• An archival copy 
• A review copy 
• A field copy 
For BLAs it is requested only to submit archival and review copies, so no field copy is 
requested. 
The archival copy includes the entire submission and is the “official” complete copy of the 
application whereas review and field copy request only parts of the complete submission. 
The archival copy acts as the official archive of the application and may be used during the 
review of the application.F19 
The archival copy includes the following information: 
• A cover letter to: 
• confirm any agreements made between the FDA and the applicant 
• identification one or more people the FDA may contact 
• any other important information about the application 
• Application Form FDA 356h serves as a cover sheet for the submission. It contains the 
applicant, the drug product, and indicates the applicant’s intention to comply with 
applicable laws and regulations. 
• All INDs, drug master files (DMFs) and other applications referenced in the application 
should be identified in the form.  
                                                
19 Federal Register Vol. 68, No. 72, April 15, 2003 – Draft Guidance - Guidance for Industry-submitting MAs 
according to the ICH CTD format http://edocket.access.gpo.gov/2003/pdf/03-8802.pdf 18248 - Federal Register / 
Vol. 68, No. 72 / Tuesday, April 15, 2003 / Notices 
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• The FDA recommends using the following format: 
o The submission content should be organized and labeled as described in 
Form FDA 356h (4/06)F20F. This form gives a comprehensive list of each section 
requested in the NDA, ANDA or BLA. 
 
The review and field copies require only a portion of the application. 
• Review copies are precise duplicates of the technical sections of the archival copy. They 
include the information needed by each review discipline for its evaluation. These copies 
facilitate the concurrent review of the application by the different review disciplines. 
Review copies that may be necessary according to Title 21, Code of Federal Regulations 
(CFR) part 314.50F21F for an individual submission includes: 
• Quality (Module 3), 
• Nonclinical (Module 4), 
• Clinical (Module 5) - safety and efficacy documents for clinical reviewer, 
• Clinical (Module 5) - safety and efficacy documents for the statistical reviewer, 
• Clinical (Module 5) - clinical pharmacology and pharmacokinetics documents (or 
bioequivalence documents for ANDAs), and 
• Clinical (Module 5) – clinical microbiology documents. 
A copy of Modules 1 and 2 should be included in each review copy including a ToC for the 
section, cover letter, a copy of the application form, any letter of reference or authorization, 
index to the entire application and the application summary. Each review copy should be 
labeled and bound separately. 
The applicant should contact the office with the responsibility for the review of its product to 
determine how many copies of each module or sections of modules should be submitted. X19 
 
                                                
20 Form FDA-356h “Application to market a new drug, biologic or an antibiotic drug for human use” (Title 21, Code 
of Federal Regulations parts 314 and 610) http://www.fda.gov/opacom/morechoices/fdaforms/internal/FDA-
356h.pdf 
21 Code of Federal Regulations, Title 21 – Foods and Drugs, Volume 5, Revised as of April 1, 2008 (CITE: 21 
CFR 314.50) http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/CFRSearch.cfm?fr=314.50 
Chapter 1 – Food and drugs administration department of health and human services 
Subchapter D – drugs for human use 
Part 314 – Applications for FDA approval to market a new drug 
Subpart B – Applications; Section 314.50 – Content and format of an application 
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The field copy which is used by FDA inspectors during pre-approval manufacturing 
inspections is a copy of the Quality section (Module 3) plus form FDA 356h and the NDA 
summary. The field copy is only requested for the NDA and ANDA (not for BLAs). This 
separately bound copy should be sent directly to the appropriate field office. X19 
 
The “Guidance for Industry-submitting MAs according to the ICH CTD format” X19X describes the 
US typical documents and their content. The content of the CTD sections is not in the scope 
of this guidance document. 
Besides the usual CTD sections, which are requested for all ICH regions the additional 
documents, are requested for an NDA or BLA in USAX19X which are listed in appendix 4 
(“ XAPPENDIX 4 X: Table of contents for an NDA in USA “). 
3.3.3 28BRegistration Procedures 
As mentioned before all NDAs are submitted to CDER. The Federal Regulation requests that 
FDA makes a final decision for an NDA within 180 days beginning with the date of filing. 
After submission to CDER the CDERs Central Document Room first handled the NDAs and 
sent them afterwards to the appropriate review divisions.X18 
The group of reviewers (each with a different technical specialty) checking the NDA makes 
several decisions within 45 days after receipt of NDA. They decide whether the NDA will be 
filed or refused and whether the NDA will have a standard or priority review. According to the 
goals of the Prescription Drug User Fee Act (PDUFA) III, 90% of BLAs and NDAs filed during 
2003 and 2007 have to be reviewed within 10 months after submission for standard review 
procedure and within 6 months for priority review applications. 
In case an NDA is subject to refuse-to-file (RTF), FDA has 60 days from receipt of the NDA 
to inform the applicant. The RTF letter must include the reason for the refusal. In order to get 
an RTF NDAs must have serious deficiencies or issues. 
The applicant may send a written request to FDA for an informal conference within 30 days 
of receipt of the RTF in case the RTF is based on defaults, duplications or incorrect format. If 
the RTF is based on licensing requirements the applicant have the opportunity to amend the 
application and resubmit it.X18 
CDER or CBER may require a pre-approval inspection of the manufacturing facilities and 
clinical trial sites during the review procedure of the NDA or BLA. Normally these pre-
approval inspections take place in parallel to the review of the content of NDAs and BLAs. 
The pre-approval inspection of the manufacturing sites and clinical trial sites, which can be 
announced or unannounced, have the purpose to check the compliance with GMP and the 
consistence with the information provided in NDA/BLA. During these inspections samples of 
medicinal product may be collected for analysis by CDER or CBER.  
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Additional to the pre-approval inspection o manufacturing sites other types of inspections 
might be carried out and can influence the NDA/BLA review process. These inspections are 
conducted by the CDER’s Biosearch Monitoring Program and can include: drug sponsors, 
clinical investigators, institutional review boards (IRBs) and contract research organizations 
(CROs). X18 
UReview at CDER 
When the NDA is submitted, it is forwarded to one of CDER’s drug review divisions, which is 
responsible for the therapeutic class responsible for this kind of application.  
During the first review phase an evaluation of the relevant parts of the application is 
performed by the responsible review functions which are medical, biopharmaceutical, 
pharmacology, statistical, chemistry and microbiology reviewers. 
Each reviewer makes an assessment of the submission in his/her area of expertise. After the 
review a written evaluation with conclusions and recommendations is issued by each 
reviewer. The written evaluation of each reviewer is forwarded to the division director or to 
the office director. He/She checks the conclusions and recommendations of each reviewer 
and decides on the actions to be taken on the submission. The outcome is that one of the 
action letters, i.e. approval letter, approvable letter or not approvable letter, is issued. The 
FDA has the possibility to use Advisory Committees throughout the review process. X18 
The following steps are identical for CBER and CDER and are described under the headline 
"Review at CDER or CBER". X18 
UReview at CBER 
For an application submitted to CBER, FDA is requested to tight review timelines and 
performance goals based on PDUFA. These timelines are only applicable for biological 
products for which user fees have to be paid, but CBER tries to review also “non-user-fee” 
applications within the same timelines. They have also some additional goals like meet the 
set timelines for responding to industry requests for meetings, providing meeting minutes of 
health authority meetings to industry or communication of results of review if sponsor 
responses to clinical hold. X18 
The following steps are identical for CBER and CDER and are described under the headline 
"Review at CDER or CBER". X18 
UReview at CDER or CBER 
Due to the US regulations the FDA is asked to inform the applicant as fast as possible of: 
• Deficiencies - which are easy to correct - particularly those contained in the CMC and the 
control sections 
• Insufficient data in any of the sections 
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• Technical changes requested to facilitate review. 
This is done by an information request letter. In case of major scientific issues, this has to be 
addressed in a formal action letter. 
This procedure was established in order to allow the applicants to submit supplements as 
early as possible during the review process and before the review period is finalized. 
The next step in the review process is the so-called “Ninety-Day Conference”. FDA will invite 
applicants to a review meeting approximately 90 days after receipt of the submission in order 
to discuss the status of review, to mention the deficiencies and to discuss other issues of 
mutual interest. In case a personal meeting cannot be arranged this meeting can be replaced 
by a telephone conference if both parties agree. 
As prerequisite for approval of an application, the FDA will check whether the medicinal 
product meets the relevant legal standards. Depending on the type of application the legal 
standards are: X18 
• In the case of full applications, these standards include requirements for safety, efficacy, 
manufacturing controls, and labeling. 
• In the case of abbreviated applications, these standards include requirements for 
manufacturing controls, labeling, and bioequivalence (if applicable). 
It is advisable that applicants look at FDA guidelines, recommendations and policy 
statements to assist in submitting NDAs and BLAs. 
The FDA notifies the applicant via an action letter if the product has been approved (approval 
letter) or unapproved (complete response letter) at the end of the review period.  
There are in principle three types of letters, which FDA can issue: approval letter, approvable 
letter, and not approvable letter. 
The FDA will issue a not approvable letter if they believe that the NDA cannot be approved. 
Within the not approvable letter any deficiencies in the NDA are described. The applicant will 
respond to a not approvable letter within 10 days of the date of the letter for full applications 
in one of the following forms: X18 
• Resubmit (i.e. a formal response to the action letter) or acknowledge the intent to file a 
resubmission to the NDA or BLA 
• Request for a reasonable extension of the review period to be able to provide the 
appropriate response 
• Request for a hearing 
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Before the FDA finalizes the review cycle and issues an approval letter they may request 
more data or ask for a clarification about existing data or some other element in the 
NDA/BLA. In such a case FDA will issue an approvable letter. With issuing an approvable 
letter FDA believes that the NDA or BLA can be approved once the applicant will provide the 
additional requested information or agrees on specific conditions (like changes in labeling). 
The approvable letter will describe the additional information requested by FDA or the 
conditions to which the applicant have to agree in order to obtain the approval. 
The approvable letter will be answered by the applicant within 10 days of the date of the 
letter or number of days specified in the letter in one of the following forms: X18 
• Resubmit (i.e. a formal response to the action letter) or acknowledge the intent to make a 
resubmission to the NDA or BLA 
• Request for a hearing 
• Withdrawal of the application 
• Request for a reasonable extension of the review period in order to be able to provide the 
appropriate response to the approvable letter. When an extension is granted, the 
applicant must respond within the agreed time period. If not done, FDA will consider the 
application as withdrawn. 
As mentioned above FDA has also the possibility to issue a complete response letter. Such a 
letter is issued if FDA will not approve the NDA, ANDA or BLA in its present form for one or 
more reasons. This procedure is laid down in revised 21 CFR Part 314.110 effective August 
11, 2008F22F. Within the complete response letter all deficits, which FDA has identified during 
the review cycle within the application for not approving the product, are mentioned. If 
possible FDA will also recommend further actions for the application in order to put the 
application in place for conditions for approval. X18 
In case FDA asks for Phase IV studies all agreements regarding the schedule and nature of 
the Phase IV study will be mentioned in the approval letter. 
If FDA approves a medicinal product the product can be put on the market. As soon as the 
product is approved for marketing FDA is obliged to make some research information from 
applicant available to public, which were evaluated through the experts of CDER or CBER. 
These documents are referred to as Drug Approval packages (formerly known as Summary 
Basis for approval). The drug approval package contains the rational for approving the 
medicinal product. In addition, it contains the approval letter, professional labeling, PIL and 
the reviews from the CBER or CDER reviewers (e.g., medical, chemistry, pharmacology, 
                                                
22 Code of Federal Regulations, Title 21 – 21 CFR Part 314.110 effective August 11, 2008 
http://edocket.access.gpo.gov/2008/pdf/E8-15610.pdf and http://law.justia.com/us/cfr/title21/21-
5.0.1.1.4.4.1.10.html dated 01.09.2009 
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clinical, statistical, etc) as well as administrative Information and correspondence. This 
information can be made available through the Freedom of Information (FOI) Act per 21 CFR 
Part 20F23F. These drug approval packages contain normally between 50 – 1500 pages. To 
make the handling of these approval packages more comfortable FDA prepares a ToC and 
identifies the pivotal studies of the medicinal product. The pivotal studies are the essential 
studies for the application on which basis the efficacy and safety of the medicinal product can 
be proven. Abstracts of the pivotal studies are also included in the ToC.18 
UOther registration procedures 
FDA has established three formal procedures to accelerate the development and review 
process. These procedures are applicable for drugs and biologics that address unmet 
medical need or for serious life-threatening diseases or conditions.F24F  
These three procedures are fast track product development, priority review and accelerated 
approval.  
UAccelerated Approval 
FDA regulations, published in 1992, allow “accelerated approval” for drugs or biologics 
products which provide meaningful therapeutic benefit…over existing treatments. This type 
of procedure is applicable for the treatment of a serious or life-threatening disease. 
The procedure allows the approval based on clinical trials using “a surrogate endpoint that is 
reasonable likely… to predict clinical benefit.” instead of using standard outcome measures 
like survival or disease progression. 
Another possibility for the use of this procedure are drugs for which the use could be 
considered safe and effective only under set restrictions which could include limited 
prescribing or dispensing. For these types of drugs FDA normally requires postmarketing 
studies after the approval. X24X 
UFast-Track Mechanism 
The Food and Drug Administration Modernization Act of 1997 (FDAMA, P.L. 105-115)F25F  
directed the secretary to create a mechanism whereby FDA could designate as “Fast Track”. 
The “Fast track” is designed for certain products that met two criteria: 
• The product must concern a serious or life-threatening condition 
• It has to have the potential to address an unmet medical need 
                                                
23 Freedom of Information (FOI) Act per 21 CFR Part 20 (cf. XXX) 
http://www.fda.gov/AboutFDA/ReportsManualsForms/StaffManualGuides/ucm138408.htm - dated 01.09.2009 
24 Susan Thaul, FDA Fast Track and Priority Review Programs, CRS Report of Congress - Order Code RS22814, 
February 21, 2008 http://www.nationalaglawcenter.org/assets/crs/RS22814.pdf - dated 01.09.2009 
25Food and Drug Administration Modernization Act of 1997 (FDAMA, P.L. 105-115) 
http://www.fda.gov/RegulatoryInformation/Legislation/FederalFoodDrugandCosmeticActFDCAct/SignificantAmend
mentstotheFDCAct/FDAMA/FullTextofFDAMAlaw/default.htm - dated 22.10.2009 
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The two main goals of the fast track are on the one hand making approval more likely and on 
the other hand the shortening of the approval time. 
After FDA has granted a fast track designation the manufacturer is encouraged to meet with 
the FDA in order to discuss development plans and strategies before the official submission 
of the NDA/BLA. The advantage of the early interaction with FDA is that issues like elements 
of clinical study designs and presentations whose absence at NDA/BLA can lead to a delay 
in approval decision of NDA/BLA can be clarified earlier. 24X 
 
On the other hand, FDA offers similar interactions to any sponsor who asks for FDA 
consultation throughout the development phases of a medicinal product. A unique option 
within Fast Track is the opportunity of a rolling submission, i.e. to submit sections of an 
NDA/BLA to FDA as they are ready, rather than the standard requirement to submit a 
complete application at one time. X24X 
 
UPriority Review 
In comparison to the fast track or accelerated approval, the priority review process starts only 
when a manufacturer officially submits an NDA/BLA. 
Therefore the priority review does not have any influence on the timing or content of steps 
taken during the drug development or the testing of safety and efficacy. 
The priority review can be used for medicinal products, which are intended to address unmet 
medical need. In such a case the duration of review (NDA/BLA) can be shortened from 10 
months (full review time for a normal NDA/BLA) to 6 months (priority review of NDA/BLA). 
The priority review is not explicitly required by law, but FDA has established it in practice, 
and various statutes, such as the PDUFA, refer to and sometimes require it. 
In appendix 5 an overview table with the comparison of mechanisms to hasten product 
availability is attached (“XAPPENDIX 5 X: Table of Comparison of Mechanisms to Hasten 
Product Availability“). X24 
 
The accelerated approval, fast track mechanism and priority review are not described here in 
more details. 
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3.4 13BCADREAC 
3.4.1 29BGeneral Information 
The UCUollaboration UAUgreement of UDUrug URUegulatory Authorities in UEUuropean U Union UAUssociated 
UCUountries (CADREAC) was a collaboration of countries, which started in 1997. The Heads of 
DRAs in the EU associated countries agreed to sign the CADREAC agreement in order to 
start a formal collaboration during the first meeting of DRAs in Central and Eastern Europe 
Countries (CEECs), 12 to 14 June 1997 in Sofia.F26 
Up to April 2007, 13 state regulatory authorities for human medicinal products of countries in 
Central, Eastern and Southern Europe had signed the CADREAC agreement:  
• Bulgaria, Czech Republic, Estonia, Hungary, Latvia, Lithuania, Poland, Romania, Slovakia 
(since 1997) 
• Slovenia (since 1998) 
• Cyprus (since 1999) 
• Turkey (since 2001) 
• Croatia (since 2005) 
Nine of the original CADREAC countries (Cyprus, Czech Republic, Estonia, Hungary, Latvia, 
Lithuania, Poland, Slovakia and Slovenia) joined the EU at 1st May 2004 and two other 
countries (Bulgaria and Romania) joined the EU at 1st January 2007, therefore in April 2007 
there were only two CADREAC states left – Croatia and Turkey. 
The mission of CADREAC was facilitation of smooth transition of regulatory conditions in EU 
associated countries to achieve regulatory standards required by Acquis Communautaire 
(compliance to article (Art.) 6 of Directive 2001/83/EECX3X amended by Directive 2004/27 X4X: “No 
medicinal product may be placed on the market of a Member State unless a marketing 
authorisation has been issued by the competent authorities of that Member State in 
accordance with this Directive or an authorisation has been granted in accordance with 
Regulation (EEC) No 2309/93. The authorisation referred to in paragraph 1 shall also be 
required for radionuclide generators, radionuclide kits, radionuclide precursor 
radiopharmaceuticals and industrially prepared radiopharmaceuticals.”, which are:  
                                                
26 http://www.dgra.de/studiengang/pdf/master_hoerner_a.pdf - dated 22.10.2009 
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• Implementation of EU regulatory standards 
• Involvement in professional activities within EU 
• Introduction of MRP 
• Introduction of CP 
• Development of common strategies 
• Preparation of meetings 
• Information exchange 
A CADREAC Standard Operating Procedure (SOP), CADREAC SOP-3 (2001) was adopted 
in April 2001, defining the responsibilities and function of a CADREAC secretariat.F27 
The DRA, which acted as CADREAC secretariat, was selected at CADREAC annual 
assembly at least one year before the term of service. 
The activities of the CADREAC secretariat started with the organization of CADREAC annual 
meeting, including drafting of the agenda and minutes of CADREAC annual meeting. The 
activities ended with drafting and presenting CADREAC annual report to be approved at 
CADREAC annual meeting and with providing all necessary information to its successor. 
If no other delegation was made, CADREAC secretariat was the principle contact point for 
CADREAC. 
The CADREAC secretariat was also responsible for: 
• Maintenance of CADREAC documents, especially keeping lists updated of 
• CADREAC agreed documents (like Common procedures, SOPs, positions) except 
Collaboration Agreement 
• DRAs – CADREAC members and observers to CADREAC 
• CADREAC observers at European Community/EMA working parties and committees 
• CADREAC experts serving as contact points for sending materials from working parties 
• Co-ordination of distribution of relevant information, esp. drafts and final versions of 
CADREAC documents and co-ordination of activities needed to obtain common 
CADREAC opinion 
• Prepare documents to be published on the CADREAC homepage 
The secretariat of CADREAC is located in Romania since March 2004. 
                                                
27 CADREAC SOP: CADREAC SOP-3 (2001) - Responsibilities and function of CADREAC secretariat 
http://old.sukl.cz/en06/en0601.htm 
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In addition to the CADREAC MSs, the following countries had the status of observers: 
Belarus, Bosnia-Herzegovina, Republic of Moldova, CH and Serbia and Montenegro. 
The CADREAC countries developed certain guidelines and procedures as a preparation for 
their EU-accession. 
A number of procedures and agreed documents have been published in the internetF28F:  
• Common procedure on the granting of MAs by CADREAC DRAs for medicinal products 
authorized in the EU by CP - in force since January 1999 X6 
• Common procedure on the granting of MAs by CADREAC DRAs for medicinal products 
authorized in the EU by MRP - in force since May 2001 (The 1st revision of the guideline - 
published June 10th, 2001 - includes the retrospective inclusion of medicinal products for 
human use authorized in EU via MRP in the Common CADREAC Simplified System) X7 
• Common CADREAC Procedure (CCP) for retrospective inclusion of centrally authorized 
medicinal products for human use in the Common CADREAC Simplified System - in force 
since May 2001 F29 
• SOPs 
• Lists of contact points  
• Lists of CADREAC observers in European Community/EMA working parties and of 
observers to CADREAC 
During the initial CADREAC initiative it was possible since January 1st, 2002 to use the 
CADREAC procedure for products authorized in EU via CP in Turkey even if Turkey was not 
a full member of CADREAC. The use of this simplified CADREAC procedure for products 
authorized via CP was restricted only to biotechnological products except for immunological 
and blood products in Turkey. Turkey did not join the CADREAC procedure for products 
authorized in EU via MRP. 
As most of the “old” CADREAC countries have meanwhile joined the EU on May 1st, 2004, 
the CADREAC initiative was dissolved. Therefore a subsequent initiative was established. 
This new initiative is called new CADREAC or nCADREAC (New Collaboration Agreement 
between Drug Regulatory Authorities in Central and Eastern European Countries). This new 
initiative has also established a CADREAC agreement, which was signed on 1st May 2005.  
The active members of this new CADREAC initiative are Bulgaria, Croatia, Czech Republic, 
Hungary, Romania and Slovak Republic. Collaborative members are Kosovo and Republic of 
                                                
28 CADREAC homepage - http://web.archive.org/web/20040605093650/http://www.cadreac.org 
29 Common CADREAC Procedure (CCP) for retrospective inclusion of centrally authorized medicinal products for 
human use in the Common CADREAC Simplified System - in force since May 2001 
http://www.milray.org/pdf/CADREAC.pdf 
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Moldova.F30F Further information can be found on the homepage of nCADREAC initiative: 
http://www.newcadreac.org/ X30X. 
 
The CADREAC secretariat is still at the Romanian health authority “National Medicines 
Agency” and has nearly the same responsibilities as in the original CADREAC initiative. The 
nCADREAC procedures which are nearly identical to the originally CADREAC procedures 
were released on January 10th, 2006.F31F, F32 
The nCADREAC procedures were only applicable for Bulgaria, Romania and Croatia as all 
other active members were already EU member states and Turkey which in the past only 
attended the CADREAC procedure for CP authorized products is no part of nCADREAC 
anymore. After the EU accession of Bulgaria and Romania on January 1st, 2007 the 
nCADREAC procedure remains for Croatia and other potential accession countries. The 
nCADREAC procedure for CP authorized products X31X can only be used in Bulgaria, Croatia 
and Romania and not in Turkey anymore. The nCADREAC procedure for products 
authorized via MRP is also only possible in Bulgaria, Croatia and Romania. X32 
 
                                                
30  http://www.newcadreac.org/members.html 
31 Procedure on the granting of marketing authorisations by new CADREAC (nCADREAC) drug regulatory 
authorities for medicinal products for human use already authorised in EU member states following the 
centralized procedure and the variation and renewal of such marketing authorisations 
32 Procedure on the granting of marketing authorisations by new CADREAC (nCADREAC) drug regulatory 
authorities for medicinal products for human use already authorised in EU member states following the mutual 
recognition procedure and the variation and renewal of such marketing authorisations 
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3.4.2 30BDossier Format – ICH CTD 
In the CADREAC countries also the ICH CTD is used as format (please refer to section X3.1 X 
ICH). 
3.4.3 31BDossier Requirements 
The dossier requirements for nCADREAC countries are based on EU requirements as their 
regulations and procedures are based on EU regulations. Therefore the principle regulatory 
requirements for getting an MAA within the EU - which are described in the NtA Volume 2B: 
"Medicinal products for human use - Presentation and format of the dossier Common 
Technical Document (CTD)" X10X - are also valid for nCADREAC countries, like Croatia. 
Additionally to the CTD dossier (Module 2 - 5) some Module 1 documents are required. 
For Croatia, as one example of an nCADREAC country, the following Module 1 requirements 
are requested (depending whether the reference product is authorized via CP or MRP/DCP): 
• For MRP/DCPX7X, X32X authorized products if submission is done in nCADREAC country after 
finalization of MRP/CDP: 
• "Application form (the appropriate national application form for the marketing 
authorisation of a medicinal product together with administrative data and samples 
required by the nCADREAC DRA concerned)  
• Dossier identical with the dossier submitted in the EU-CMSs in MRP 
• Consolidated list of questions raised by CMSs within the MRP and Applicant response 
document in MRP (day 65 responses to questions raised by CMSs within the MRP) 
and later responses  
• Updated Assessment Report (UAR) of RMS, including harmonised SPC (if European 
DMF Procedure has been used, the assessment report on the restricted part should be 
requested from RMS directly)  
If there is only RMS Assessment Report available, the applicant should provide 
information on the MRP:  
• list of CMSs  
• history of the MRP 
• break out session minutes, if applicable  
• information about the reasons for withdrawal(s)  
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• the letter of RMS about the completion of the procedure (first use, repeat use) with 
SPC attached  
• In case that variations have been accepted after conclusion of the MRP, a list of these 
variations has to be part of the submission; the documentation submitted in the EU-
MSs to support these variations shall be annexed to the original dossier  
• variation assessment report(s), if applicable  
• the letter of RMS about the completion of the variation procedure with SPC attached 
• In case the application in the nCADREAC concerned candidate countries (nC-CCC) is 
submitted later than 9 months after the authorisation in EU-RMS and concerns a new 
active substance, the latest available PSUR (Period Safety Update Report)  
• List of post-authorisation commitments imposed in MRP and the status of their 
fulfillment, if any  
• Declaration of the applicant that  
• he will deal with nCADREAC DRA concerned similarly as he or relevant MAH deals 
with DRAs of EU-MSs, especially he will keep the product authorised by the 
nCADREAC DRA concerned identical with the EU-MSs, i.e. in the post-authorisation 
phase he will notify and implement all urgent safety measures simultaneously in the 
EU-MSs and the nC-CCCs and he will submit and implement all variations, once 
accepted in the EU-MSs, without unnecessary delay   
• dossier submitted to the nC-CCC is identical to the dossier submitted in the EU-
CMSs for MRP, including all information submitted to support any variation which 
has been applied for and accepted at the time of submission of the application in the 
nC-CCC as well as information concerning post-authorisation commitments, if any 
(i.e. the documentation reflects the situation of the product, which is in the EU-MSs 
at the time of submission of the application in the nC-CCC)   
• the submitted proposal of SPC in local language is the translation of SPC as last 
approved in MRP 
• Declaration of the MAH in RMS and if necessary, also of the holder of restricted part of 
DMF (see Annex 1). " 
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The evaluation of the dossier and the assessment procedure remain country specific. Each 
nCADREAC DRA will review the dossier submitted for simplified procedure individually. 
Based on the individual evaluation of each nCADREAC DRA, each nCADREAC DRA will 
create an AR and will send the report of the outcome to the RMS and a copy to the 
CADREAC secretariat. 
• MRP/DCPX7X, X32X – if submission is done in nCADREAC country during MRP/DCP: 
• "Application form (the appropriate national application form for the marketing 
authorisation of a medicinal product together with administrative data and samples 
required by the nCADREAC DRA concerned)  
• Dossier identical with the dossier submitted in the EU-CMSs in MRP 
• Assessment Report of RMS including SPC as approved in the RMS in English 
language (if European DMF Procedure has been used, the assessment report on the 
restricted part should be requested from RMS directly)  
• Declaration of the applicant that:  
• he will deal with nCADREAC DRA concerned similarly as he or relevant MAH deals 
with DRAs of EU-MSs, especially he will keep the product authorised by the 
nCADREAC DRA concerned identical with the EU-MSs, i.e. in the post-authorisation 
phase he will notify and implement all urgent safety measures simultaneously in the 
EU-MSs and the nC-CMSs and he will submit and implement all variations, once 
accepted in the EU-MSs, without unnecessary delay  
• dossier submitted to the nCADREAC DRA concerned is identical to the dossier 
submitted in the RMS and EU-CMSs for MRP, if applicable  
• he will inform the nCADREAC DRA concerned on each step of the relevant MRP  
• Declaration of the MAH in RMS and if necessary, also of the holder of restricted part of 
DMF"  
 
The applicant provides the nCADREAC DRA with the information on all steps of the MRP in 
due time as defined for MRPs in the ” Best practice guide for DCP and MRP, October 1996” 
as currently revised in May 2007 X17X. 
The assessment procedure remains country specific. Each nCADREAC DRA will review the 
dossier submitted for simplified procedure individually. 
Each nCADREAC DRA will create an AR and will send the report on the outcome to the 
RMS and a copy to the nCADREAC secretariat. 
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• CPX6X, X31X authorized products: 
• "application form (the appropriate national application form for the marketing 
authorisation of a medicinal product) 
• modules 1, 2 and 3 of the dossier as accepted by the EMEA and detailed list of 
contents of modules 4 and 5, providing that these parts are submitted on request 
• proposed SPC, PIL in national language and the labelling in national language 
unless otherwise specified in the attached table; SPC and PIL are translations of the 
texts approved or in the case of earlier submission of the texts submitted in the EU 
without changes 
• final CHMP Assessment Report including all annexes (see Note below) 
• final Commission Decision including all annexes (see Note below) 
• declaration by the applicant that 
• the dossier submitted, or, where appropriate, the parts submitted thereof are 
identical to the dossier of a product authorised in the EU by the centralised 
procedure (in the case of an earlier submission, to be identical to the dossier 
submitted to EMEA), including all information submitted to support any variation 
which has been applied for and accepted at the time of submission of the 
application for marketing authorisation at the nCADREAC DRA concerned as 
well as information concerning post-authorisation commitments, if any 
• all subsequent variations to this dossier, once accepted in the EU, will also be 
submitted and implemented without delay by the applicant in the nC-CCC 
• all urgent safety measures will be immediately notified to the nCADREAC DRA 
concerned and implemented according to local regulatory requirements 
simultaneously as in the EU or as soon as possible 
•  in the case where the marketing authorisation will be suspended or withdrawn 
in the EU (either by the initiative of the MAH or by EC), nCADREAC DRAs 
concerned will be notified immediately 
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• copy of the declaration by MAH in the EU (the Declaration is sent to the EMEA) 
that 
• an application is being submitted to one or more nCADREAC DRAs, indicating 
the countries concerned, pertaining to the name of the product, the Community 
Marketing Authorisation number, the MAH in the EU as well as the proposed 
MAH in the nC-CCC  
• he agrees that the EMEA may make available to the nCADREAC DRA 
concerned any information to the quality, safety and efficacy of the product 
concerned (the extent of this information shall not exceed that which is made 
available to EU MSs by the EMEA) 
• list of all resolved/outstanding post-authorisation commitments 
• If the application is submitted later than 6 months after the date of the Commission 
Decision, then the latest available Periodic Safety Update Report (PSUR), which 
should include any new pharmacovigilance data, shall be submitted. 
• Similarly, if any variations to the marketing authorisation in the EU have been 
applied for and accepted at the time of submission of the application for 
marketing authorisation in the nCADREAC countries, relevant details should be 
provided. The information submitted to the EMEA to support these variations 
should also be submitted in the nCADREAC DRAs concerned and may be 
annexed to the original 
dossier (see table of dossier requirements). The following documents should 
also be provided: 
• list of all variations to the marketing authorisation that have been approved in 
the EU, safety, transfer or renewal approved procedures at the time of the date 
of submission of the application in the nCADREAC DRAs concerned 
• Commission Decisions granting marketing authorization for the medicinal 
product for human use, Commission Decision amending the marketing 
authorisation as a consequence of an approved type II variation, Annex II 
application, Renewal, Annual Reassessment, transfer of the marketing 
authorisation or safety procedure, if issued by European Commission, as well 
as for an approved type IA, IB variation (every six months) 
• Notifications on a type IB variation to the terms of the marketing authorisation, 
issued by the EMEA;  
• Notifications of the minor changes in labelling or package leaflet not connected 
with the SPC (Art. 61.3 Notification) 
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• Acknowledgement of receipt of a valid notification for type IA variation to the 
terms of the marketing authorization 
• Variation assessment reports, if issued 
• samples as specified in attached table." 
 
3.4.4 32BRegistration Procedures - Example Croatia 
The nCADREAC procedures relating to regulatory activities for products authorized in EU via 
CP is operational since January 2006 and is described in the document “Procedure on the 
granting of marketing authorisations by new CADREAC (nCADREAC) drug regulatory 
authorities for medicinal products for human use already authorised in EU member states 
following the centralised procedure and the variation and renewal of such marketing 
authorisations”. X31 
The document describes the simplified CADREAC procedure for the granting of MAs by 
CADREAC DRAs for centrally authorized medicinal products for human use and the post-
authorization activities – VARs, RENs and handling of pharmacovigilance information - of 
such MAs. 
This simplified nCADREAC procedure for products authorized in EU via CP described in this 
document is optional and can only be initiated at the EU MAH`s request. This means that 
there is no legal obligation to use the simplified nCADREAC procedure. 
The original simplified CADREAC procedure has entered into force on 1st January 1999, the 
nCADREAC procedure for CP authorized products has come into force dated January10th, 
2006. 
The procedure itself consists of the following five stepsX31X: 
 
1. “Initiation of the procedure 
The EU MAH initiates the procedure and notifies the EMEA (see Annex 1) that an application 
will be submitted in one or more nCADREAC DRAs and indicates: 
• the nCADREAC DRA concerned 
• the name of the product in the EU, pharmaceutical form(s), strength(s) authorised in 
the EU 
• International Nonproprietary Name (INN) or common name of the active substance(s) 
• the Community Marketing Authorisation number(s) 
• the EU MAH 
• the proposed MAH in the nC-CCC 
• the proposed name of the product in the nC-CCC 
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Furthermore, the EU MAH declares that the EMEA and the European Commission may 
make available to the nCADREAC DRA concerned any information in relation to the quality, 
safety and efficacy of the above medicinal product, using the form attached as Annex 1. 
The EMEA subsequently includes this information in the relevant database. 
 
2. Submission of the application 
The applicant (i.e. proposed nCADREAC MAH) submits the application to the nCADREAC 
DRA concerned. The addresses of the nCADREAC DRAs are provided in Annex 3. 
Furthermore, the proposed nCADREAC MAH certifies that the application is identical with the 
application accepted in the EU with the exception of the following parameters, where 
relevant: MAH, pack sizes (not all pack sizes are necessarily authorised in nC-CCC), the 
name of the medicinal product (in substantiated cases only)." 
 
3. Timing 
It is possible to submit the applications either after the finalization of the EU CP (after issuing 
the final Commission Decision) or during the ongoing CP. This is dependent on the 
nCADREAC countries concerned. In case of an early submission in the nCADREAC country 
the applicant has to inform the nCADREAC DRAs about the submission and the successful 
validation of the MAA in the CP. This is done by submitting a letter from EMA informing the 
applicant of the positive outcome of the validation and about the adopted timetable for the 
CP or the CHMP opinion. The simplified nCADREAC procedure can be finalized first after 
the submission of the final Commission Decision to the nCADREAC DRAs. In Croatia the 
timing for the evaluation of the application takes according to the guideline 5 months and 
submission of the application is first possible after finalization of the CP. 
 
4.  “Outcome of the procedure 
The nCADREAC DRA concerned informs the EMEA (the Head of Unit EMEA Post-
Authorisation Evaluation of Medicines for Human Use), with copy to the applicant, at the end 
of the procedure on its outcome using the form provided in Annex 2. 
In case of a favourable outcome (i.e. recognition of the Commission Decision granting the 
EU marketing authorisation), the following information will be provided: 
• name of the medicinal product in the nC-CCC 
• national Marketing Authorisation Number(s) 
• name of the MAH in the nC-CCC 
• date of issue of national Marketing Authorisation 
• authorised pharmaceutical form(s), strength(s), pack size(s) 
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• any differences between SPC, PL, and labelling approved in the nC-CCC and the EU 
where relevant 
In case of disagreement with the Commission Decision granting the EU marketing 
authorisation, the scientific conclusions which led to such disagreement are communicated. 
The nCADREAC DRA concerned will also inform the other nCADREAC DRAs concerned in 
case of any disagreement with or modification of the Commission Decision. 
 
5.  Follow-up to the procedure 
Upon receipt of information regarding the outcome of the procedure, the EMEA will include 
such information in the relevant database. 
The EMEA will keep its scientific committee, the CHMP informed about the finalisation of any 
procedure which resulted in a disagreement with or modification of the Commission Decision 
initiated in accordance with the above described framework. Where necessary, the EMEA 
will inform the nCADREAC DRAs concerned of the CHMP's consideration of the issue 
(especially in case of disagreement with the Commission Decision)." 
 
The guidance which describes the nCADREAC procedure for products authorized in EU via 
MRP (simplified nCADREAC MRP) is called “Procedure on the granting of marketing 
authorisations by new CADREAC (nCADREAC) drug regulatory authorities for medicinal 
products for human use already authorised in EU member states following the mutual 
recognition procedure and the variation and renewal of such marketing authorisations”. X32 
The aim of this guidance which describes the nCADREAC procedure for products authorized 
in EU via MRP (simplified nCADREAC MRP) is the description of a procedure which can be 
used by each nCADREAC DRA for granting a MA of a medicinal product which has been 
authorized in the EU MSs following the MRP including subsequent VARs and RENs. 
The simplified nCADREAC procedure offers the possibility of harmonization of SPC, PIL and 
documentation of medicinal products authorized in the EU MSs following the MRP with the 
nCADREAC MSs. 
It should be also considered that harmonization of innovative products authorized by 
nCADREAC DRAs with those authorized in the EU is one of the conditions for harmonization 
of their generics in the future. X32 
The original simplified CADREAC procedure for products authorized in EU via MRP has 
entered into force on 3rd May 2001, whereas the simplified nCADREAC procedure for 
products authorized in EU via MRP is in place since January10th, 2006. 
The mentioned documentX32X describing the simplified nCADREAC procedure for products 
authorized in EU via MRP is divided into the following sections:  
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• “Principles 
• Responsibilities of concerned parties 
• MA procedure 
• VARs to the MA 
• Handling of Pharmacovigilance information 
• RENs of MAs  
• Annexes 1 – 4” 
 
UPrinciples of the simplified nCADREAC procedure 
Before starting with the description of the procedure itself the principles of the procedure and 
the responsibilities of the concerned parties are described for a better understanding of the 
procedure. 
The basic principle of the nCADREAC procedure is the mutual recognition of the EU MRP, 
i.e. the recognition of the assessment of the RMS (and CMSs) in EU. The scope of the 
nCADREAC procedure is to offer a possibility of a procedure, which can be used by any 
nCADREAC DRA for granting a MA of a medicinal product, which has been authorized in the 
EU MSs following the MRP including subsequent VARs and RENs. The assessment of the 
RMS can be assumed to be relevant for nCADREAC area because it can be expected that 
differences in medical practice between the EU MSs and nCADREAC area are generally not 
of major importance for public health. X7X ,X32 
The use of the nCADREAC procedure is not mandatory, but voluntary. The applicant and the 
nCADREAC DRAs can decide whether to use the nCADREAC procedure or not. The 
simplified procedure as such is initiated by the applicant (RMS MAH or headquarter of 
company) with the submission of an application for MA to a nCADREAC DRA with an 
additional procedure specific documentation.X7X , X32 
The nCADREAC DRA specifies individually which products could be subjects to the 
procedure and there are in principle three options depending on the respective country which 
products can be included in the nCADREAC procedure:X7X , X32 
1.  „only products submitted for MRP in MSs with full dossier and submitted for the 
simplified procedure to nCADREAC DRA from CC also with full dossier and 
subsequently for their line extensions, 
2. in addition to products mentioned under 1. also line extensions of products based on 
full dossier, which passed MRP, but the first product in the line is not harmonised in the 
country of the nCADREAC DRA concerned - simplified procedure applied on the line 
extension, can therefore start only after harmonisation of the first product in the line, 
achieved by variations,  
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3. all products submitted for MRP, including generics.“ 
The applicant has to ensure the identity of the dossier and SPC submitted, as well as 
identical post-approval development, urgent safety measures and VARs of the product in the 
EU-MSs and in the countries of the nC-CCC. 
The only acceptable differences in nCADREAC procedure are the name of the medicinal 
product and name of the MAH compared to MRP. In addition, it is not necessary to apply for 
all package sizes in the nC-CCC which have been applied for and which are authorized in 
the CMSs. Legal status of the product is based on the national regulations and the decision 
is made by the nC-CCC. 7X ,X32 
The RMS has the duty to provide the updated AR to the applicant or to respective 
nCADREAC DRA directly. 
In addition, nCADREAC DRA concerned should be provided with all necessary information 
also in the post-approval phase (e.g. rapid alerts, urgent safety restrictions (USRs), VARs) 
via the applicant or directly by the RMS, based on the declaration on information sharing of 
the RMS MAH. In each EU-MS and in the nCADREAC DRAs, contact points have been 
established for communication. 7X ,X32 
If questions or concerns to the EU-RMS AR are raised by the nCADREAC DRA, documents 
in addition to the submitted dossier may be required by the nCADREAC DRA from the 
applicant, or additional assessment according to the usual national procedure may be carried 
out. 
It remains a national nC-CCC decision to establish a special track for processing these 
MAAs in the nCADREAC DRA with possible acceleration. 
National legislation of each nCADREAC country is applicable for all requirements of dossier 
submission, e.g. number of copies, samples, acceptance of electronic dossiers and 
regulation of fees. 7X , X32 
The nCADREAC DRAs keep their responsibilities for granting MAAs, approving VARs and 
RENs and supervising safety measures within their respective territories according to their 
national regulations and national legislations.X7X ,X32 
Each nCADREAC DRA can decide about the starting point of the procedure. The procedure 
will be started after submission of the MAA to the nCADREAC DRA. There is the possibility 
to start the procedure at any time after completion of the respective (first) recognition 
procedure by the EU CMSs, i.e. after the day 90, (further on described as variant I) or to start 
the procedure already when the MA is granted only by the RMS (further described as variant 
II).  
It is allowed that experts of nCADREAC DRA concerned or nCADREAC observers 
participate in a break-out session of MRP, based on a written agreement of the applicant in 
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the RMS, in case that an application is pending at a nCADREAC DRA and EU-CMSs in 
parallel. 7X ,X32 
The nCADREAC DRA decides whether just one or both of the described variants are 
practiced. The submission must comply with the administrative requirements of the nC-CCC. 
All requirements for dossier submission e.g. number of copies, samples, acceptance of 
electronic dossiers and the regulation of fees are in the national responsibility of the nC-CCC 
and local legislations are applicable for these issues. The specific national requirements of 
each nCADREAC DRA are listed in the Annex 4 of the document - „Table of specific national 
requirements of nCADREAC DRAs concerned“ of the document "Procedure on the granting 
of marketing authorisations by new CADREAC (nCADREAC) drug regulatory authorities for 
medicinal products for human use already authorised in EU member states following the 
mutual recognition procedure and the variation and renewal of such marketing 
authorisations” X7X,X32X (see XAPPENDIX 6 X). 
In addition also issues like intellectual property (IP) rights and confidentiality remain in the 
responsibility of the nC-CCC. 
It should be emphasized that variant II was in the past (at the original CADREAC procedure) 
only possible in Slovakia but pre-submission consultation was required. In all other 
nCADREAC and CADREAC (new EU-MSs) countries only variant I was and is possible – 
submission of the MAA any time after completion of the respective MRP, when an updated 
AR is available - whereas in Czech Republic, Hungary and Latvia variant I was possible after 
day 90 of the MRP. Therefore for most of the CADREAC and nCADREAC countries only 
variant I was and is feasible, i.e. for all current nCADREAC countries only variant I is 
accepted. 
 
UResponsibilities of the concerned parties 
One other important aspect for the nCADREAC procedure are the concerned parties which 
are involved in the nCADREAC procedure - which are the applicant/MAH in the nCADREAC 
area, the MAH in the RMS, the CA of the RMS and the nCADREAC DRA - and their different 
jobs and responsibilities in the nCADREAC procedure. 
 
The applicant/MAH in the nCADREAC area has to ensure that the dossier submitted is 
identical to the dossier submitted in the CMSs. 
He has to take care that the declaration according to Annex 1 X7X,X32X (see XAPPENDIX 7 X) will be 
available also from restricted part of EDMF holder (manufacturer of active substance), if 
EDMF procedure has been used. 
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The applicant/MAH is responsible that the medicinal product will be kept identical in the post-
marketing phase and that all information on the course of the MRP as required for variant II 
will be submitted to the nCADREAC DRA in time. 
The MAH in the RMS has to sign a declaration on the information sharing and participation of 
experts of nCADREAC DRA concerned or observers in break-out sessions of the Mutual 
Recognition Facilitation Group (MRFG), if appropriate X7X,X32X (see XAPPENDIX 7 X) and has to sent 
this declaration to the national authority of the RMS and a copy to the nCADREAC DRA. 
 
The competent authority (CA) of the RMS has to make available the updated AR and if 
necessary post-approval information (like rapid alerts, USRs) to MAH in the EU or 
nCADREAC DRA directly. 
RMS should provide nCADREAC DRA concerned with all necessary information also in the 
post-approval phase (like rapid alerts, USRs) via the applicant or directly, based on the 
declaration on information sharing of the RMS MAH. Contact points in each EU-MS and in 
the nCADREAC DRAs have been established for communication. 7X ,X32 
 
The nCADREAC DRA concerned has to ensure to keep information submitted and 
generated during this procedure confidential and has the duty to send the report on the 
outcome of the procedure in the nC-CCC to the RMS (see XAPPENDIX 8 X) and a copy of the 
report to the nCADREAC secretariat. In case of disagreement or modification other than 
defined, the report will include a justification and will be also sent to all nCADREAC DRAs. 
 
UDescription of the procedure for getting a MA 
According to the document „Procedure on the granting of marketing authorisations by new 
CADREAC (nCADREAC) drug regulatory authorities for medicinal products for human use 
already authorised in EU member states following the mutual recognition procedure and the 
variation and renewal of such marketing authorisations”X32X the initiation of the nCADREAC 
procedure is done by the RMS MAH. Practically, it is also possible that the headquarter of a 
company initiates the procedure, especially in cases where local affiliates are MAH in RMS. 
The initiator of the procedure notifies the EU-RMS that an MAA will be submitted in one or 
more nC-CCCs. In addition, the initiator of the procedure, RMS MAH, submits a written 
declaration to the DRA of the RMS wherein he declares that the DRA of the RMS may make 
available to the nCADREAC DRA any information regarding quality, safety and efficacy of 
the concerned product(s) and in the case that variant II is used he agrees with the 
participation of the nCADREAC expert in the break out session (see XAPPENDIX 7 X). 
It should be considered, that the nCADREAC procedure itself and the evaluation of dossier 
are not described in detail in the nCADREAC procedure document. X7X, X32 
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As mentioned before, the nCADREAC procedure for a product authorized in EU via MRP 
offers two different variants, which can be used to apply for a MA. In the following these two 
different variants are described. 7X ,X32 
 
UDescription of the procedure for getting a MA - Variant I - after finalization of MRP 
For variant I of the simplified procedure the application for MA is submitted any time after 
completion of the respective MRP when an updated AR is available. 
The documents which have to be submitted by the applicant for this variant I were already 
described in section "X3.4.3 X Dossier requirements". 
 
UDescription of the procedure for getting a MA - Variant II – in parallel with MRP 
For variant II, the MAA is submitted after the RMS issued the AR and before the finalization 
of the MRP. 
Therefore it is advisable that the applicant consults the relevant nCADREAC DRA before the 
submission in order to clarify any open issues. 
Due to the time point of submission of the MAA, for variant II less documents are necessary 
because some of the documents requested for variant I are not yet available for variant II 
(like updated AR including harmonized SPC, consolidated list of questions raised by CMSs 
and the consolidated response of the applicant, PSUR, VARs and AR for VARs). 
The documents which have to be submitted by the applicant for this variant II are described 
in section "X3.4.3 X. Dossier requirements". 
In the two mentioned documents describing the nCADREAC procedure for products 
authorized in EU via CP or MRPX31X, X6X, X32X,X7X the legal background, requirements and timelines for 
the nCADREAC procedures are described. 
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3.5 14BASEAN 
3.5.1 33BGeneral Information Regarding ASEAN 
Another important factor which should be mentioned and discussed in detail is the ASEAN 
countries (please refer also to the section "X2 X Status as of today"). X8 
The ASEAN was established on 8 August 1967 in Bangkok by the five original member 
countries (Indonesia, Malaysia, Philippines, Singapore and Thailand). Meanwhile five 
additional countries (Brunei Darussalam, Vietnam, Laos, Myanmar and Cambodia) joined 
ASEAN. 
In 1999 a harmonization initiative was started among the 10 ASEAN countries. One aim of 
this harmonization should be to harmonize quality guidelines that are valid for all countries 
involved. Another focus lies in the technical co-operation. Therefore the ACCSQ PPWG was 
established. The objective of the ACCSQ PPWG is the development of “harmonization 
schemes of pharmaceuticals' regulations of the ASEAN member countries to complement 
and facilitate the objective of ASEAN Free Trade Area (AFTA), particularly, the elimination of 
technical barriers to trade posed by these regulations, without compromising on drug quality, 
safety and efficacy." 8 
The strategy of the ACCSQ PPWG is the “exchange of information on the existing 
pharmaceutical requirements and regulation implemented by each ASEAN member 
countries, to study the harmonized procedures and regulatory systems implemented in the 
ICH region, development of common technical dossiers with a view of arriving at MRAs 
(Mutual Recognition Arrangements)." 8 
 
From August 2003 – December 2004 each ASEAN country should implement a trial 
implementation period for the ASEAN requirements (like ATCD and ACTR). The full 
implementation of the ASEAN requirements was originally planned for January 1st, 2005. The 
transition period for the ASEAN requirements was extended to December 31st, 2008 as it 
was not possible for the ASEAN countries to implement the ACTD until January 1st, 2005.  
The full implementation of ACTD for new products was planned to be done in the ASEAN 
countries at different points in time between 2005 and 2008, which are summarized attached:  
• Singapore and Malaysia by December 2005 
• Thailand by December 2006 
• Indonesia and Vietnam by December 2007 
• Philippines, Cambodia, Laos and Brunei by December 2008. 
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As the full implementation of the ASEAN requirements (like ACTD and ACTR) in the ASEAN 
countries is not yet finalized, a prolongation/transition period was done. There is an interim 
period agreed wherein ACTD and national formats allowed in most of the ASEAN countries, 
whereas in some countries like Singapore ICH CTD is accepted.  
The full implementation of ACTD for new products was expected by 31 December 2008 
whereas the full implementation for currently registered products is expected to be done until 
01 January 2012. According to information received from the ASEAN countries (January 
2009) some of the ASEAN countries still accept the CTD-format for MAAs of NCEs and 
NBEs whereas for RENs and VARs only the ACTD-format is accepted by ASEAN countries. 
According to the information of the “forum institute seminar on October 21st and 22nd in 
Cologne” the full implementation of ACTD becomes mandatory by end of 2008 for MAAs and 
already registered products have to be transferred to ACTD until 2012. 
 
All regulatory agencies in these 10 countries have a relatively weak infrastructure and limited 
resources. The agencies are structured differently and standards of scientific guidelines are 
not well established. A big problem of the agencies is the lack of consistency and the lack of 
transparency especially regarding the evaluation of dossier. To solve these problems they 
are constantly improving with more dialogues with the industry. 
In all ASEAN countries a Certificate of a Pharmaceutical Product (CPP) from the reference 
country is required and builds the basis of the drug approval as the DRAs don’t have the 
possibilities, capacities and scientific know-how to make a full evaluation of the submitted 
dossier (especially with regard to preclinical and clinical data).  
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3.5.2 34BDossier Format – ASEAN CTD 
As mentioned before the ASEAN countries established the ACTD as their format for 
submissions. It is a standard derived from the ICH CTD. The ASEAN CTD is a guideline of 
the agreed upon common format for the preparation of a well-structured ACTD application 
that will be submitted to ASEAN regulatory authorities for the registration of pharmaceuticals 
for human use.F33F  
The ACTD is similar to the ICH CTD. The ICH CTD is divided into 5 modules whereas the 
ACTD contains of 4 parts. The reason for doing this is the fact that the ASEAN countries 
normally receive a reference application, which is a dossier which was already approved in 
other countries in the world (mostly EU and USA) and make the evaluation of the parts 
mainly based on the overviews and summaries. 
Based on this, the need for detailed documentation is in most of the ASEAN countries less 
compared to the ICH countries, e.g. most study reports are not required to be submitted. 
The Module 1 of the CTD containing the regional registration and administrative information 
is still presented as Part 1 of the ACTD. 
The Module 2 of the CTD does not exist itself for the ACTD. The Quality Overall Summary 
(QOS) and the overview and summaries of the nonclinical and clinical documentation (similar 
like the documents in ICH Module 2) are included at the beginning of these Parts. Part II of 
the ACTD contains the pharmaceutical-chemical-biological documentation (the quality 
information), which corresponds to the ICH Module 3. The nonclinical information is 
presented as Part III of the ACTD (equivalent to ICH Module 4) and the clinical 
documentation is contained in Part IV of the ACTD (to be consistent with ICH Module 5). 
The differences between ICH-CTDF34F and ACTDF35F are presented in the attached comparison 
pyramid: 
 
                                                
33 The ASEAN Common Technical Document (ACTD) for the registration of pharmaceuticals for human use – 
organization of the dossier  
http://www.hsa.gov.sg/publish/etc/medialib/hsa_library/health_products_regulation/western_medicines/files_guide
lines.Par.22449.File.dat/ACTD_OrganizationofDossier.pdf 
34 http://upload.wikimedia.org/wikipedia/en/a/a9/CTD_Pyramid.jpg - dated 27.04.2009 
http://www.ectdblog.com/2008_05_01_archive.html 
35 http://www.ectdblog.com/2008_05_01_archive.html 
http://1.bp.blogspot.com/_Yjwi3JtqDOY/SERNIifkrEI/AAAAAAAAKsQ/Zr22lcsU1R8/s1600-h/actd.png 
 64
 
 
 
As demonstrated above the ACTD is organized in four partsX33X: 
• Part I: ToC, Administrative Data and Product Information 
• Part II: Quality Document 
• Part III: Nonclinical Document 
• Part IV: Clinical Document 
The details of the different parts of ACTD are provided in appendix 9 (“ XAPPENDIX 9 X: Table 
of Contents for ACTD”). 
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3.5.3 35BDossier Requirements 
The requirements for the dossier for the ASEAN countries are in principle very similar to the 
requirements for the ICH countries. For ASEAN a guideline exists where the quality 
requirements for a MAA for an NBE and an NCE are described.F36F The detailed information of 
the dossier requirements for ASEAN countries is provided in XAPPENDIX 10 X (“Dossier 
requirements for quality part of the dossier for ASEAN countries”).  
Additionally there are similar guidelines for the nonclinicalF37F and clinical documentation.F38F As 
the guidelines are in principle very similar to the ICH CTD regulations, they will not be 
described here again in details. 
The only important thing is to remember that the nonclinical overview and summary as well 
as the clinical overview and summary is put at the beginning of part 3 and 4 followed then by 
the study reports and literature. For some ASEAN countries these nonclinical and clinical 
overviews and summaries are sufficient and no additional study reports need to be 
submitted. In most cases it is sufficient to submit some publications from the mentioned 
studies in addition to the nonclinical and clinical overviews and summaries. 
But for the full evaluation (which means a complete evaluation of the MAA dossier) in 
Singapore it is mandatory to submit the whole data package (full CMC, full nonclinical and 
full clinical data package). So far Health Sciences Authority (HSA) also accepts the ICH CTD 
dossier for MAAs although it would be appreciated to submit the dossier in ACTD format. 
Additionally in Singapore there are additional requirements existing besides the ACTD and 
ACTR requirements. In Singapore there are some specific documents requested from the 
HSA like the preparation for a specific QOS. 
                                                
36 The ASEAN Common Technical Dossier (ACTD) for the registration of pharmaceuticals for human use – Part II 
Quality 
http://www.hsa.gov.sg/publish/etc/medialib/hsa_library/health_products_regulation/western_medicines/files_guieli
nes.Par.28201.File.dat/ACTD_PartIIQuality_Apr05.pdf 
http://www.hsa.gov.sg/publish/hsaportal/en/health_products_regulation/western_medicines/guidelines.html 
37 The ASEAN Common Technical Dossier (ACTD) for the registration of pharmaceuticals for human use – Part III 
Nonclinical document 
http://www.hsa.gov.sg/publish/hsaportal/en/health_products_regulation/western_medicines/guidelines.html 
http://www.hsa.gov.sg/publish/etc/medialib/hsa_library/health_products_regulation/western_medicines/files_guide
lines.Par.59468.File.dat/ACTD_PartIIINonClinical_Nov05.pdf 
38 The ASEAN Common Technical Dossier (ACTD) for the registration of pharmaceuticals for human use – Part 
IV Clinical document 
http://www.hsa.gov.sg/publish/hsaportal/en/health_products_regulation/western_medicines/guidelines.html 
http://www.hsa.gov.sg/publish/etc/medialib/hsa_library/health_products_regulation/western_medicines/files_guide
lines.Par.54671.File.dat/ACTD_PartIVClinical_Nov05.pdf 
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Within the “Guidance on medicinal product registration in Singapore”F39F the dossier 
requirements for the dossier for MAAs are described. 
Within this guidance document the preparation of the QOS for NCEs (described in 
APPENDIX 8 of the guideline) and QOS for NBEs (described in APPENDIX 9 of the 
guideline) is described. X39 
The QOS for NCEs should be presented as a summary of the quality part (CMC part) of the 
NDA. X36X It is requested to submit a hard copy as well as an electronic copy for review. In 
principle the content of the QOS for NCEs is very similar to the QOS for the ICH dossier. 
There is some additional information requested like indicating for each section the “hard copy 
location/pages and e-copy location/file number”.  
Additionally the applicant has to fill out a tick box for Drug Substance (DS) general 
information. 39 
"For NCEs the following information are requested: X 
 
Check appropriate tick box 
 DMF (open) is attached 
 DMF (open and restricted) and Letter of Access to be submitted by 
DDMMYYYY (within month of Pharmaceutical Regulatory and 
Information Systems (PRISM) submission) or 
Letter of Access to the DMF filed with HAS (015:_____) is provided 
 CEP (Certificate of suitability from European Directorate for the Quality 
of Medicines & HealthCare (EDQM)) for DS is attached. 
CEP number: 
 CEP for raw materials and excipients is attached 
 DS meets the current Pharmacopoeia of the United States (USP)/ 
European Pharmacopoeia (Ph.Eur.)/Japanese Pharmacopoeia (JPh) 
(delete as appropriate) requirements 
 DS meets other pharmacopoeia standards 
 DS meets in-house specifications 
 DS meets other pharmacopoeia standards. Analytical methods and 
appropriate analytical method validation data are included in the dossier. 
 DS meets in-house specifications. Analytical methods and appropriate 
analytical method validation data are included in the dossier. 
 
 
                                                
39  Guidance on Medicinal Product Registration in Singapore (effective January 1, 2009) 
http://www.hsa.gov.sg/publish/hsaportal/en/health_products_regulation/western_medicines/guidelines.html 
http://www.hsa.gov.sg/publish/etc/medialib/hsa_library/health_products_regulation/western_medicines/files_guide
lines.Par.15295.File.dat/Guidance%20on%20Medicinal%20Product%20Registration%20in%20Singapore%20200
9_Complete%20with%20Appendices.pdf 
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Whereas for NBEs the table looks like this: 
 
Check appropriate tick box 
 CEP for raw materials and excipients is attached 
 Plasma Master file (PMF) 
 Site Master File (SMF) 
 DS meets in-house specifications. Analytical methods and appropriate 
analytical method validation data are included in the dossier." 
 
There are also some recommendations how specifications, validation of analytical methods 
or batch analyzes should be presented. 
 
In principle the QOS prepared for the ICH countries can be used also for Singapore. In some 
special cases it might be necessary to add some tables specifically requested for Singapore. 
But it can be discussed with HSA in most cases whether additional work is really needed as 
in principle the information requested are identical to the QOS for ICH countries. 
 
3.5.4 36BRegistration Procedures 
The different registration procedure for ASEAN countries will be described on the example of 
Singapore. Singapore is one of the founder countries of ASEAN and is one of the leading 
countries within ASEAN. 
On the homepage of the HSAF40F they described their responsibilities and functions: 
“The Therapeutic Products Division (TPD) is responsible for the registration of medicines and 
the continual review of approved medicinal products. TPD will facilitate the timely introduction 
and availability of new and innovative quality medicines in Singapore and the region, 
including medicines targeted for diseases prevalent in the region. 
The main activities relating to the control of medicinal products include: 
• Evaluation and approval of applications for new product licenses, amendment and REN of 
existing product licenses, as well as the continual review of registered medicinal products.  
• Evaluation and approval for import of unregistered medicinal products on a named patient 
basis.  
• Approval for the import of medicinal products for the purpose of re-export. 
                                                
40 Homepage of Health Sciences Authority – health products regulations - medicines: 
http://www.hsa.gov.sg/publish/hsaportal/en/health_products_regulation/western_medicines.html 
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• Evaluation and approval of applications for licenses for the purpose of importation of 
registered medicinal products on a per consignment basis.  
• Evaluation, approval and monitoring of clinical trials on medicinal products.  
• Secretariat support for the Medicines Advisory Committee (MAC) and the Medical Clinical 
Research Committee (MCRC).” 
 
In Singapore exists in principle 3 types of registration procedures: X39 
• Full evaluation route 
• Abridged evaluation route 
• Verification route 
Before submission of the MAA for an NBE or NCE the applicant should check which type of 
procedure is applicable for the MAA of the medicinal product (“pre-submission consultation”). 
The full evaluation route is applicable if no DRA has granted the MA for the medicinal 
product before. 
The abridged evaluation route applies to MAAs of NCEs or NBEs if at least one DRA has 
approved the medicinal product before submission of the dossier in Singapore. 
 
The verification route can only be used if the medicinal product is already approved by two 
HSA reference DRAs (so called benchmarked DRAs) (US (FDA), EU (EMA), AUS 
(Therapeutic Goods Administration (TGA)), United Kingdom (UK) (Medicines and Healthcare 
products Regulatory Agency (MHRA)) and Canada (Health Canada)) and if ARs from these 
two DRAs are available. This procedure is only possible for NCEs, not for NBEs due to the 
complexity of NBEs. 
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3.5.4.1 61BFull Evaluation Route 
The full evaluation route is applicable for MAAs of NCEs and NBEs if no other DRA has 
approved the medicinal product as defined by World Health Organization (WHO) at the time 
of submission. 
Using this evaluation route the Therapeutic Products Division (TPD) will provide first 
evaluation and approval of the dossier in the world for a new innovative product which has 
not received any authorization by any other DRA worldwide. This evaluation time takes 270 
working days. 
This route is applicable for innovative products containing an NBE or NCE (NDA-1) or a 
registered chemical or biological entity used in a new dosage form, new combination of 
registered chemical/biological entities (NDA-2) or subsequent strengths of innovative 
products (NDA-3). X39 
The ICH CTD as well as the ACTD are accepted submission formats for the MAA using the 
full evaluation route. 
The applicant should inform HSA at least two months before submission about the intended 
submission date. 
As the HSA will perform a complete evaluation of the dossier it is necessary to provide them 
with a complete CTD dossier. Full information on chemical/biological development, 
pharmaceutical/genetic development, toxicological and pharmacological data and clinical 
data must be submitted to support the MAA. For the quality part of the dossier all information 
regarding DS and Drug Product (DP) need to be submitted. For nonclinical part the complete 
dossier including all pharmacological, pharmacokinetic and toxicological data must be 
submitted. All documentation (including all study reports from Phase I, II and III with tables 
and appendices) has to be submitted for the clinical part of dossier. 
 
3.5.4.2 62BAbridged Evaluation Route 
The abridged evaluation route applies for MAAs of NCEs or NBEs if at least one DRA has 
approved the medicinal product before submission of the dossier in Singapore. All facts 
regarding product quality and direction of use (including dosing regimen(s), indication(s) and 
patient group(s)) should be the same as approved by the competent DRA in the reference 
country. 
For the abridged evaluation route the HSA will perform only an abridged evaluation of the 
dossier. This abridged evaluation of dossier takes 180 working days. 
The technical dossier requires the complete quality part (CMC documentation) for DS and 
DP and the nonclinical overview. For clinical data package the clinical overview, summaries 
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of clinical efficacy and clinical safety, synopsis of relevant studies (mainly Phase II and III), a 
tabular listing of the clinical development program and study reports of pivotal studies are 
requested (the tables and appendices of the pivotal study reports can be submitted upon 
request of HSA). X39 
In case of a life-saving drug the applicant can ask for priority review if there is unmet medical 
need. 
The following aspects are considered for acceptance for priority review: X39 
• Drug is intended for a life threatening disease/condition and demonstrate potential to 
address a local unmet medical need 
Unmet medical need is defined by: X39 
• Absence of treatment options 
• Lack of save and effective alternatives and the drug would be a significant improvement 
compared to available alternatives, as demonstrated by 
• Evidence of increased efficacy in treatment, prevention or diagnosis or 
• Elimination/reduction of treatment-limiting adverse drug reactions 
 
Local public health concerns which may lead to priority review are the following diseases: 
• Cancers 
• Infectious diseases: dengue, tuberculosis, hepatitis, malaria 
 
The justification why the application should be considered for priority review should be 
submitted together with the request for priority review. The justification should contain 
information how the product is expected to benefit for patients by: X39 
• How serious is the disease? 
• Seriousness of the disease condition, local & worldwide morality rates, anticipated 
morbidity and defibrillation as consequence of the disease 
• What is the clinical relevance in the local population? 
• Local epidemiology data & requests trough “named –patient” exemptions 
• Is there evidence for unmet medical need? 
• Unmet needs, available treatment options and inadequacy of available therapies 
• How is the drug going to address the identified unmet medical need? 
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• Extend to which the product is expected to have a major impact on medical practice, its 
major benefit, and unmet medical needs can be addressed 
• What is the scientific basis? 
• The strength of evidence supporting the claims of addressing unmet medical needs, or, 
of significant improvements compared to available treatment 
 
The written request for priority request with justification has to be submitted at the time point 
of filing the application. The applicant will be informed of the outcome at the point of 
acceptance of application after screening. HSA has also the right to reject the request for 
priority review if is considered appropriate. X39 
 
3.5.4.3 63BVerification Route 
The verification route can only be used if the medicinal product is already approved by two 
benchmarked DRAs (so called reference authorities) and if ARs from these two DRAs are 
available. These benchmarked DRAs or reference authorities are FDA (US), EMA (EU), TGA 
(AUS), MHRA (UK) and Health Canada (Canada). 
The applicant has to decide and declare which of the two reference authorities is the primary 
reference agency because all facts regarding product quality and direction of use (including 
dosing regimen(s), indication(s) and patient group(s)) should be the same as approved by 
the chosen primary reference agency. The verification route dossier has to be submitted at 
least 3 years from the date of approval by the chosen primary reference authority. The 
primary reference authority is defined as the reference authority for which qualifying 
supporting documents, as outlined in the "Guidance on medicinal product registration in 
Singapore" will be submitted by the applicant.X39 
The assessment using the verification route is based on the full ARs of the reference DRAs. 
Therefore the complete quality and clinical ARs are requested to enable the effective 
verification process. The ARs should also include all annexes and all questions & answers. 
The quality part of the dossier (pharmaceutical-chemical-biological documentation (QOS and 
ICH Module 3)) should include the initial submitted dossier to the primary reference authority, 
all questions and answers between primary reference authority and applicant (answers 
should be accompanied by the supporting documentation used in responses of questions) as 
well as all reports and/or documentation pertaining to post-approval VARs approved by the 
primary reference authority. X39X Additionally the nonclinical overview must be submitted. As 
clinical data package the clinical overview, summaries of clinical efficacy and clinical safety, 
synopsis of relevant studies (mainly Phase II and III), a tabular listing of the clinical 
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development program and study reports of pivotal studies are requested (the tables and 
appendices of the pivotal study reports can be submitted upon request of HSA). X39 
As mentioned before the complete ARs as well as other supporting documents from the 
primary reference agency are requested as tabulated below X39X: 
Primary reference 
agency 
Documentary requirements 
AUS TGA • Clinical and quality ARs, including all annexes, 
questions an answer documents between the 
applicant and the agency 
• Delegate’s overview 
• Pre- Australian Drug Evaluation Committee 
(ADEC) response 
• ADEC minutes 
• ARs and/or documents pertaining to post-
approval VARs, if applicable 
Health Canada • Clinical and quality ARs, including all annexes, 
questions an answer documents between the 
applicant and the agency 
• ARs and/or documents pertaining to post-
approval VARs, if applicable 
EMA • Summary of CHMP opinion 
• European ARs (i.e. Rapporteur, CoRapporteur 
as well as the joint clinical and joint quality 
ARs), including all annexes, questions an 
answer documents between the applicant and 
the agency 
• ARs and/or documents pertaining to post-
approval VARs, if applicable 
UK MHRA • Clinical and quality ARs, including all annexes, 
questions an answer documents between the 
applicant and the agency 
• ARs and/or documents pertaining to post-
approval VARs, if applicable 
US FDA • Clinical and quality ARs (unredacted), including 
all annexes, questions an answer documents 
between the applicant and the agency 
• ARs and/or documents pertaining to post-
approval VARs, if applicable 
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The ARs must be unredacted or unedited. Reports available from public domain are not 
acceptable. 
Additionally, the following documents have to be submitted to HSAX39X: 
• Official approval letter or an equivalent document from relevant primary reference agency 
that certifies the registration status of the DP 
• GMP certificate for DP of the primary reference agency 
• SPC/PIL currently approved by the primary reference agency 
• “Official letter declaring that the application as submitted to HSA or similar direction(s) of 
use, indication(s), dosing regimen(s) and/or patient group(s) have not been rejected, 
withdrawn, approved via appeal process or pending deferral by any competent DRA with 
reasons in each case if applicable 
• Official letter declaring that all aspects of the product’s quality intended for sale in 
Singapore are UidenticalU as currently approved by the primary reference agency. This 
includes, but is not limited to, the formulation, site(s) of manufacture, release and shelf-life 
specifications, primary packaging and the PI/PIL. For example, if product was approved 
by FDA and EMA and the assessment report was from EMEA, the Singapore proposed 
product and PI/PIL should be identical to the currently approved EMEA product.” 
 
The data package submitted to HSA must be identical to the data package submitted to the 
reference authorities. Should there be differences between the dossier submitted to the HSA 
compared to the dossier submitted to reference authorities this will not delay the processing 
of the application by HSA but may lead to a switch of the dossier to an abridged evaluation 
route. The switch to an abridged evaluation route might be done if significant undisclosed 
differences between dossier submitted to HSA and reference authorities have been detected. 
The verification route procedure is only possible for MAAs of NCEs, not for MAAs of NBEs 
due to the complexity of NBEs. The verification route takes only 60 working days..X39 
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3.6 15BCHINA 
3.6.1 37BDossier Format 
In China there is no special format required, therefore the ICH CTD can be used. 
 
3.6.2 38BDossier Requirements 
The basis for the dossier requirements as well as the registration procedures in China are 
laid done in the “Drug Registration Regulation (SFDA Order 28)”.F41F  
There in the general principles, the basic requirements, clinical trials of drugs, application 
and approval of new drugs, generic drugs or imported drugs as well as applications for Over 
the Counter (OTC) drugs are described. 
In Chapter 4 “Application and Approval of New Drugs” of this drug regulation the definition of 
new drugs are described in article 45: “SFDA may use special approval process for the 
following new drug, where detail regulation will be promulgated separately: 
1. New drug material and its preparation, active ingredients and its preparation extracted 
from plant, animal and minerals, which have not been marketed in China and; 
2. chemical drug raw material and its preparations, and/or biological product that have not 
been marketed domestically or outside China; 
3. New drugs for AIDS, cancer and orphan disease that are superior to the marketed 
drugs. 
4. New drugs which treat diseases for which there is no effective therapy. 
 
For those drugs meeting the above provisions of this Regulation, during the drug registration, 
the applicant may apply for a special approval, SFDA shall organize specialist meeting to 
decide whether to use special approval for the drug application.  
Detailed provisions of special approval shall be promulgated separately.” 
 
The details regarding dossier requirements for NCEs are provided in annex 2 of the drug 
registration regulation “Registration Categories and Application Information Requirements of 
Chemical Drugs”F42F and for NBEs in annex 3 of the drug registration regulation “Registration 
Categories and Application Information Items Requirements of Biological Products”.F43 
                                                
41 Drug Registration Regulation (SFDA Order 28) (Translation by RDPAC, for Member use only) 
Drug Registration Regulation was approved on June 18, 2007 by SFDA executive meeting and is hereby 
published, which become effective from October 1, 2007. SFDA Commissioner, Shao Minli, July 10, 2007 
42 Annex 2: Registration Categories and Application Information Requirements of Chemical Drugs 
43 Annex 3: Registration Categories and Application Information Items Requirements of Biological Products 
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According the paragraph I “registration categories” of annex 2 of the drug registration 
regulation “Registration Categories and Application Information Requirements of Chemical 
Drugs” X42X the following registration categories are covered as NCEs: 
1) “New chemical entity never marketed in any country. 
i. Drug substance and its preparations made by synthesis or semi-synthesis. 
ii. Chemical monomer (including drug substance and preparation) extracted from 
natural sources or by fermentation. 
iii. Optical isomer (including drug substance and preparation) obtained by chiral 
separation or synthesis. 
iv. Drug with fewer components derived from marketed multi-component drug. 
v. New combination products. 
vi. A preparation already marketed in China but with a newly added indication not yet 
approved in any country. 
2) Drug preparation with changed administration route and not marketed in any country 
3) Drug marketed ex-China, including:  
i.Drug substance and its preparations, and / or with changed dose form, but no change of 
administration route. 
ii.Combination preparations, and / or with changed dose form, but no change of 
administration route. 
iii.Preparations with changed administration route and marketed ex-China. 
iv.A preparation already marketed in China but with a newly added indication approved 
ex-China. 
4) Drug substance and its preparation with changed acid or alkaline radicals (or metallic 
elements), but without any pharmacological change, and the original drug entity already 
approved in China. 
5) Drug preparation with changed dose form, but no change of administration route, and the 
original preparation already approved in China, 
6) Drug substance or preparation following national standard.” 
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The documents which are requested for an MAA dossier of an NCE are described in 
paragraph II “Application dossier item” of annex 2 of the drug registration regulation 
“Registration Categories and Application Information Requirements of Chemical Drugs” X42X are 
divided to the following four parts: 
a) Summary 
b) Pharmaceutical data 
c) Pharmacology and toxicology study information 
d) Clinical Study Information 
 
The detailed list of documents required within these four parts is provided in appendix 11 
(“ XAPPENDIX 11 X: Dossier requirements for an NCE in China“).42X 
The dossier requirements in principle are quite similar to the requirements for ICH region, 
only the administrative part of the dossier where local documents are requested differs. 
For further details the table of the application information items is provided in appendix 12 
(“ XAPPENDIX 12 X: Table of application information item for China“). 
 
The dossier requirements for NBEs are described in annex 3 "Registration Categories and 
Application Information Items Requirements of Biological Products"X43X. In paragraph 1 the 
different registration categories of NBEs are described: 
 
1) “Biological products not yet marketed at domestic or overseas. 
2) Mono-Clonal Antibody 
3) Gene therapy, somatic cell therapy as well as the preparations. 
4) Allergen products. 
5) Multi component products with bioactivity extracted from, or by fermentation from human 
and / or animal tissues and / or body fluid, 
6) New combination product made from the already marketed biological products. 
7) A product that is marketed already overseas but not yet marketed domestic. 
8) Some of the strains used for preparing of micro-ecological products not yet approved. 
9) Products with not completely same structure with the already marketed products and not 
yet marketed at domestic or overseas (including Amino Acid Locus Mutation / Absence, 
modification caused by a different expression system, deletion, changed interpretation, 
as well as chemical modifications of the product). 
10) Products with a method of preparation different with the already marketed one, (such as 
use of different expression system, host cells).  
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11) Products first time made with DNA recombination technology (such as use of 
recombination technology to replace the synthesis technology, tissue extraction or 
fermentation technology). 
12) Products transformed from non-injection into injection, or topical use into systemic use, 
and not yet marketed at domestic or overseas. 
13) The marketed products with a change in dosage form but no change in route of 
administration. 
14) Products with a change in route of administration (excluding the above Category 12). 
15) Biological products admitted with National Standards.” 
 
The documents which are requested for an MAA dossier of an NBE are described in 
paragraph II “Application dossier item” of annex 3 of the drug registration regulation annex 3 
"Registration Categories and Application Information Items Requirements of Biological 
Products" X41X, X43X are divided to the following five parts: 
a) Summary information  
b) Pharmaceutical Study Information  
c) Pharmacology and Toxicology Study Information 
d) Clinical Study Information  
e) Others  
 
The detailed list of documents required within these five parts is provided in appendix 13 
(“ XAPPENDIX 13 X: Dossier requirements for an NBE in China“). 
 
As for the NCE the dossier requirements in principle are quite similar to the requirements for 
ICH region, only the administrative part of the dossier where local documents are requested 
differs. 
 
For further details the table of the requirement of application information is provided in 
appendix 14 (“ XAPPENDIX 14 X: Table of application information items for China”). 
Since November 2009 China is classified as climatic zone IVB which needs to be taken into 
consideration regarding the stability data needed for a new MAA. 
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3.6.3 39BRegistration Procedures 
According to the current information there are two different registration procedures available 
in China.  
On the one hand there is the standard review procedure which is applicable for most of the 
NDAs. The review time for an NDA for an NCE takes approx. 13.5 months whereas the NDA 
for an NBE takes approx. 24 months. During the standard review procedure it is not possible 
to have any consultation of CDE in order to discuss topics of the NDA procedure. Also rolling 
submission of the NDA dossier is not possible for the standard review procedure. 
The second registration procedure which is established by SFDA as of January 1st, 2009 is 
the special review procedure. This new procedure is applicable for NCEs or NBEs which are 
not yet approved in any market, for new medicinal products which are used for treatment of 
AIDS, malignant tumor and/or rare disease and have obvious clinical therapeutically 
advantages and for new medicinal products which treat diseases for which there is no 
effective therapy. The review time for an NDA under this special review procedure takes 
approx. 12 months. Another advantage of the special review procedure is that a rolling 
submission is permitted (e.g. safety, stability, CMC development, etc.) and also pre- and in-
process consultation at CDE during the NDA review process is allowed. The advantage of 
special review procedure will be lost once the drug is approved in any country worldwide. 
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Please find enclosed a summary table comparing the two different review procedures: 
 Standard Review Procedure Special Review Procedure 
(SFDA issued in Jan. 2009) 
Scope Most applications go through 
this Standard Review 
Procedure 
1. NCE or new bio-product 
which are not yet 
approved in any market 
2. New drugs which are 
used for treatment of 
AIDS, malignant tumor 
and/or rare disease and 
have obvious clinical 
therapeutically 
advantages 
3. New drugs which treat 
diseases for which there 
is no effective therapy 
Timeline 
(Chemical Drugs) 
IND: 10.5 months 
NDA: 13.5 months 
IND/Clinical Trial Application 
(CTA): 8 – 9 months 
NDA: 12 months 
Rolling 
Submission 
Not allowed Allowed (e.g. safety, stability, 
CMC development, etc.) 
CDE Consultation No Pre- & In-process 
consultation is permitted 
 
 
 80
3.7 16B razil 
3.7.1 40BDossier Format 
The format and content of an MAA of a medicinal product, which is called Product 
Registration Dossier (PRD) in Brazil is defined by the type of product. 
There exists respective format and content regulations for the following categories of 
medicinal products: 
• New products 
• Similar products 
• Generic products 
• Herbal medicinal products 
• Biological and blood products 
• Allergenic products 
• Specific medicinal products 
• Medicinal products exempt from registration 
• Dynamized medicinal products 
The following product types are regarded as biological product and have to comply with the 
guidelines in Resolution RDC 315 of 26-Oct-2005F44F: 
• Vaccines 
• Hyperimmune serums 
• Blood by products 
• Biomedicines (products obtained from biological fluids or animal tissues and obtained by 
biotechnological processes) 
• Probiotics 
• Biological products formulated with live; attenuated or inactivated microorganisms 
• MAbs 
• Allergens 
 
                                                
44 Resolution RDC 315 of 26-Oct-2005 - Brazilian Official Gazette of 10/31/05 
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Antibiotics and conjugated estrogens are not regarded as biological products. 
For this dissertation only the types “new products” and “biological products” are relevant and 
the regulatory requirements for these two types of products were analyzed. 
 
There is no special format like the CTD-format (ICH-countries), the ACTD (ASEAN countries) 
or Medicines Registration Form (MRF) (South Africa) for providing the PRD to the Brazilian 
Health Surveillance Agency (ANVISA). It is only important that the whole documentation 
which is required is contained in the PRD and that all documentation is in Portuguese. 
For most types of medicinal products (i.e. NBEs and NCEs) the PRD should contain: 
Administrative documents: 
• Petition formularies 
• Receipt of the payment of the respective fee 
• Copy of the operating license 
• Copy of the inscription of the responsible professional at the professional council 
• Copy of the dossier notification protocol of the pilot batches manufacturing 
• GMP Certificate issued by the ANVISA or copy of the protocol of the inspection request 
• Copy of the operating authorization and of the special operating authorization, if 
applicable 
 
Technical documents, including: 
• Manufacturing and quality control (QC) 
• Labeling 
• Clinical and non-clinical studies (when applicable) 
 
In December 2009 new requirements regarding labeling documentation (RDC 47-2009F45F) 
were published which need to be taken into consideration for a new MAA. 
 
Detailed information which is required for NBEs and NCEs are described in the next section 
(section X3.7.2 X Dossier requirements). 
 
                                                
45 Resolution RDC 47 – 2009 of 08 September 2009 - Novas Regras para Bulas de Medicamentos 
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3.7.2 41BDossier Requirements 
According to the Brazilian law (Resolution RDC 136 of 29-May-2003F46F) a product is regarded 
as a new product if the product is not yet approved for marketing in Brazil by Brazilian Health 
Surveillance Agency (ANVISA). 
The resolution RD 136 X46X defines the following medicinal products as new medicinal products: 
• A product containing a synthetic or semi-synthetic active pharmaceutical ingredient (API) 
(isolated or in association) 
• New pharmaceutical forms, new strengths, new routes of administration and new 
therapeutic indications in Brazil, of a product containing a synthetic or semi-synthetic API. 
This product have to be developed by a pharmaceutical laboratory which is not MAH of 
products containing already the specific API 
• A product that results from: 
• A modification of the pharmacokinetic properties 
• Withdrawal of an API of a product already registered at the ANVISA 
• New salts, isomers, although the corresponding molecular entity has been already 
approved for registration 
• Reference products: A reference product is defined as the innovator product which is a 
new product approved for marketing in Brazil and on which generic applications can make 
reference to. For this innovator product the efficacy and the 
• Safety were proven by appropriate scientific studies approved for marketing in BrazilF47F,F48F. 
 
The dossier requirements for biological products are slightly different than for other new 
medicinal products. 
                                                
46 RESOLUTION - RDC Nº 136 OF MAY 29, 2003 - UNION OFFICIAL GAZETTE OF 02/06/2003 
47 Law 9.787 of 10-Feb-1999 - Brasília, February 10th 1999, 178th of the Independence and 111st of the Republic 
- FERNANDO HENRIQUE CARDOSO; José Serra 
48 Decree 3.961 of 10-Oct-2001 
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The dossier requirements for a new medicinal product in Brazil are quite similar than in other 
countries. Nevertheless there are also some differences compared to e.g. EU, like requesting 
manufacturing batch records for DP, stability data for 30°C/75% rh for long term stability and 
the mandatory request for Phase III clinical data independent of the clinical indication. 
Based on the Brazilian regulations and experiences some administrative documents (like 
CPP, Power of Attorney, GMP certificates, manufacturing authorizations, Authorization for 
the use of trademark) are required for new medicinal products which are imported to Brazil. 
The detailed list of administrative documents required are provided in appendix 15 
(" XAPPENDIX 15 X: Administrative documents are required for new medicinal products which 
are imported to Brazil”). 
For the technical dossier (pharmaceutical/chemical/biological, preclinical and clinical 
documentation) there are in principle similar documents required than in the ICH region. A 
detailed list of required documents for NCEs and NBEs are provided in appendix 16 
(“ XAPPENDIX 16 X: Dossier Requirements (pharmaceutical/chemical/biological, preclinical and 
clinical documentation) for Brazil”). 
 
3.7.3 42BRegistration Procedures 
The applicant submits the registration dossier (PRD) to the ANVISA. The registration dossier 
contains of administrative documents, petition formularies, the technical report, the preclinical 
and clinical studies report and the price report. For products which are manufactured outside 
Brazil and have to be imported the applicant has to inform the ANVISA if the product will be 
imported as bulk product, in primary package or as final product. All documents have to be 
submitted in Portuguese. The official documents, which are CPP and GMP certificates, have 
to be certified and legal translated, besides a notary copy of the original. 
 
UNormal registration procedure 
The PRD is submitted at the “Unidade de Atendimento e Protocolo” (UNIAP) (Services and 
Filing Unit) – subordinated to the Gerência Geral de Gestão Administrativa e Financeira, 
(General Office of Finance and Administration) of the ANVISA.F49 
                                                
49 http://www.anvisa.gov.br- dated 22.07.2009 
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The medicinal product registration approval process is divided into three steps:F50 
• Step I: Filing 
• Preliminary documental analysis at the UNIAP 
• Step II: Review 
• Analysis by the general office of drugs (Gerência-geral de Medicamentos) (GGMED) 
• Step III: Approval 
• Publication of the Product Registration Approval in the Brazilian Official Gazette (Diário 
Oficial da Uniao) (DOU) 
 
UStep I: Filing 
The PRD review process starts when the applicant fills out the petition formularies 
electronically at the ANVISA electronic system. These petition formularies go to the 
respective technical area of the ANVISA for a preliminary analysis until the complete 
application is submitted to UNIAP. 50 
 
Due to internal processes it might happen that the technical area starts with the revision of 
PRD first when the complete application was submitted and the PRD is complete. 
After submission of the PRD to UNIAP the applicant receives a process number which is a 
reference number. This number serves to follow up the registration process and any other 
post-marketing application to be submitted for the medicinal product once it is already 
registered at the ANVISA. After receipt of the process number, the PRD is checked whether 
it complies with the list of documents required by the respective legislation (depending on 
type of product) by making a documental analysis. Should it be recognized that the 
documents are not in line with those documents requested, UNIAP adds an identification of 
“incomplete documentation”. Then the process goes to the respective technical area to be 
revised.F51F  
As soon as the application is sent to the technical area of the ANVISA for a preliminary 
analysis, the applicant can follow the whole review process at the ANVISA’s website. X49X In 
case of incomplete applications these information are placed in a specific site location that 
applicants can easily find out about their status.50 
 
 
 
                                                
50 Private information received from Susan Koepke, Regulatory Affairs Director – Latin America, Merck Serono 
51 Resolution RDC 314 of 09-Dec-2004) 
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The applicant has to access the electronic submission at the ANVISA’s websiteX49X to complete 
the process documentation. The applicant submits “complementation of documents” using 
the appropriate front page. If the “complementation of documents” is not performed on the 
ANVISA website by the applicant before the start of the process review, the application will 
be rejected. 50 
Additionally an application is rejected if the respective fees are not paid by the applicant or 
when the electronic petition number used by the applicant was already utilized for another 
procedure. 50 
 
UStep II: Review 
After finalization of step I (preliminary documental analysis by UNAIP), the MAA is forwarded 
to the ANVISA’s General Offices Divisions or Units which are responsible for the review of 
this respective type of application.50 
For the evaluation process of new medicinal products and biological the responsible division 
is Coordenação de Pesquisa, Ensaios Clínicos, Medicamentos Biológicos e Novos (New 
Medicinal Products, Biologicals, Research and Clinical Studies Division) (GPBEN). This 
division is divided into several units. For biological products the review procedure is 
performed by the Coordenação de Produtos Biológicos e Hemoterápicos (Hemotherapic and 
Biologic Medicinal Products Coordination) (CPBIH) and for synthetic medicinal products the 
evaluation is performed by Coordenação de Medicamentos Sintéticos e Semi-Sintéticos 
(Synthetic and Semi- Synthetic Medicinal Products Coordination) (COMSI). 
ANVISA may request additional data or information during the evaluation process of the 
application. Based on the outcome of the review process the approval is granted or not and 
the results are published at the DOU. 50 
 
The review of the PRD for new medicinal products is applicable for any new medicinal 
product application including herbal medicinal products, blood products and products subject 
to special control (narcotics and related substances). 
The review process consists of the following steps: 50 
The administrative and the technical documents are checked by the GPBEN reviewer. 
In parallel the nonclinical and clinical documentation is sent to ad hoc consultants. They will 
review the nonclinical and clinical documentation and will prepare an expert report with a 
recommendation whether the medicinal product can be approved or not. Today the CATEME 
(Câmara Técnica de Medicamentos), the technical board for medicinal products, which 
previously discussed the PDR, evaluates only overall aspects related to medicinal products.  
The final decision concerning the granting of a MA is made by the GPBEN. 50 
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In case the new medicinal product is a biological product there are some differences 
between the review process compared to the above described process. 50 
For biological products the CPBIH is the responsible unit for checking the administrative and 
technical documentation and the information available regarding the product and/or 
manufacturers. Based on their review CPBIH decides whether a QC analysis of three 
batches has to be performed at the QC laboratory. The documents for these three batches 
are part of the PRD. If the CPBIH comes to the conclusion that the product has to undergo 
the QC analysis they will ask the applicant to send the respective samples to the “Instituto 
National de Controle de Qualidade em Saúde” (National institute of quality control and 
health) (INCQS). The INCQS is a unit of the Fundação Oswaldo Cruz (Oswaldo Cruz 
Foundation (FIOCRUZ)), which is linked to the Ministry of Health (MoH) with the goal to 
implement actions in the scientific and health technology areas. 50 
If the applicant has no samples of the required batches available he has to inform the CPBIH 
and INCQS accordingly and has to provide samples and documentation of three other 
batches. The samples accompanied by the respective documentation have to be provided to 
INCQS within 30 days. The applicant can apply for an extension of the deadline (up to two 
periods) in written format. In case the samples are not provided to INCQS within the timeline 
the application is regarded as rejected. 50 
The review of the quality part of a biological medicinal product application is also within the 
responsibility of INCQS. During the review of the quality party INCQS may request additional 
documents or information from the applicant. In case a request from INCQS arrives, the 
applicant has 30 days to answer the questions. Should an answer to the request not be 
possible within 30 days the applicant can apply for an extension of deadline (in total two 
extensions are possible). If the requests are not answered at all, the application will lead to 
an unapproved MA. 50 
 
During the general review process of the different divisions and units the applicant may 
receive requests for additional data/information in case an issue is not clear in the PRD 
and/or more information is needed. For answering such a request a 30 day period is 
planned. The applicant can apply for an extension of these 30 day period. The application for 
extension may be done by fax or by submitting a request to the ANVISA. 
During this “review process” (step II) the applicant can check the review status of his 
medicinal product on ANVISA’s website section called “Consulta à Situação de Processos”.X49X 
The applicant can ask for meetings with the respective technical staff member in charge of 
the applicant to discuss major issues. 50 
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UStep III: Approval 
After finalization of the review process the GPBEN is responsible for the final decision 
relating to the application. 
If the application is regarded as approvable, the MA will be granted which will be published in 
the DOU. Additionally ANVISA can provide a product registration certificate which is 
available for the applicant upon request. 50 
If the application is regarded as non-approvable, a publication of this refusal/ non-approval is 
made in the DOU. The applicant can apply for another review in case he can assess it 
appropriate. The decision for not approving a PRD of a medicinal product is mainly based on 
a lack of clinical data to support efficacy and safety and a lack of manufacturing and QC data 
to support quality of the final product. 50 
 
A typical publication in DOU of a PRD which was approved contains the following 
information:  
• Name of the company 
• Generic name of the product 
• Trademark (brand name) of the product 
• Therapeutic class 
• Product registration number 
• Marketing presentations 
• Expiry period 
• Process number (the one designated at the submission) 
• Type of approval being granted: New product, Similar product and Generic product 
 
The registration procedure for a new medicinal product (NCEs and NBEs) currently takes 
between 8 and 12 months. This is longer as originally described in the Law 6.360 of 
23.09.1976.52 F  Therein it is mentioned that the registration approval should be granted within 
a period of 90 days from the date of submission unless a request comes up during the review 
process. The formal review period which is established by ANVISA for a new biological 
product is 180 days. 50 
                                                
52 Law nº 6.360, of September 23, 1976 -  
OFFICIAL JOURNAL OF THE UNION OF SEPTEMBER 24, 1976  - Brasilia, September 23, 1976; 155 of 
Independence and 88 of the Republic. - Ernesto Geisel, 
Paulo de Almeida Machadohttp://www.anvisa.gov.br/hotsite/genericos/legis/leis/6360_e.htm 
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UProcedure for priority review/accelerated approval 
ANVISA established the priority review with the publication of the Resolution RDC 28 of 
04.04.2007F53F modified by Resolution RDC 16 of 13.03.2008F54F. 
 
Conditions for priority review: 
• When post registration review is essential to avoid a lack of medicinal products that is the 
only one in the Brazilian market with a specific API, association, strength or 
pharmaceutical form 
• When post registration review is essential to avoid a lack of medicinal product for the 
Unified Health System (SUS) 
• When post registration applications refer to fractioned market presentations as 
established by Decree 5775/2006F55 
• Post registration and registration of medicinal products directed to SUS programs 
including vaccines and exceptional medicinal products 
• Registration of medicinal products used in the prophylaxis or treatment of orphan drug 
diseases (diseases which have no commercial value) or emergent and re-emerging 
diseases 
 
Priority review procedure 
The application has to be made electronically on ANVISA’s internet site at Serviços/ 
Atendimento/ Arrecadação Eletrônicos/ Peticionamento Eletrônico. The applicant has to 
enter his login and password. 
The applicant has additionally to fill in a specific form directly online at the website. 
Additionally the following documents have to be provided: 
• Rationale to support the priority review request (informing the process submission 
number) 
                                                
53  Resolution RDC 28 of 04.04.2007 - RESOLUÇÃO RDC No- 28, DE 4 DE ABRIL DE 2007 - Dispõe sobre a 
priorização da análise técnica de petições, no âmbito da Gerência- Geral de Medicamentos da ANVISA, cuja 
relevância pública se enquadre nos termos desta Resolução. - DIRCEU RAPOSO DE MELLO 
54 Resolution RDC 16 of 13.03.2008 - RESOLUÇÃO Nº 16, DE 13 DE MARÇO DE 2008 Altera a Resolução - 
RDC nº 28, de 4 de abril de 2007, que dispõe sobre a priorização de análise técnica de petições no âmbito da 
Gerência Geral de Medicamentos da ANVISA - DIRCEU RAPOSO DE MELLO 
55 Decree 5775/2006 - DECRETO No- 5.775, DE 10 DE MAIO DE 2006 
Dispõe sobre o fracionamento de medicamentos, dá nova redação aos arts. 2o e 9o 
do Decreto no 74.170, de 10 de junho de 1974, e dá outras providências - Brasília, 10 de maio de 2006; 185o da 
Independência e 118o da República - LUIZ INÁCIO LULA DA SILVA, José Agenor Álvares da Silva 
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• The original fee payment receipt which will be generated during the electronic submission 
as release from payment and is automatically attached to the process during the 
electronic procedure 
• Major documents which support the priority review request like official letters and links to 
regulatory authorities in other countries which support the recognition of the orphan drug 
status 
• Inform the applicant’s e-mail address 
 
All these additional documents have to be submitted as pdf-documents. 
 
The priority review is divided into different phases. First of all, the priority request application 
is reviewed by a Technical Committee of GGMED of the ANVISA which takes a mean time of 
20 days. This technical committee of GGMED will check the compliance of the request 
according to Resolution-RDC-28/2007 X53X. They will issue a report to the GGMED General 
Manager who will then send the application for priority review in case the criteria are fulfilled. 
After ANVISA has received the "green light" for priority review from GGMED General 
Manager, they have 75 days period time for review the priority request applications 
concerning medicinal products. This time is only applicable if no query is written. As soon as 
a query is issued, the whole review will take longer than the 75 days. 
The applicant can follow the review status at the homepage of ANVISA under: 
http://www.anvisa.gov.br/servicos/consulta_documentos.htm.F56 
                                                
56 http://www.anvisa.gov.br/servicos/consulta_documentos.htm - dated 22.07.2009 
 90
4 3BComparison of the Pharmaceutical Legislation and 
Regulatory Requirements for a Marketing Authorization 
Application of a New Biological Entity and a New 
Chemical Entity within the Different Countries and 
Regions 
As already discussed during the analysis of the pharmaceutical legislation and regulatory 
requirements for NCEs and NBEs in the different regions and countries it is obvious that the 
requirements for an MAA dossier for an NBE or NCE are more or less similar or even 
identical between the different regions and countries. The basis for the requirements 
(content) for an MAA dossier of an NBE or NCE is certainly set and developed by ICH. 
Based on the ICH requirements, a lot of non-ICH-countries adapt their requirements what 
have to be contained in an MAA dossier for an NBE or NCE to the ICH requirements (please 
refer to NtA Vol. 2). 
The CTD format which was developed in order to have one global format for submissions in 
the ICH region is also used and accepted in quite a lot of non-ICH-countries.  
In some non-ICH-countries there are no special requirements on a dossier format. They 
accept every dossier format as long as the required documents are contained in the dossier 
(examples are countries in LA like Argentina, Colombia or Brazil). Nevertheless, there are 
also countries which have their own format and request to submit the dossiers in their special 
format. Examples for these are e.g. South Africa, which uses the so-called MRF or the 
ASEAN countries which even developed their own ACTD format. 
 
Countries which are very “near” to the EU (mainly countries in SEE) or even have the 
intention to become EU MS in the future have implemented the EU guidelines, regulations 
and requirements in their national law. Countries like Serbia or the CADREAC country 
Croatia therefore request the original EU dossier. 
 
Based on experiences during the last years it can be said that a lot of non-ICH-countries 
have very similar requirements as the EU.  
If the EU dossier for an MAA of an NBE or NCE is submitted in non-ICH-countries the 
chance is very high to obtain approval. 
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Nevertheless, there is on the other hand a quite high risk to submit the EU dossier in the 
non-ICH-countries due to confidentiality and IP issues. One issue in the non-ICH-countries is 
the fact that the applicant is often not absolutely sure whether the dossier submitted is kept 
confidential and never knows who might receive the dossier or a copy of the dossier. The risk 
is especially very high in countries where no patent protection or dossier protection is 
available and where a very strong generic industry, mainly local generic industry, is located. 
This risk is especially applicable for the pharmaceutical-chemical-biological part of the 
dossier, i.e. Module 2.3 QOS and Module 3. The differences between dossier and dossier 
requirements for NCEs and NBEs are mainly within the CMC part of the dossier. The main 
differences between NCEs and NBEs occur in the DS part and the appendices. For detailed 
information please refer to the attached table in appendix 3 (“ XAPPENDIX 3 X: Differences NBE 
and NCE with regard to Module 2 and 3”). X12X The NBE is defined not only by the molecule 
itself but also by the manufacturing process. Based on this, the requirements on the CMC 
documentation which needs to be provided are higher and more complex than the 
documentation for NCEs. 
Due to this confidentiality issue most of the companies submit in the non-ICH-countries a 
dossier - a so-called international dossier - with a reduced content especially regarding the 
CMC part where the highly confidential information is located. This is even more important 
for NBEs as within the CMC part the whole molecule, characterization and manufacturing 
process is described very detailed. It is advisable to reduce the CMC part for an MAA for an 
NBE and an NCE and to eliminate the highly confidential information in order to avoid that 
generic companies can easily copy the product.  
Therefore as mentioned before a lot of companies create an international dossier which 
contains less information within the DS part and the appendices of the dossier. For an NBE 
especially the sections 3.2.S.2 (3.2.S.2.2 Description of Manufacturing Process and Process 
Controls, 3.2.S.2.3 Control of Materials, 3.2.S.2.5 Process Validation and/or Evaluation, 
3.2.S.2.6 Manufacturing Process Development), 3.2.S.3. Characterization (3.2.S.3.1 
Elucidation of Structure and other Characteristics) and 3.2.A.2 Adventitious Agents Safety 
Evaluation are often shortened and the highly confidential information is reduced or 
completely deleted. For the MAA dossier of an NCE it is also advisable to check whether 
some sections in the CMC part can be reduced in order to avoid providing highly confidential 
information to every authority within the world. 
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It is important that the non-ICH-countries receive the complete dossier which means that all 
sections of the ICH dossier should be contained even in the international dossier. 
If an applicant just deletes some sections of the ICH dossier and submit an “incomplete” 
dossier the risk is very high that the authorities will ask for the missing sections. Therefore it 
is strongly recommended that only the content in some sections (especially in sections 
3.2.S.2 and 3.2.S.3) should be reduced, so that there is a complete dossier only with 
reduced content submitted to the authority. This approach minimizes the hazard that the 
authorities recognize that some information are missing and will maybe not ask for additional 
information. One possibility to make these changes within the dossier is the creation of an 
MAA dossier for an NBE or NCE with the determination of a high granularity for documents in 
order to be able to exchange some documents or parts of documents quite easily for the 
international countries (e.g. in order to avoid to provide highly confidential information to 
these countries). This might reduce the workload for the people writing CMC documentation 
if high granularity documents are available (e.g. for each section and subsection one 
separate document is available), so that for the non-ICH countries only some documents can 
be used without making visual that a section or information is missing. 
Countries within the non-ICH region where the EU dossier needs to be submitted are AUS, 
Croatia (as CADREAC country), Israel, South Africa, South Korea and CH. Based on my 
experiences in these countries there is no chance to submit only a reduced dossier as they 
will ask for the missing information. AUS, Croatia and CH are not seen as critical countries 
as they have some IP rights and patent protection laws in place. In countries like Israel, 
South Africa and South Korea there is the possibility to ask the authorities to sign a 
confidentiality agreement for the dossier submitted. This might be useful for some applicants 
even they cannot be 100% sure whether the authorities really keep the dossier confidential. 
 
There are also some non-ICH-countries (like China, Taiwan, Mexico) which request more 
information and data for CMC part of the dossier as normally requested in the EU. China 
often requests more detailed information for NBEs (like details about the structure of the 
molecule, the vector (in case a vector is used), the manufacturing process or the 
characterization). Taiwan and Mexico request batch records for at least one batch which are 
normally not submitted to authorities as these are also confidential information. Mexico also 
requests some additional raw data (batch records of three batches for each manufacturer 
combined with corresponding Certificates of Analysis (CoAs) for DS, DP as well as for the 
excipients and chromatograms) in order to check the dossier very accurate. Without 
submission of these information the dossier is seen as incomplete and will not be evaluated. 
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The main focus for most of the regions outside ICH is laid done in the CMC section of the 
dossier as this is their main field of expertise. Therefore it is highly recommended that the 
CMC section should be as complete and comprehensive as possible to avoid questions. 
Based on the experiences most of the questions from non-ICH-countries will come back for 
this section of the dossier whereas for nonclinical section normally no or only very few 
questions are raised. For the clinical part of the dossier it depends on the country whether 
they have experts on the field or not whether questions are raised. There are countries within 
non-ICH-countries like AUS, CH or Singapore which are very experienced and have a lot of 
experts for the clinical section. They will definitely raise also questions for the clinical section 
of the dossier. 
As some non-ICH-countries do not have so many expertise in the nonclinical and clinical field 
it is very important for them to receive a CPP from a benchmarked country like USA, EU, JP, 
CH, AUS or Canada. The CPP proofs that a benchmarked country has accessed the dossier 
and has granted based on their scientific evaluation the MA for the medicinal product. 
 
The requirements within the nonclinical section (Module 4) and clinical section (Module 5) of 
the dossier are mainly identical within the different countries and regions.  
In some non-ICH-countries it is sufficient to submit the Module 2 documents as nonclinical 
and clinical information (i.e. nonclinical and clinical overview as well as nonclinical and 
clinical summary). Modules 4 and 5 are sometimes not requested (e.g. in some LA countries) 
or it is sufficient to submit publications of the studies presented in Module 4 and 5. The study 
reports presented in Modules 4 and 5 are often not requested for these countries. As 
mentioned for some non-ICH-countries it is important to receive some publications of the 
clinical studies. This proofs that the studies are finalized and that the results of the studies 
were presented to scientific community and were made published. This is for countries which 
do not have the expertise and man power to evaluate the clinical section of a dossier (all 
study reports) by themselves very important. Some countries will grant an approval for some 
indications only after the study results are published in a publication (e.g. Malaysia). 
In the other non-ICH-countries (e.g. the benchmarked countries like AUS, Canada and CH 
as well as SEE, some Asian countries or LA countries) it is recommended to submit the 
identical documentation for nonclinical and clinical part as in the EU. For the LA countries 
some parts of the dossier or even the whole dossier needs to be submitted in Spanish (for 
nearly all LA countries) or in Portuguese (e.g. for Brazil) to the authorities.  
Other difference between the requirements within the different countries and regions are with 
regard to Module 1 of the MAA dossier. Module 1 differs partly heavily dependent on the 
country or region. But some documents of Module 1 are required in nearly every country. An 
example for a document of Module 1 which is requested at least in all non-ICH-countries 
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except AUS, Canada and CH are the CPP. Other administrative documents like GMP 
certificates of manufacturer or CoAs are also required in most of the countries, at least in 
non-ICH. Labeling documents (SPC, PIL, mock-ups) are requested in every country 
worldwide within Module 1. Some countries in the non-ICH-region do not have a 
differentiation between a SPC (labeling information for health care professionals) and a PIL 
(labeling document for patients). They only have combined information which is intended to 
be used by health care professionals as well as by patients. For the creation of such a 
labeling document it is important that all essential information for the health care 
professionals are included as well as the document is in an intelligible language for the 
patients. 
 
To sum up the differences between the requirements between the different regions and 
countries are mainly focused on Module 1 requirements. The dossier itself (Modules 2 – 5) is 
nearly identical for all regions. As mentioned above an international dossier with reduced 
content of CMC information should be created to avoid difficulties regarding confidentiality 
and/or IP issues. For the nonclinical and clinical section it is often enough to provide the 
Module 2 documents to some non-ICH-countries. This should be checked with the country 
before providing the dossier. For the clinical section it is advisable to provide some 
publications in addition or instead of the full study reports to the non-ICH-countries.
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Comparison of different registration procedures in the different countries and pro/con arguments for each procedure: 
 
Country/Region Procedure Pro Con 
EU National procedure * might be useful for a medicinal product 
which is specifically intended only for one EU 
MS 
* not possible if product shall be 
registered in more than one EU MS 
* not possible for products which fall 
under Regulation 726/2004 
MRP 
 
 
* can be used for medicinal products which 
already have a MA in at least one EU MS 
* “recognition” procedure – RMS gives an 
opinion and CMS recognized it (no new 
evaluation of the dossier by CMS)  
* updated AR from RMS has to be prepared 
within 90 days of receipt of the valid 
application 
* each CMS has the obligation to recognize 
the MA granted by the RMS within a period of 
90 days 
* not possible for products which fall 
under Regulation 726/2004 
* often not really a “recognition” 
procedure - CMS does not accept the 
recommendation of RMS 
* in total quite long registration time 
(from RMS until national MAs in CMS 
are granted) 
* quite long registration time for initial 
MA in RMS (210 days) 
* national phase in CMS takes 
sometimes a lot of time (several 
months) (depending on the country) 
* different MAHs in the different EU MS 
DCP * procedure faster than MRP 
* the DCP is open for medicinal products 
which are not yet approved in any EU MS at 
the time of application 
* submission of the MAA dossier is done to 
the RMS and the CMSs in parallel  
* AR from RMS is prepared in consultation 
* for medicinal product with no MA in an 
EU MS the DCP can be used 
alternatively 
* often not really a “recognition” 
procedure - CMS does not accept the 
recommendation of RMS 
* initial MA not issued by RMS alone 
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Country/Region Procedure Pro Con 
with the CMSs 
* this AR is the basis for the RMS and CMSs 
to agree the terms for the MA 
* RMS,CMS phase can be quite short (120 
days) 
* quite long registration time (210 days) 
if after phase I (120 days) no agreement 
is reached 
* sometimes long national phases 
(depending on the country) 
* different MAHs in the different EU MS 
CP * scientific evaluation done by CHMP (in 
which representatives of each EU MS are in) 
* one scientific opinion valid for the EU and 
Norway, Iceland and Liechtenstein 
* one registration for EU and Norway, 
Liechtenstein and Iceland 
* is optional for other innovative new 
medicinal products 
* the MAAs have to be submitted directly to 
the EMA in London  
* identical MA with identical label throughout 
EU 
* only one MAH for all countries 
* the CP is compulsory for medicinal 
products derived from biotechnology 
and for new active substances for 
certain therapeutic areas like acquired 
immune deficiency syndrome (AIDS), 
cancer or viral diseases  
* identical MA with identical label 
throughout EU 
* if the CHMP opinion is negative no 
registration in EU and European 
Economic Area (EEA) 
* long registration time (246 days 
without clock-stops) (210 days scientific 
evaluation, 36 days for the preparation 
of the annexes to the Commission 
Decision plus 30 days) 
 Accelerated assessment 
procedure 
 
* for medicinal products of major therapeutic 
interest, and procedures for obtaining 
temporary authorizations subject to certain 
annually reviewable conditions  
* request for accelerated assessment 
procedure is submitted to CHMP and CHMP 
decide about the acceptance for accelerated 
* cannot be used for all types of 
products  
* only for medicinal products of major 
therapeutic interest, and procedures for 
obtaining temporary authorizations 
subject to certain annually reviewable 
conditions  
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Country/Region Procedure Pro Con 
assessment procedure 
* scientific evaluation done by CHMP in 150 
days 
* At any time during the MAA, the 
CHMP may decide to continue the 
assessment under standard CP 
timelines (210 days) and to withdraw 
the granting of the accelerated 
assessment procedure. This might 
happen in case the CHMP is the 
opinion that it is no longer appropriate 
to conduct an accelerated assessment 
USA Full application * valid for all NDAs and BLAs 
* quite short review time (10 months (at least 
for 90 % of NDAs and BLAs)) 
* long review times (10% of BLAs and 
NDAs needs more review time then 10 
months) 
Accelerated Approval * applicable only for drugs or biologics 
products which provides meaningful 
therapeutic benefit…over existing treatments  
*applicable for the treatment of a serious or 
life-threatening disease 
* the procedure allows the approval based on 
clinical trials using “a surrogate endpoint that 
is reasonable likely… to predict clinical 
benefit.” instead of using standard outcome 
measures like survival or disease progression
* can be used for drugs for which the use 
could be considered safe and effective only 
under set restrictions which could include 
limited prescribing or dispensing 
* cannot be used for all types of 
products  
* only applicable for serious or life-
threatening disease 
 
Priority Review * can be used for medicinal products which 
are intended to address unmet medical need  
* timing of the application (NDA/BLA) can be 
* the priority review process starts only 
when a manufacturer officially submits 
an NDA/BLA 
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Country/Region Procedure Pro Con 
shortened from 10 months to 6 months  * does not have any influence on the 
timing or content of steps taken during 
the drug development or the testing of 
safety and efficacy 
Fast track mechanism * is designed for certain products (product 
must concern a serious or life-threatening 
condition and has potential to address an 
unmet medical need) 
* close interaction with FDA – “discuss with 
FDA development plans and strategies 
before the official submission of the 
NDA/BLA” 
* issues like elements of clinical study 
designs and presentation whose absence at 
NDA/BLA can lead to a delay in approval 
decision of NDA/BLA could be clarified earlier 
with FDA 
* shortening approval time (6 months instead 
of 10 months) 
* opportunity of a rolling submission, i.e. to 
submit sections of an NDA/BLA to FDA as 
they are ready, rather than the standard 
requirement to submit a complete application 
at one time 
* only applicable for serious or life-
threatening disease which have 
potential to address unmet medical 
need 
* cannot be used for all types of 
products 
* similar interactions to any sponsor 
who asks for FDA consultation 
throughout the development phases of 
a medicinal product 
 
Croatia National procedure *only applicable for products which are 
authorized in EU via national procedure 
* not mandatorily the identical dossier as 
submitted in EU has to be submitted 
* no real option as Croatian authority 
accept national procedure only for 
products which are authorized in EU via 
national procedure 
* complete evaluation of the dossier is 
done 
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Country/Region Procedure Pro Con 
* a lot of questions especially for CMC 
expected as complete evaluation is 
done 
CADREA procedure MRP * applicable for all products authorized in EU 
via MRP 
* CADREAC procedure can be done in 
parallel or after finalization of MRP 
* less or even no questions as Croatia 
recognized the EU procedure outcome 
* no complete evaluation of dossier is done 
(ARs are therefore very important for 
evaluation) 
* identical dossier as submitted for MRP 
has to be submitted (confidentiality!) 
 
CADREA procedure DCP * applicable for all products authorized in EU 
via DCP 
* CADREAC procedure can be done in 
parallel or after finalization of DCP 
* less or even no questions as Croatia 
recognized the EU procedure outcome 
* identical dossier as submitted for DCP 
has to be submitted (confidentiality!) 
 
CADREA procedure CP * applicable for all products authorized in EU 
via CP 
* less or even no questions as Croatia 
recognized the EU procedure outcome 
* identical dossier as submitted for CP 
has to be submitted (confidentiality!) 
 
Singapore Full evaluation route * is applicable for MAAs of NCEs and NBEs if 
no other DRA has approved the medicinal 
product as defined by WHO at the time of 
submission 
* is applicable for innovative products 
containing an NBE or NCE (NDA-1) 
* ICH CTD as well as A-CTD dossiers are 
* complete ICH dossier must be 
submitted for evaluation  
(confidentiality!) 
* long review time (270 working days) 
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Country/Region Procedure Pro Con 
acceptable 
Abridged evaluation route * applies for MAAs of NCEs or NBEs if at 
least one DRA has approved the medicinal 
product before submission of the dossier in 
Singapore 
* all facts regarding product quality and 
direction of use (including dosing regimen(s), 
indication(s) and patient group(s)) should be 
the same as approved by the competent DRA 
in the reference country 
* not complete ICH dossier is requested 
(regarding nonclinical less information are 
needed) (complete CMC part, nonclinical 
overview and clinical data package (clinical 
overview, summaries of clinical efficacy and 
clinical safety, synopsis of relevant studies 
(mainly Phase II and III), a tabular listing of 
the clinical development program and study 
reports of pivotal studies are requested)) 
 
* only abridged evaluation is performed 
* this abridged evaluation of dossier which 
takes 180 working days 
* in case of a life-saving drug the applicant 
can ask for priority review if there is unmet 
medical need. 
* all facts regarding product quality and 
direction of use (including dosing 
regimen(s), indication(s) and patient 
group(s)) should be the same as 
approved by the competent DRA in the 
reference country 
 
 
* for CMC and clinical part of the 
dossier the complete documentation is 
requested 
 
 
 
 
 
* only abridged evaluation is performed 
 
* this abridged evaluation of dossier 
which takes 180 working days 
* no guarantee that HAS will accept the 
priority review for the life-saving drug 
Verification route * can only be used if the medicinal product is 
already approved by two benchmarked DRAs 
(so called reference authorities) and if ARs 
* is only possible for MAAs of NCEs 
* is not possible for MAAs of NBEs due 
to the complexity of NBEs 
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from these two DRAs are available  
* these benchmarked DRAs or reference 
authorities are FDA (US), EMA (EU), TGA 
(AUS), MHRA (UK) and Health Canada 
(Canada). 
* the assessment using the verification route 
is based on the full ARs of the reference 
DRAs. Therefore the complete quality and 
clinical ARs are requested to enable the 
effective verification process 
* very fast evaluation time (only 60 working 
days) 
* the verification route dossier has to be 
submitted at least 3 years from the date 
of approval by the chosen primary 
reference authority 
* submission of all authority 
correspondence, Answers to 
Objections, ARs needed 
(confidentiality!) 
 
China Standard review procedure * applicable for most of the NDAs 
 
* long review times especially for NBEs 
(The review time for an NDA for an 
NCE takes approx. 13.5 months 
whereas the NDA for an NBE takes 
approx. 24 months)  
* no consultation of CDE in order to 
discuss topics of the NDA procedure 
possible during the procedure 
* rolling submission of the NDA dossier 
is not possible for the standard review 
procedure 
Special review procedure * applicable for NCEs or NBEs under certain 
circumstances: 
• which are not yet approved in any 
market 
• for new medicinal products which are 
used for treatment of AIDS, malignant 
* the advantage of special review 
procedure will be lost once the drug is 
approved in any country worldwide 
* usage in practical not really as China 
might normally not be the first country 
who issues the MA 
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Country/Region Procedure Pro Con 
tumor and/or rare disease  
• have obvious clinical therapeutically 
advantages and for new medicinal 
products which treat diseases for which 
there is no effective therapy  
* the review time for an NDA under this 
special review procedure takes approx. 12 
months 
* rolling submission is permitted (e.g. safety, 
stability, CMC development, etc.)  
* pre- and in-process consultation at CDE 
during the NDA review process is permitted  
* review time only 1.5 months shorter 
than standard review procedure 
 
Brazil Normal registration 
procedure 
* according to law the registration approval 
should be granted within a period of 90 days 
from the date of filing unless a request arises 
during the review process 
* the formal review period which is 
established by ANVISA for a new biological 
product is 180 days 
* in practice the registration times are 
quite long (between 8 and 12 months) 
* the formal review period for NBE 
which is established by ANVISA is 180 
days 
 
Procedure for priority 
review/accelerated 
approval 
* short review time (75 or 90 days) but only if 
no inquiry is issued 
 
* longer review time as soon as inquiry 
is issued 
* only applicable under very strict 
conditions (like medicinal products used 
in the prophylaxis or treatment of 
neglected diseases (orphan drugs) or 
emergent and re-emerging diseases) 
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Short evaluation of different registration procedures in different countries on the 
examples of EU, Croatia and China: 
 
EU:  
In EU it depends on the type of product which procedure can be used. 
 
CP: 
In the CP the MAA dossier will be submitted to EMA in London. There is no choice to submit 
only the MAA for several EU MSs. 
For the coordination of the procedure the EMA adopts one CHMP member as Rapporteur as 
well as a second CHMP member as Co-Rapporteur. The applicant can make proposals for 
the choice of the Rapporteur and Co-Rapporteur, but finally the CHMP will decide who will be 
Rapporteur and Co-Rapporteur. 
In comparison to MRP and DCP only one MAH is used within the CP (MAH identical in all 
MSs). This MAH is also only mentioned on the folding box of the medicinal product within the 
EU. 
In addition the complete labeling (SPC, PIL, packaging materials) are content wise identical 
but have to be translated in all 23 national languages (including Norway and Iceland). 
National requirements (like national contact point, package size) can be mentioned simply in 
the so-called “blue- box”. 
Co-promotion is not possible for CP authorized product but as mentioned before in the “blue-
box” the national contact person can be mentioned. 
If co-marketing is intended a new registration is necessary. As Co-marketing partner for a CP 
authorized product a partner is needed who is represented in all 25 EU MSs. This can be 
seen as discrimination of middle-sized businesses as they often are not represented in all 25 
MSs. 
The basis fee for a CP application for which a full dossier needs to be presented are 254100 
€ (25500 € fee for each additional strength or pharmaceutical form including one 
presentation, submitted at the same time as the initial application for authorization, 6400 € for 
each additional presentation of the same strength and pharmaceutical form, submitted at the 
same time as the initial application for authorization). In case a CP application for which a full 
dossier needs not be presented the fees is only 164200 €. The registration costs for the CP 
are therefore higher compared to MRP and DCP. 
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Another issue at the CP is the danger with the trade name. For a CP it is mandatory that the 
applicant has a trademark which is accepted in all 25 EU MSs. For this it is absolutely 
advisable to make a “trademark-check” at the EMA (according to drug law). In addition it is 
mandatory that the applicant may ask for protection of the trademark at the European 
trademark office in Alicante. 
Until Q4, 2005 (the date of submission is crucial for the application of the data protection 
periods) the data protection of the dossier are generally 10 years from first MA onwards for 
all products authorized through CP or ex-concertation procedure. At the MRP/DCP the data 
protection varies between 6 and 10 years depending on the EU MSs (10 years for national 
MAs granted by the following EU MSs: Belgium, Germany, France, Italy, the Netherlands, 
Sweden, UK and Luxemburg; 6 years for national MAs granted by the following EU MSs: 
Austria, Denmark, Finland, Ireland, Portugal, Spain, Greece, Poland, Czech Republic, 
Hungary, Lithuania, Latvia, Slovenia, Slovakia, Malta, Estonia, Cyprus and also Norway, 
Liechtenstein and Iceland). 
The new protection periods of ‘8+2+1’ are applicable only for reference medicinal products 
for which the MAA has been submitted as of 30 October 2005 for MRP, DCP and national 
procedures and as of 20 November 2005 for CP according to the revised Community 
Legislation. Directive 2004/27/EC X4X, amending Directive 2001/83/EC X3X, and Regulation (EC) 
No 726/2004 X2X have introduced new rules concerning the periods, from the initial MA of the 
reference product, during which generic product applicants cannot rely on the dossier of the 
reference product for the purposes of submitting an application, obtaining MA or placing the 
product on the market. 
Generic companies are allowed to submit their MAAs (which leads to the granting of a MA) 
after 8 years - this period is called “data exclusivity” but the launch of the product is first 
allowed after 10 years – this period of 10 years is called “market exclusivity”.  These periods 
are applicable for national procedures, MRP, DCP and CP authorized products. 
The applicant has the possibility to extend the market exclusivity period for 1 additional year 
(‘8+2+1’) if within the first 8 years an indication enlargement or a new indication is granted 
via CP, MRP or DCP. It is essential that the MA of the new therapeutic indication within the 
first 8 years represents a significant clinical benefit in comparison with the existing therapies. 
The additional year of market protection is applicable for the global MA for the reference 
medicinal product. Generic products, with or without the new therapeutic indication, may not 
be placed on the market until expiry of the eleventh year. 
The big advantage for the CP is that at the end of the evaluation phase one scientific opinion 
from the all EU MSs and finally one commission decision which is valid for EU, Norway, 
Iceland and Liechtenstein is received.  
 105
In case a negative CHMP opinion and as consequence a negative commission decision is 
made the applicant has the possibility to ask for an appeal procedure. During the appeal a 
new Rapporteur and Co-Rapporteur out of the CHMP members are appointed. The newly 
selected Rapporteur and Co-Rapporteur evaluate the same dossier as in the original 
procedure again. It is not allowed to submit new data during the appeal procedure. At the 
end of the appeal procedure a CHMP opinion and a commission decision is issued. This is 
then the final decision. There is not the possibility to make an appeal again. 
In case in the CP a negative decision is made this is associated with a prohibition to market 
the medicinal product in the complete EU. 
Another possibility is the opportunity to withdraw the MAA as soon as a negative decision 
threat. The applicant has then the possibility to submit a new MAA after updating the dossier 
via CP or maybe (depending on the product) via MRP or DCP.  
In the MRP and DCP the applicant can choose the EU MSs where he will apply for a 
registration. 
Another difference between the CP and DCP and MRP is the decision about the prescribing 
status (“prescription only”) of a medicinal product. During the CP it is decided whether a 
medicinal product is prescription only or not. In comparison, during the MRP and DCP the 
prescription status is not decided as this decision is made by each MS nationally. This 
means that a harmonization of the prescribing status of a medicinal product during an MRP 
or DCP is nearly impossible. In addition there is only in Germany the § 49 German Drug Law 
("Arzneimittelgesetz") (AMG) with an automatically obligation for medicinal product as 
prescribing drugs. 
 
 
MRP or DCP: 
The MRP can be used for MAAs of new as well as well-known substances. In general the 
applicant applies for an MAA in one particular MS - the so-called RMS. The national MAA in 
the RMS should take 210 days. After the granting of the MA in the RMS, the MRP can be 
started. The applicant will submit the MAA dossier to the selected CMSs (the applicant can 
choose the CMSs, there is no obligation to file the MA in all EU MSs). As basis for the mutual 
recognition of the CMSs the AR of the RMS is used. The RMS acts as mediator during the 
MRP. 
The DCP offers an alternative to the MRP and applies where a medicinal product has not 
previously been granted a MA at the time of application. The main procedural difference 
between the MRP and DCP is that for a DCP an initial MA is not issued by the RMS. Instead 
of this, the CMSs participate early in the registration process by contributing to the 
preparation of the AR by the RMS. This AR builds the basis for the RMS and CMSs (the 
applicant can choose the CMSs, there is no obligation to go to all EU MSs) to agree the 
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terms for authorization. Compared to the MRP also the timelines are different. The applicant 
submits the MAA to the RMS. By day 70 the RMS forwards the preliminary AR, SPC, PIL 
and labeling to the CMSs and to the applicant. Then the RMS and CMSs have time until day 
105 to reach a consensus by updating the preliminary AR to become final AR, SPC, PL and 
labeling. Then the procedure is closed. In case no consensus between RMS and CMSs is 
reached at day 105 it might be possible to get a consensus until day 120 after resolution of 
minor points by updating the preliminary AR to become final AR, SPC, PIL and labeling. 
If no consensus is possible at all the RMS will stop the clock at day 105 and ask the 
applicant to answer the open questions within three months. After valid submission of the 
answers to the questions from RMS and CMSs the RMS will start the clock at day 106 again. 
Then the RMS will update the preliminary AR to prepare a draft AR, draft SPC, draft PIL and 
labeling and will forward the documents to CMS. If by day 120 consensus is reached the 
procedure will be closed. After the closure of the procedure the CMSs have 30 day period to 
grant the MA (subject to acceptable translations). 
One advantage of the MRP or DCP is that the applicant can choose the RMS. Also the 
CMSs can be chosen and there is no obligation to register the product in all 25 EU MSs. 
Therefore the procedure is often less complex regarding the numbers of translations as 
market potential is often seen only in a few MSs and only in these MSs submissions are then 
made. Based on this also the costs for the procedure are cheaper compared to CP. 
The MRP or DCP can be repeated until all 25 EU MS are included. There is also the 
possibility to withdraw certain MSs from the MRP or DCP without withdrawal of the whole 
procedure. Within a MRP or DCP at maximum 25 national registrations in 25 EU MSs are 
possible. The SPC is identical in all EU MSs whereas the PIL is not harmonized (i.e. PIL can 
differ from MS to MS due to national requirements). Also as mentioned before the 
prescription status is not regulated through the MRP. 
In addition at a MRP or DCP different MAHs are possible (from 1 to 25 different MAHs). Also 
co-promotion and co-marketing are possible without any issue for MRP or DCP products. In 
addition there is the possibility to transfer MAs e.g. to license holders. 
For products authorized via MRP or DCP also different trademarks are possible. Through the 
usage of different trademarks within the different countries in the EU a better protection 
against parallel- and re-import is given. 
A disadvantage for the MRP or DCP in the past (until Q4, 2005) was the fact that the data 
protection in the different EU/EEA states are between 6 and 10 years. The time of data 
protection starts with the first grant of a MA in the EU. In some EU MSs the data protection 
takes only 6 years (e.g. Denmark) whereas in other EU MSs (e.g. Germany) the data 
projection takes 10 years. Therefore this is very heterogeneous and not harmonized. 
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Meanwhile this disadvantage is compensated as the general protection period ‘8+2+1’ is 
homogenous for MRP, DCP and CP since October 2005. 
In case the applicant has to choose between CP and MRP/DCP I would recommend using 
the MRP/DCP. 
The MRP or DCP offers the applicant more flexibility and more options (please refer to 
advantages and disadvantages mentioned above). 
The applicant has the opportunity to choose the RMS. It is recommended to choose a RMS 
which have a good and profound scientific standing for the specific indication in the EU and 
can defend the product during the MRP or DCP. Another important aspect for the choice of a 
RMS is the fact how fast the registration times for the MRP or DCP is to be able to start the 
MRP or go on with DCP as fast as possible. Another factor might be the fact to choose the 
country as RMS which needs the medicinal product mostly or choose the country which 
might have the biggest market potential (biggest business volume). The advantage of the 
MRP is the fact that the applicant can market the product already in the RMS after the 
approval even the MRP is still ongoing. The import to other countries is also possible. 
 
The accelerated procedures are mostly only possible for medicinal products for life-
threatening diseases which address unmet medical needs. 
 
Croatia: 
In Croatia it depends on the type of product which procedure can be used. As Croatia is 
member of nCADREAC and has adopted and implemented the EU legislation the same 
prerequisites for the different registration procedures applies as in EU. The applicant has to 
use the same procedure for applying a MA as it was done in EU. It means if a product is 
authorized via CP in EU, the nCADREAC procedure for products authorized in EU via CP 
has to be used in Croatia and if a product is authorized via MRP or DCP in EU, the 
nCADREAC procedure for products authorized in EU via MRP or DCP has to be used. The 
identical dossiers as submitted in EU including all answers to questions, ARs and final 
approval letters or commission decision has to be submitted in Croatia. Therefore the 
applicant has no real choice for the procedure as it is binding due to the used EU procedure. 
Sometimes applicants might be concerned about confidentiality of the dossiers while 
submitting them in Croatia but in fact as the identical dossier is requested and a statement to 
confirm this has to be submitted there is no real alternative if the applicant would like to get a 
registration in Croatia. 
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China: 
In China there are two registration procedures - the normal registration procedure and in 
addition the accelerated procedure called special review procedure. This special review 
procedure is only possible as long as no MA for this medicinal product is granted worldwide 
and only possible for new medicinal products (NCEs or NBEs) which are used for treatment 
of AIDS, malignant tumor and/or rare disease and which have obvious clinical therapeutically 
advantages and for new medicinal products which treat diseases for which there is no 
effective therapy. The advantage of special review procedure will be lost once the drug is 
approved in any country worldwide and it might be in reality quite unrealistic that China might 
be the first country who issues the MA for a new product especially as the registration time is 
quite long and special clinical date are needed (e.g. like local studies). The advantage in 
case of review times for the accelerated procedure is only 1.5 months compared to standard 
procedure. Another advantage of this special review procedure is the fact that rolling 
submission is allowed (e.g. safety, stability, CMC development, etc.). The biggest advantage 
of this special review procedure is the fact that pre- and in-process consultation at CDE 
during the NDA review process is permitted, so the applicant has to the opportunity to be in 
close contact with CDE during the review process. This is not possible for the standard 
review procedure. Based on the differences between special and standard review procedure 
the applicant has to evaluate for a new product very carefully whether a special review 
procedure is possible - whether all prerequisites are fulfilled. In case all prerequisites for 
applying of special review procedure are fulfilled the applicant has to decide whether to use 
this procedure. It might be useful to do the first submission of MAA in China in order to use 
the special review procedure. In this case a very good planning regarding submission of MAs 
in different countries has to be made to ensure that China is the first country who issues the 
MA. 
 
Conclusion of different registration procedures in the different countries: 
In most of the countries different registration procedures exist. The different registration 
procedures have often well defined prerequisites under which circumstances which type of 
registration procedure can be used (please refer to the table "Comparison of different 
registration procedures in the different countries and pro/con arguments for each procedure" 
page 95 ff) - so it is mostly not possible for the applicant to choose by themselves the type of 
registration procedure. The accelerated procedures are in some countries only possible for 
MAAs of NCEs and not for NBEs due to the complexity of NBEs. In most countries fast track 
procedures are only applicable for serious or life-threatening disease which have potential to 
address unmet medical need or for life-saving drugs or only for orphan drugs. The "normal" 
registration procedures are applicable for all kind of products and can be used by the 
applicant for all kind of MAAs. Therefore it is advisable that the applicant evaluates very 
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carefully before submission of an MAA which type of registration procedure can be used in 
which country for which type of product. In case of doubt or open questions it is advisable 
that the applicant may ask for a consultation meeting with the authority of the concerned 
country. After the registration procedures are chosen for each country the applicant can 
submit the MAA. 
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5 4BDevelopment of the Global Regulatory Strategy for a New 
Marketing Authorization Application for a New 
Compound 
In the following chapter the development of a new compound (NBE or NCE) will be described 
and the main differences between the development of an NBE and an NCE will be 
addressed shortly. In addition a regulatory strategy for an NBE on the example of a mAb is 
provided. The development of a new compound (NBE or NCE) in general as well as for the 
proposed regulatory strategy for an NBE described here on the example of a mAb is based 
on my personal experience in pharmaceutical industry. 
 
5.1 17BDevelopment of a New Compound 
This chapter is based on own experience and research in pharmaceutical industry for several 
years. 
The global development of a new compound (NBE or NCE) is divided in several stages: 
• CMC development 
• Nonclinical development 
• Clinical development 
 
The whole development for a global compound which should be submitted and approved 
worldwide should be based on the existing ICH guidelines for quality (quality (Q) guidelines), 
nonclinical (safety (S) guidelines) and clinical (efficacy (E) guidelines) and if applicable the 
multidisciplinary (M) guidelines. In addition to the applicable ICH guidelines it is important to 
take also some national guidelines into consideration e.g. stability guidelines (especially 
guidelines for stability data for climatic zone III, IVA and IVB) or some clinical guidelines. 
At the beginning of a global development of a new compound it is advisable to create a 
global plan covering a short summary for the development of a new compound with regard to 
quality, nonclinical and clinical (divided into the different indications in development). 
Additionally trademark issues, IP issues and regulatory issues need to be mentioned within 
the global plan. In addition product objectives (short term, midterm and long term objectives) 
and marketing aspects (e.g. financial analysis like sales forecast for the indications in 
development) and financial aspects (like costs for research and development, cost of goods 
or net present value) should be mentioned within this global plan. This global plan contains 
also the key risks as well as opportunities for the development.  It is recommended to make a 
so called SWOT analysis (Strengths, Weakness, Opportunities and Threats) for the whole 
development. In addition it is recommended to provide for each section within this global plan 
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a short risk analysis (risks and opportunities). This global plan will not contain all mentioned 
sections at the beginning of development but will grow during the development and will be 
updated with new aspects and information. In parallel or shortly after the creation of the 
global plan the global route map should be created (e.g. as excel or MS project file). This 
global route map should cover the main goals for all areas (like quality, nonclinical, clinical) of 
the development from starting of development until approval of MAA and launch of the 
product with the approx. timelines for the different phases and tasks of the development. 
In addition to this global plan and the global route map it is recommended to prepare 
development plans for the different areas of development, i.e. one quality development plan, 
one nonclinical development plan and one clinical development plan. The timing for the 
creation of the quality development plan, nonclinical development plan and clinical 
development plan differs based on status of development. First the quality and nonclinical 
development plans will be created as these areas are first in the development of a new 
compound. It is important that at least the main part of the nonclinical development should be 
finalized before the clinical development is started. Before starting the clinical development 
the clinical development plan will be created. Based on the clinical development plan also a 
regulatory development plan with the submission strategy should be created. The regulatory 
development plan contains the main regulatory strategy, the relevant regulations and 
guidelines to be considered, risk analysis and recommendations. It is also advisable to 
include some information on competitive products if available. Within the regulatory 
development plan shortly the CMC strategy, nonclinical strategy as well as the clinical 
strategy is summarized to build based on them the regulatory strategy. 
In parallel or shortly after the creation of the different development plans, route maps for 
each of different development areas (one route map for quality, one for nonclinical, one for 
clinical and one for regulatory) with the main goals, tasks and timelines (e.g. excel or MS 
project can be used) will be created.  
The global plan, the global route map as well as the development plans for the different 
areas of development and the route maps for the different development areas are living 
documents and need to be updated during the different development phases. To be able to 
create such a global plan and to ensure the proper development of a new compound a global 
development team should be created. This global development team should consist at least 
of representatives from the following functions: one representative from CMC, one 
representative from nonclinical (ideally one from toxicology and one from pharmacology), 
one representative from clinical, one representative from regulatory affairs and one 
representative from marketing. In addition the team should be led by a team leader and 
should have also one project manager as member for all project coordinating work. The 
adequate time point for creation of such a global development team is after finalization of 
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Phase 0 - before starting with clinical trials. This team might be later in development get 
some additional team member based on the necessity, e.g. somebody from drug safety, 
biomarker department, commercial department, pricing department, legal department or 
trademark department. This global development team will prepare the global plan and the 
global route map with the support of the different involved functions. 
Based on the global development team it is recommended to build up some "subteams" in 
order to ensure a good communication line and easy decision making processes. These 
subteams should be divided by the functions, e.g. one CMC subteam, one nonclinical 
subteam, one clinical subteam and one regulatory subteam. These subteams should also 
prepare their plans (i.e. CMC development plan, nonclinical development plan, clinical 
development plan and regulatory development plan). It is advisable that within these 
subteams also the global team leader or at least the project manager of the global team is a 
permanent member in order to ensure the consistency of the project and for coordination of 
the project. One of the subteams is the CMC subteam led by the CMC representative of the 
global team. The CMC subteam should consist of the different functions of CMC (e.g. 
pharmaceutical development unit, analytical /QC unit, clinical trial supply unit, quality 
assurance unit, qualified person) as well as one representative of regulatory affairs and the 
global team leader or at least one project manager of the global team. The major points 
which are discussed in such a subteam can then be transferred via the leader of the subteam 
to the global team. 
There should be a nonclinical subteam led by the nonclinical representative of the global 
team. The nonclinical subteam should consist of the different functions of nonclinical (e.g. 
toxicology, pharmacokinetic, pharmacodynamics, biomarkers) as well as one representative 
of regulatory affairs and the global team leader or at least one project manager of the global 
team. 
In addition there should be established a clinical subteam led by the clinical representative of 
the global team. The clinical subteam should consist of the different areas of clinical (e.g. 
clinical operations, drug safety, maybe different clinicians (based on different indications), 
data management, statistics) as well as one representative of regulatory affairs and the 
global team leader or at least one project manager of the global team. 
In addition there should also be established a regulatory subteam led by the regulatory 
representative of the global team. The regulatory subteam should consist of the different 
functions of regulatory (e.g. regulatory therapeutical area (who is normally the representative 
in the global team), regulatory operations, labeling, and regulatory international).  
The most important points which are discussed in such a subteam can then be transferred 
via the leader of the subteams to the global team for information and also for decision 
making.  
 113
Additional subteams might be established based on the status of development and the 
necessity seen by the global team. It is important to have these teams and subteams in order 
to ensure an easy communication flow (that everybody who needs to be informed is 
informed) and that also the decision making process can be handled quite easily. In general 
the global team has to make the final decisions for the project. Sometimes, especially for the 
critical strategic and cost intensive decisions (like "go" for Phase III study or not), it is 
necessary that the global team has to ask the upper management for final confirmation and 
agreement of their decisions/proposals.  
In general the described steps, plans and activities needed are valid for the development of 
NCE as well as an NBE. The main differences between the development of an NCE and an 
NBE appear in the CMC development as the CMC development for an NCE is different from 
an NBE (please refer to CMC development plan). 
 
In the following the different recommended development plans will be discussed in more 
details: 
 
CMC development plan: 
All aspects regarding the CMC development should be covered. The plan should be 
prepared and updated by the CMC subteam. 
The whole CMC development will be done according to ICH guidelines and requirements 
(“Q” ICH guidelines) in order to be able to receive MAs in ICH region as well as in many non-
ICH-countries as a lot of non-ICH countries following ICH requirements. In addition some 
national regulations and guidelines may be taken into consideration (e.g. stability 
requirements for ASEAN countries or stability requirements for some LA countries regarding 
climatic zones III and IVA/IVB) in order to capture all needed requirements to be able to get 
MAs in all countries worldwide. 
Within the CMC development plan the CMC development strategy is described which 
includes the objective of the CMC development program as well as the development 
strategy. 
It is important to have the final formulation which is intended for submission of MAA ready 
before starting the Phase III trials. 
All guidelines and regulations with regard to stability requirements should be taken into 
consideration in order to be able to roll-out the MAA with all requested data to all countries 
worldwide. 
At the end of the plan there should be a decision tree to be able to decide for go/no go based 
on results of the proposed study program and short explanation for go/no go criteria should 
be provided. 
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This decision tree contains also so called “Decision points”. One of these points is the 
decision to start the nonclinical development based on the results and the compound 
identified so far. If the results are promising the decision will be positive and the nonclinical 
development will be started. Based on experiences normally at the beginning of CMC 
development there are 100 compounds from which maybe 15-20 compounds (15-20%) will 
pass this first decision point and will go into nonclinical development. 
 
At the beginning of a development of a new compound there are a lot of laboratory actions 
needed to find first a compound which can be further development. If this compound is found 
then the preclinical development will be started. In this stage normally not the final 
formulation of the DP is available but a so-called “pre” formulation. During the preclinical 
development also the CMC development is ongoing to develop other formulations, e.g. more 
stable or better compliant formulations for animals and humans. The final formulation should 
be available before starting the Phase III clinical studies in order to perform the pivotal Phase 
III studies with the final formulation which will be then also submitted to apply for the MA. In 
certain cases it is sometimes needed to also make changes at the formulation during Phase 
III clinical studies. These changes should be discussed with the authorities before submitting 
the changes in an IND amendment (USA) or CTA amendment (EU) to the authority. 
 
In general the described steps, plans and activities needed are valid for the development of 
NCE as well as an NBE. The main differences between the development of an NCE and an 
NBE appear in the CMC development as the CMC development for an NCE is different from 
an NBE. An NCE is a clear defined molecule whereas an NBE consists of a more complex 
structure. The influence of the manufacturing process on the molecule/substance needs also 
to be considered. An NCE is defined by the product itself whereas an NBE is not only defined 
by the product itself but also by the manufacturing process. Therefore the manufacturing 
processes of an NCE and an NBE differ. Each single change at the manufacturing process of 
an NBE might have therefore a big impact on the molecule whereas changes at the 
manufacturing process for an NCE will have no or only very little influence on the product. 
One critical topic regarding the CMC development of an NCE is often the definition of the 
starting material for the manufacturing process. Another critical issue especially for NCEs are 
the impurities. The impurities have to be characterized and analyzes very detailed according 
to the valid guidelines. It is strongly recommended to discuss such topics in advance with the 
authorities. 
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Nonclinical development plan: 
All aspects regarding the nonclinical development should be covered. The plan should be 
prepared and updated by the nonclinical subteam. 
The whole nonclinical development will be done according to ICH guidelines and 
requirements (“S” ICH guidelines) in order to get MAs in ICH region as well as in many non-
ICH-countries as a lot of non-ICH countries follow ICH requirements. In addition some 
national regulations and guidelines may be taken into consideration in order to capture all 
needed requirements to be able to get MAs in all countries worldwide. 
Within the nonclinical development plan the nonclinical development strategy is described 
which includes the objective of the nonclinical development program as well as the 
development strategy. 
All requested toxicological studies should be performed before starting the clinical 
development.  
If combination products are under development combination toxicological studies should be 
taken into consideration (especially if the single compounds are quite toxic). If no experience 
with the combination of products exists it is advisable to perform a combination toxicological 
study. In case of some doubts it might be helpful to ask for an authority meeting to clarify this 
question. 
At the end of the nonclinical development plan there should be a decision tree to be able to 
decide for go/no go based on results of the proposed study program and short explanation 
for go/no go criteria should be provided. 
This decision tree contains also so called “Decision points”. One of these points is for sure 
the decision to go on with clinical development based on the results of the nonclinical 
studies. If the results are promising the decision will be positive and the clinical development 
will be started. 
Based on experiences normally at the beginning of CMC development there are 100 
compounds from which maybe 15-20 compounds (15-20%) will pass this first decision point 
and will go into nonclinical development. Based on the results of the nonclinical development 
maybe 2-3 compounds (max. 10-15% out of nonclinical development) will then pass the 
second decision point and go into the clinical development. 
 
Clinical development plan: 
All aspects regarding the clinical development should be covered. The plan should be 
prepared and updated by the clinical subteam. 
The whole clinical development will be done according to ICH guidelines and requirements 
(“E” ICH guidelines) in order to receive MAs in ICH region as well as in many non-ICH-
countries as a lot of non-ICH countries following ICH requirements. In addition some national 
 116
regulations and guidelines (e.g. Chinese regulation or regulation from Brazil or Turkey) might 
be taken into consideration in order to capture all needed requirements to be able to get MAs 
in all countries worldwide. 
Within the clinical development plan the clinical development strategy is described which 
includes the objective of the clinical development program as well as the development 
strategy. The main part of the clinical development part is covered with the detailed clinical 
considerations divided into: 
• Choice of endpoints 
• Choice of design and objectives 
• Choice of population 
• Choice of dose and dosing regimen 
• Choice of control group 
• Number of subjects and duration of exposure 
• Trial design issues 
• Statistical issues 
• Safety issues 
• Regulatory issues 
• Pediatric investigational plan (PIP) 
• Other issues 
Besides the clinical consideration also information for the health economics strategy as well 
as medical affairs strategy should be included into the plan. Some considerations regarding 
biomarkers which become more and more important in order to be able to develop patient 
tailored medicinal drugs should be included into the clinical development plan. At the end of 
the plan there should be a decision tree to be able to decide for go/no go based on results of 
the proposed study program and short explanation for go/no go criteria should be provided. 
This decision tree contains also so called “Decision points”. Within the clinical development 
plan there should be two very important decision points. The first decision point should be 
after finalization of Phase II studies. If the results of the performed Phase I and Phase II 
studies are promising and positive the clinical development should go on and the pivotal 
Phase III studies should be initiated. In case the results are only borderline or even negative 
it should be very carefully evaluated whether clinical development should go on or should be 
stopped. 
The second important decision point with the clinical development is after finalization of 
Phase III trials. Based on the results of the pivotal Phase III studies it should be decided 
whether to apply for a MA or not. In case the results of the performed Phase III studies are 
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positive and meet their endpoints the dossier should be prepared to be able to apply for a 
MA. In case the results are only borderline or even negative it should be very carefully 
evaluated whether a MA submission should be done and whether the development should 
go on or should be stopped. 
Based on a lot of experiences normally at the beginning of CMC development there are 100 
compounds from which maybe 15-20 compounds (15-20%) will pass the first decision point 
and will go into nonclinical development. Based on the results of the nonclinical development 
maybe 2-3 compounds (max. 10-15% out of nonclinical development) will then pass the 
second decision point and go on into the clinical development. The third decision point within 
the clinical development whether to initiate Phase III studies based on results of Phase I and 
II studies normally pass only maximum one compound. This means in total that normally only 
1 % of the compounds which started in the CMC development will pass all decision points 
and will go in Phase III clinical trials and have the chance to get a MA and can be launched 
and marketed after successful registration. 
 
Regulatory development plan: 
All aspects regarding the regulatory development should be covered. The plan should be 
prepared and updated by the regulatory subteam. 
The regulatory development plan is mostly based on the clinical development plan. Therefore 
it is recommended to establish first the clinical development plan and afterwards the 
regulatory development plan. 
Within the regulatory development plan a summary of the project is provided as well as the 
regulatory issues, risk assessment and recommendations. All available and to be considered 
guidelines and regulations are mentioned, divided into quality guidelines, nonclinical and 
clinical guidelines. It is recommended to include also some regulatory information on 
competitive products as well as information on combination partners for the new compound if 
applicable. Also some information regarding the cooperation with license partners, if 
applicable should be included in the regulatory development plan. Shortly there should the 
supply chain strategy as well as the nonclinical and clinical development strategy be 
mentioned based on the CMC, nonclinical and clinical development plans. 
Then the regulatory development plan should have a chapter with all the regulatory activities 
like clinical trial licenses, import licenses, manufacturing licenses, orphan drug applications (if 
applicable), fast track status (if applicable), authority advice strategy (like scientific advices), 
DMFs and CEPs, master data sheet preparation, application for INN/ United States Adopted 
Name (USAN), Anatomical Therapeutic Chemical / Defined Daily Dose Classification (ATC 
code), pediatric trials and roll-out strategy to countries worldwide. The MA strategy chapter 
contains target indications, timing of submissions in the different regions, dossier type, 
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electronic submissions, project plan creation, application fees and the regional strategies for 
initial MAA (in EU, USA, SEA,...). Finally a short chapter regarding life cycle management 
should be included (which might be created and filled with content first during the 
development phases). 
If the regulatory strategy and the corresponding timelines for the MA submission are fixed in 
the regulatory development plan, the next steps can be initiated. Based on the planned 
submission timelines a submission team should be created latest 1 year (better 1,5 or 2 
years) before planned first submission of the MAA. This team consists of representatives of 
the different disciplines (from CMC, nonclinical, clinical and regulatory) who are responsible 
for creating the MA dossier for submission of the MAA to the authorities. The representatives 
of the different disciplines are the authors of the different CTD sections of the dossier. 
Besides the authors of the documents for the MA dossier also a representative from 
marketing, pricing and the global team leader or one of the project managers of the global 
team should be members of the submission team in order to follow and to implement the 
submission strategy accordingly. The submission team will create a route map containing all 
CTD documents, authors and timelines for preparing the different sections of a dossier 
(example of such a route map, see XAPPENDIX 17 X). 
As EU and USA are still the most important markets the submission normally will be made 
first in these two countries. Therefore the submission team works first for the submissions in 
EU and USA. But as also other countries gets more and more important also the 
preparations for the other countries should be started. Therefore a submission strategy for 
the roll-out to the other countries is initiated ideally already in the regulatory development 
plan or even during the preparation of dossier for the first MA submissions in EU and USA. 
 
In the following the regulatory strategy for an NBE on the example of a mAb is presented. To 
be able to develop a regulatory strategy and a submission strategy first a short description of 
a mAb is provided to be able to develop for this kind of medicinal product a global regulatory 
strategy. 
It is important to know that there is not only one definition of a biotech product. For the 
purpose of this dissertation a biotech product is a medicinal product manufactured by 
genetically modified micro-organisms or cell lines (refer to Ph. Eur. monograph on Products 
of recombinant DNA technology). Such products also fall under the definition of the EU 
Regulation 726/2004 X2X and include drugs like mAbs. 
The differences between the submission strategy for an NBE and an NCE are shortly 
discussed at the end of the summary and discussion section (please refer to X5.5 X. Summary 
and Discussion). 
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5.2 18BShort Introduction of a Monoclonal Antibody 
First a short description of a mAb is provided to be able to develop for this kind of medicinal 
product a global regulatory strategy. 
 
5.2.1 43BDefinition 
A mAb is a specific antibody which is made by one type of immune cell. These immune cells 
are all clones of a unique parent cell. 
“Monoclonal antibodies (mAb or moAb) are monospecific antibodies that are the same 
because they are made by one type of immune cell which are all clones of a unique parent 
cell. Given almost any substance, it is possible to create monoclonal antibodies that 
specifically bind to that substance; they can then serve to detect or purify that substance. 
This has become an important tool in biochemistry, molecular biology and medicine. When 
used as medications, the non-proprietary drug name ends in -mab.”F57 
 
5.2.2 44BAntibody structure 
Antibodies consist of four polypeptide chains held together by disulfide bonds:  
The two heavy chains are made up of the VH domain and 3 constant regions. 
The two light chains are made up of the VL domain and one constant region. 
The constant regions have a conserved amino acid sequence and exhibit low variability. 57 
 
antigen binding site antigen binding site 
 Heavy 
chain 
Light  
chain 
VL VL 
VH VH 
 
                                                
57 http://en.wikipedia.org/wiki/Monoclonal_antibodies - dated 10.05.2010 
 120
5.2.3 45BAntibody Function 
Antibodies have two major functions: X57 
• Recognize and bind antigen  
• Induce immune responses after binding 
The variable region mediates binding 
• Affinity for a given antigen is determined by the variable region 
• The variable region confers absolute specificity for an antigen 
The constant region mediates immune response after binding 
• Different classes of constant regions generate different isotypes 
• Different isotypes of antibody have differing properties 
 
 
 
 
 
 
 
Constant 
  region 
 
Variable 
region  
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5.2.4 46BTypes of Monoclonal Antibodies 
 
  
Murine mAb Chimeric mAb Humanized mAb Human mAb 
 
Murine mAb: 
• Consists only of murine cells 
• High incidence of hypersensitivity 
• High levels of neutralizing antibodies 
 
The murine mAbs are quite similar to the human mAbs but not completely identical. 
Therefore the human immune system recognizes mouse antibodies as foreign and rapidly 
removing them from circulation and causing systemic inflammatory effects. Such responses 
are recognized as producing HACA (human anti-chimeric antibodies) or HAMA (human anti-
mouse antibodies). Therefore murine mAbs have a high incidence of hypersensitivity 
reactions. The solution would be to generate human antibodies directly from humans. This 
would mean that human have to be treated with antigens in order to produce antibodies. This 
is generally not seen as ethical therefore the companies tried to find other solutions to create 
“more” human like antibodies. 
One possible approach is that DNA is taken that encodes the binding protein of monoclonal 
mouse antibodies and is merged with human antibody-producing DNA. Normally mammalian 
cell cultures are used to express this DNA and produce these half-mouse and half-human 
antibodies. Depending how big the part of the mouse antibody is used, it is a chimeric or a 
humanized antibody. X57 
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Chimeric mAb: 
• The variable region of the mAb consists of murine cells, the rest of the mAb consists of 
human cells 
• Quite high incidence for hypersensitivity 
•  Low levels of neutralizing antibodies 
 
Humanized mAb: 
• Only the upper ends of the variable regions of the mAb consists of murine cells, the rest of 
the mAb consists of human cells 
• Hypersensitivity is lower compared to murine or chimeric mAbs but still possible 
•  Low levels of neutralizing antibodies 
 
In newer times scientists were successful to create “fully” human antibodies in order to avoid 
some of side effects of chimeric or humanized antibodies. Two successful approaches were 
identified: X57 
• phage display-generated antibodies 
• mice genetically engineered to produce more human-like antibodies 
 
Human mAb: 
• The complete mAb consists of human cells  
• Incidence for hypersensitivity is very low 
• Low levels of neutralizing antibodies X57 
 
5.2.5 47BGoals of Monoclonal Antibodies 
• Activity  
• High specificity for a target critical to tumor growth and survival 
• Able to achieve meaningful clinical benefit 
• Utility 
• Can be used as single agent or in combination 
• Minimal overlapping toxicities 
• Potential targets present across tumor types and stages of disease 
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For cancer there are currently several treatment options: 
  MAbs Tyrosine 
Kinase 
Inhibitors 
Chemo-
therapy 
Radiation 
Specificity for a 
target 
Absolute 
specificity 
Variable 
specificity 
Low 
specificity 
Low 
specificity 
Toxicity Low Low/moderate High Moderate 
Administration IV IV/oral IV/oral Local 
Half-life Days to 
weeks  
Hours to days Hours to 
days 
NA 
 
5.2.6 48BCancer Treatment 
As mentioned above one big field for mAbs is the option as cancer treatment. If used as 
cancer treatment mAbs "bind only to cancer cell-specific antigens and induce an 
immunological response against the target cancer cell. Such mAb could also be modified for 
delivery of a toxin, radioisotope, cytokine or other active conjugate; it is also possible to 
design bispecific antibodies that can bind with their Fab regions both to target antigen and to 
a conjugate or effector cell. In fact, every intact antibody can bind to cell receptors or other 
proteins with its Fc region." X57X  
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Example for mAbs for cancer: 
"ADEPT, antibody directed enzyme prodrug therapy; ADCC, antibody dependent cell-
mediated cytotoxicity; CDC, complement dependent cytotoxicity; MAb, monoclonal antibody; 
scFv, single-chain Fv fragment." X57X  
 
 
 
5.2.7 49BConclusion Monoclonal Antibodies 
• MAbs are excellent therapeutic agents in oncology 
• When used as a single agent or when used in combination 
• High specificity to target 
• Manageable side effect profile 
• MAb engineering has evolved over time 
• Immune responses to murine antibodies led to the creation of chimeric, humanized, 
and human antibodies 
• Hypersensitivity has remained as a class effect of antibodies 
 
 125
5.2.8 50BManufacturing Process of a New Biotech Product, 
Example of a Monoclonal Antibody 
The next step after some general aspects of mAbs is to define a biotech product and to 
explain shortly the general manufacturing process of a mAb: 
The main difference between an NCE and an NBE is the influence of the manufacturing 
process on the molecule/substance. An NCE is defined by the product itself whereas an NBE 
is not only defined by the product itself but also by the manufacturing process. Each single 
change at the manufacturing process of an NBE might have therefore a big impact on the 
molecule. 
The general manufacturing process of an NBE as example of a mAb can be described as 
follows: 
• First, an appropriate micro-organism or cell line has to be selected that is known to be 
able to manufacture similar proteins. 
• These are usually either 
• Bacteria (e.g. E. coli) or 
• Yeast (e.g. Saccharomyces) or 
• Mammalian cell lines (e.g. Chinese Hamster Ovary [CHO] cells) 
• Second, the gene sequence (vector) encoding for the desired protein needs to be inserted 
in the genome of the so-called host cell line 
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Transfection of cells X50 
 
Host DNA
Recombinant 
DNA 
Host cell
Vector DNA
Transfected cells
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Glycosylation 
• The genetic sequence defines the amino acid sequence of a protein 
• However, many biotech drugs also contain complex carbohydrates, i.e. they are in 
essence glycoproteins not just proteins 
• The process by which these carbohydrates are attached to the protein is called 
glycosylation 
• Glycosylation often impacts on the biological activity, immunogenicity and 
pharmacokinetics of biotech drugs 
• Glycosylation is usually very sensitive to manufacturing changes 
 
Master Cell Bank (MCB) 
• Once a cell line is identified which produces the desired protein in the required quality and 
quantity a so-called Master Cell Bank (MCB) is created, i.e. 
• the cells are suspended in a defined storage medium (e.g. fetal calf serum) and equal 
amounts are distributed in vials (typically 200-300) 
• These vials are then refrigerated in liquid nitrogen at -77 K (-196°C) 
• MCB is usually stored at - 70°C or lower 
• This MCB will be source of all material manufactured through the whole life-cycle of a 
drug, i.e. one MCB results in one product 
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To sum up there is a short general overview how to produce a mAb. 
A general representation of the methods used to produce mAbs58 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
                                                
58 http://en.wikipedia.org/wiki/Biomarker - dated 25.08.2010 
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General biotech manufacturing scheme X50 
 
Active pharmaceutical ingredient, Drug Substance 
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Conclusion: 
A biotech product is defined not only by the product but also by the process. This is clearly 
reflected in the structure and content of the dossier for a biotech product. 
 
5.3 19BDevelopment of a Monoclonal Antibody 
This chapter is based on my own experience in pharmaceutical industry for several years. 
Based on the general development activities (see chapter X5.1 X) and the global plan (see 
XAPPENDIX 18 X) a regulatory strategy for a mAb called Monotuximab is developed. The 
development takes place in the indications squamous cell cancer of the head and neck 
(SCCHN), Hodgkin lymphoma and breast cancer. 
 
5.3.1 51BCompound & Mode of Action 
Monotuximab is a humanized mAb of the immunoglobulin G1 (IgG1) class targeting the 
human epidermal growth factor receptor (EGFR)." The epidermal growth factor receptor 
(EGFR; ErbB-1; HER1 in humans) is the cell-surface receptor for members of the epidermal 
growth factor family (EGF-family) of extracellular protein ligands. The epidermal growth factor 
receptor is a member of the ErbB family of receptors, a subfamily of four closely related 
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receptor tyrosine kinases: EGFR (ErbB-1), HER2/c-neu (ErbB-2), Her 3 (ErbB-3) and Her 4 
(ErbB-4). Mutations affecting EGFR expression or activity could result in cancer. EGFR exists 
on the cell surface and is activated by binding of its specific ligands, including epidermal 
growth factor and transforming growth factor α (TGFα).59 
Compared to chemotherapy Monotuximab specifically targets and binds to EGFR. This 
binding inhibits the activation of the receptor and the subsequent signal-transduction 
pathway. The results of this inhibition are a reduction of the invasion of normal tissues by 
tumor cells and the spread of tumors to new sites. It is also believed to inhibit the ability of 
tumor cells to repair the damage caused by chemotherapy and radiotherapy and to inhibit the 
formation of new blood vessels inside tumors, which appears to lead to an overall 
suppression of tumor growth.  
 
5.3.2 52BDevelopment Objectives 
• Registration of Monotuximab first in EU and USA and afterwards roll-out to JP and to non-
ICH-countries for the indication SCCHN 
• Finalize the ongoing clinical studies in Hodgkin lymphoma and breast cancer with positive 
results (meeting the endpoints) 
• Registration of new indication Hodgkin lymphoma in ICH and non-ICH-countries after 
positive studies 
• Registration of new indication breast cancer in ICH and non-ICH-countries after positive 
studies 
• Establish Monotuximab as important part of the gold standard treatment regimens in 
tumors where EGFR is expressed 
 
 
 
 
 
 
 
 
 
 
                                                
59 http://en.wikipedia.org/wiki/Epidermal_growth_factor_receptor 
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5.4 20BDevelopment of the Global Regulatory Strategy for a 
Monoclonal Antibody 
This chapter is based on my own experience in pharmaceutical industry for several years. 
 
5.4.1 53BExecutive Summary of the Regulatory Strategy 
The global regulatory strategy for the mAb Monotuximab is focused on achieving fastest path 
to market in EU and US followed by other important markets. The initial filing is planned for 
the indication SCCHN, most commonly known as head and neck cancer. SCCHN represents 
95% of all head & neck cancers and is associated with a very poor prognosis. SCCHN is 
characterized by a high EGFR expression rate of 90-100%. There is a high unmet medical 
need in the treatment of SCCHN comprising 
• improved survival of patients with recurrent and/or metastatic disease 
• enhancement of radiotherapy  
• need for new treatment options  
• higher response rates can minimize the surgery of early stage disease (organ 
preservation) 
As mentioned above SCCHN represents an area of high unmet medical need and an orphan 
indication at least in USA, which allows access to favorable regulatory mechanisms, 
including fast track status and priority review as well as Orphan Drug Designation. In EU the 
indication SCCHN does not fall under the Orphan Drug Designation and also not under the 
accelerated registration procedure, so only the normal assessment procedure is possible in 
the EU. 
Positive outcomes of the ongoing Phase II studies 001 and 002 will trigger the decision for a 
pivotal Phase III trial in SCCHN. The design of the pivotal Phase III trial will be discussed 
with FDA and EMA/CHMP, preferably via a parallel (harmonized) scientific advice. 
The design of the pivotal Phase III trial in SCCHN might be complicated by potentially 
different opinions of EMA/CHMP and FDA with respect to clinical endpoint and comparator 
arm. FDA will most likely prefer a primary survival endpoint in SCCHN, whereas EMA/CHMP 
might consider a surrogate endpoint like progression-free survival (PFS) as a basis for 
approval. A potential pivotal trial in SCCHN is planned to be powered for a survival endpoint, 
which might offer the option for earlier approval based on a planned interim analysis with a 
surrogate endpoint like PFS. Thereby a single global study could potentially satisfy both EMA 
and FDA. 
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All guidelines which should be taken into consideration for the development are listed in 
XAPPENDIX 19 X. 
 
As EU and USA are still the most important markets the submission will be made first in 
these two countries. Therefore the submission team works first for the submissions in EU 
and USA. But as also other countries gets more and more important also the preparations for 
the other countries should be started. Therefore a submission strategy for the roll-out to the 
other countries is initiated ideally already in the regulatory development plan or even during 
the preparation of dossier for the first MA submissions in EU and USA. 
In the following the proposed submission strategy for roll-out to international (non-ICH) 
countries) for the developed mAb Monotuximab is presented: 
 
5.4.2 54BRegulatory Activities 
5.4.2.1 64BClinical Trial Licenses 
A Phase II study for the combination of Monotuximab and radiation in SCCHN is currently 
ongoing. Participating countries are Germany, Spain, France, Belgium, Portugal, UK, USA, 
CH, Russia, China, Taiwan, South Korea, Singapore, Brazil, Argentina, Venezuela, Chile and 
Mexico. 
 
5.4.2.2 65BOrphan Drug Application 
Monotuximab has been designated as an orphan medicinal product for the treatment of 
SCCHN in the USA in September 2006. Orphan product designation provides 7 years of 
marketing exclusivity in the US, and possible tax credits for development costs. In addition a 
waiver can be requested regarding the user fees for a MA in the US. 
 
5.4.2.3 66BFast Track Status 
The application for fast track status in the US in SCCHN was granted in Q1, 2007. Fast track 
designation provides as described before more visibility and a higher level of commitment of 
FDA resources. It allows for greater access to FDA consultations and for a ‘rolling 
submission’ of portions of the MA as they become available which facilitates the FDA review 
process. The priority review process and accelerated approval strategies are available in 
addition to the fast track program. 
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5.4.2.4 67BAuthority Advice Strategy 
Positive outcomes of study 001 and 002 will trigger the decision for a pivotal Phase III trial in 
SCCHN. Open issues will then be discussed with the FDA at an End-of-Phase II meeting. 
CMC and clinical topics will most likely be addressed in separate meetings. 
In addition there is the need for getting a feedback from EMA/CHMP, especially with respect 
to the design of a global pivotal clinical trial in SCCHN. Due to the possibility of different 
views of EMA/CHMP and FDA on endpoints and comparator the option for a parallel clinical 
scientific advice should be explored. The same information (study synopsis, etc.) will be 
submitted to both authorities including a cover letter allowing exchange of information 
between both parties. The context would be a request for an End-of-Phase II meeting with 
the FDA and for scientific advice with the EMA, respectively. CMC and non-clinical issues 
could also be covered by the EMA advice as appropriate, maybe as alternative also a 
separate meeting should be planned (as planned for USA). The timing of a parallel scientific 
advice will be critical since the EMA Scientific Advice Working Group meeting is only once a 
month. The FDA should therefore be informed at least 4 months before an anticipated joint 
meeting of the authorities. Following the harmonization of advice, the pivotal study protocol 
may be submitted to FDA for the Special Protocol Assessment (SPA) procedure, to provide a 
binding agreement for the pivotal trial and registration strategy. 
Besides the meetings with EMA and USA also meetings with some national EU authorities 
should also be taken into consideration. These meetings with national EU authorities should 
not overlap from a timing point of view with a concurrent EMA advice procedure on the same 
topic. Consequently, once data from studies 001 and 002 become available, questions on 
the pivotal Phase III study design should only be discussed with national EU authorities 
before approaching the EMA. These meetings should be held with national EU authorities 
prior to taking a decision for the proposal of Rapporteur and Co-Rapporteur. 
 
5.4.2.5 68BMarketing Authorization Strategy 
Depending on the results of studies 001 and 002, a pivotal Phase III study is planned to 
achieve first registration in SCCHN in EU (via CP) and US.  
 
5.4.2.6 69BTarget Indications and Key Labeling Statements 
Treatment of patients with SCCHN in combination with radiation therapy for locally advanced 
disease. 
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Monotuximab is used concomitantly with radiation therapy. It is recommended to start 
Monotuximab therapy one week before radiation therapy and to continue Monotuximab 
therapy until the end of the radiation therapy period. 
Prior to the first infusion, patients must receive premedication with an antihistamine and a 
corticosteroid. This premedication is recommended prior to all subsequent infusions. 
Monotuximab is administered once every two weeks. The initial dose is 500 mg 
Monotuximab per m² body surface area. All subsequent weekly doses are 390 mg 
Monotuximab per m² each. 
 
5.4.2.7 70BTiming of Submission in Regions 
The marketing authorization strategy is focused on initial approval in SCCHN in EU and US. 
Parallel submissions in both regions are currently targeted for Q1,11. The approved 
indications will then be expanded to JP and non-ICH countries. For some countries also 
parallel submissions to EU and US are possible and will be evaluated whether to do or not. 
 
5.4.2.8 71BDossier Type 
The initial applications in EU and US will be based on a dossier in CTD format. 
 
5.4.2.9 72BElectronic Submission 
The initial application in EU and US in 2011 is expected to be based on an eCTD 
submission. 
 
5.4.3 55BRegional Strategies for Initial Application in ICH 
As EU and USA are still the most important markets the preparation of the dossier will be first 
done for these two countries. 
5.4.3.1 73BEU 
The potential pivotal clinical trial in SCCHN will be a controlled Phase III study with a survival 
endpoint. In EU there might also be the option for an earlier approval based on PFS as 
endpoint based on an interim analysis. A decision on potential Rapporteur/Co-Rapporteur 
countries for the CP has not yet been taken. The choice will be based on the oncology 
expertise at the corresponding national EU authority. Another criteria could be an established 
working relationship between the pharmaceutical company and the authority. Based on the 
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above mentioned criteria the EU authorities in Sweden, Germany, France, Netherlands or 
UK are potential candidates. 
 
5.4.3.2 74BUS 
As stated above, the potential pivotal clinical trial in SCCHN will be a controlled Phase III 
study, likely with a survival endpoint. Given the indication and the high unmet medical need, 
it is anticipated that a successful trial will result in a full approval in the US. Assuming a 
successful designation as a fast track product, it is recommended that a ‘rolling’ submission 
will be used, whereby full portions of the application could be submitted for FDA review prior 
to submission of the complete dossier. This strategy could facilitate the priority review clock 
(which only starts counting upon receipt of the last piece of the dossier).  
Details on the registration strategy and mechanisms applied would be determined during the 
End of Phase II meeting. 
 
5.4.4 56BMarketing Authorization Strategy for Roll-out to Japan 
and to non-ICH-countries for the Monoclonal Antibody 
Monotuximab 
As EU and USA are still the most important markets the preparation of the dossier will be first 
done for these two countries. As also other countries gets more and more important the 
preparations for the other countries should be initiated in parallel or shortly after the dossier 
preparation for EU and USA. Therefore a submission strategy for the roll-out to the other 
countries is initiated ideally already in the regulatory development plan or even during the 
preparation of dossier for the first MA submissions in EU and USA. 
 
In the following the proposed submission strategy for roll-out to international (JP and non-
ICH) countries for the developed mAb Monotuximab is presented. 
The submission strategy is prepared based on own professional experiences and personal 
feedback from the different countries and regions (e.g. feedback received due to surveys 
made for the different countries and regions).  
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5.4.4.1 75BRegistration Scenarios 
5.4.4.1.1 79BScenario 1: Early Stage Submission before Finalization 
of MA in EU and USA 
This scenario covers the submission of the ICH dossier in Q3, 2011 as submitted in USA and 
in EU (via CP). 
The dossier, which will be submitted in EU and USA in Q1, 2011, will be used for this 
scenario. 
After finalization of the MA in USA and EU (e.g. in EU approx. in Q1, 2012, in USA maybe 
already in Q3/Q4, 2011), the updated global dossier (containing all changes which have to 
be done during the registration procedure (in EU changes in CP based on the questions by 
the CHMP)) and the EU/USA CPP will be submitted to the non-ICH DRAs. The submission 
of this updated dossier containing all changes made during the registration procedures in EU 
and USA will be necessary to bring these countries in line with the dossier as approved in EU 
and USA. As sometimes differences in the approved dossier between the US and EU are 
possible which cannot be implemented in one global dossier (or maybe also it is not desired 
to implement all changes requested from EU and US into the updated global dossier) it might 
happen that it has to be decided to use only the EU or the US approved dossier as basis for 
the updated global dossier for roll-out to international countries. 
This strategy is the preferred one although it does not comply with most of the countries 
formal requirements (CPP of the intended Country of origin (CoO) for an authorized and 
marketed product). If it cannot be accepted at all (according to the estimation of local 
representatives in the different countries), the scenario as described in 5.4.4.1.2 will apply. 
To summarize, the advantages of scenario 1 cover 
• Early submission 
• Necessity of updating the dossier after registration procedure only once resulting in 
reduced costs 
• One global dossier for ensuring a high grade of compliance 
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5.4.4.1.2 80BScenario 2: Submission after Finalization of MA in EU 
and USA 
 
This scenario covers the use of the ICH dossier in Q2, 2012 as approved in EU and/or USA, 
with availability of the CPP for the MAA. It covers strictly the formal requirements of most of 
the non-ICH-countries. 
An international submission of this dossier will be done with the EU/USA CPP, showing that 
the product is authorized (and marketed). 
Summarizing, the advantages of this strategy cover 
• The fact of availability of the EU/USA CPP 
• No updates and therefore no costs for VARs 
• One global dossier for ensuring a high grade of compliance 
• A high level of formal acceptance by the countries 
 
On the other hand, this strategy brings out a delay for submission of at least six months in 
comparison to scenario 1. Nevertheless, it is evident that a lot of countries will have to use 
this strategy. 
 
5.4.4.2 76BArea Strategies 
5.4.4.2.1 81BAsia 
 
Based on experiences and surveys in the SEA countries regarding the acceptability of the 
above described scenarios revealed that many of the countries cannot accept to start with 
scenario 1 due to the missing ICH (EU and/or USA) approval and due to the necessity of the 
availability of the EU/USA CPP. 
Therefore scenario 1 can be followed only in AUS, JP and South Korea. 
Scenario 2 can be applied for China, Hong Kong, India, Indonesia, Malaysia, Philippines, 
Singapore, Taiwan, Thailand and Vietnam. 
For JP no CPP is needed, so scenario 1 can be followed. In practice often additional 
activities and studies are needed, so that a submission in parallel or shortly after EU and 
USA is often not possible. Nevertheless if all prerequisites are fulfilled a parallel submission 
to EU and USA in JP is possible and should be taken into consideration (as JP is also a 
growing market with big market potential). 
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5.4.4.2.2 Latin America 
 
In LA early stage submission as mentioned in scenario 1 is not possible in any country due to 
the missing EU/USA approval and the missing EU/USA CPP. Therefore scenario 2 will be 
used in all countries. 
Countries, where scenario 2 has to be followed are Argentina, Brazil, Chile, Colombia, Costa 
Rica, Dominican Republic, Ecuador, El Salvador, Guatemala, Honduras, Mexico, Nicaragua, 
Panama, Peru, Uruguay and Venezuela. 
Neither strategy 1 nor country specific strategies have to be applied for LA. 
 
5.4.4.2.3 82BMiddle East 
 
In the ME countries the CPP from the CoO for an approved and marketed product is the 
basis for all registrations. In the case of a centrally authorized product also an EU CPP can 
be used. For Lebanon and Syria in addition to the EU CPP a CPP from the CoO have to be 
submitted with the MAA. 
Consequently scenario 2 will be the general strategy for this area. 
For Bahrain, Egypt, Kuwait, Iraq, Iran, Lebanon, Oman, Qatar, Saudi Arabia, Syria, United 
Arab Emirates and Yemen only scenario 2 can be used. 
 
5.4.4.2.4 83BSwitzerland, Eastern Europe, South Africa, Israel and 
Turkey 
For CH no CPP is needed therefore scenario 1 will be followed. Submission can be done in 
parallel to EU and US and should be done if the necessary resources to do the submission 
are available. Otherwise submission will be done after approval in EU and USA. 
For EE, South Africa, Israel and Turkey a survey regarding the necessity for a CPP has been 
made which revealed that most countries require a CPP from the CoO. For CP authorized 
products also the EU CPP is acceptable. 
South Africa accepts any CPP and does not request a CPP at the time of submission: 
Scenario 1 will be followed and the EU/USA CPP - if requested - may be sent later. 
Turkey and Russia do not request a CPP at the time of submission, therefore scenario 1 can 
be followed and the EU/USA CPP - if requested - may be sent later. 
For Belarus, Croatia, Israel, Kazakhstan, Montenegro, Serbia and Ukraine scenario 2 has to 
be applied. 
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5.4.4.2.5 84BAfrica 
For AFR, the situation is quite complex due to the link of many African countries to a French 
MA and the French price. The Francophone African countries need the availability of the 
French MA as prerequisite for applying a MA in these countries. For the majority of countries 
it is necessary to wait for the availability of the French price for the product. The earliest 
submission for these countries will consequently be in Q2/Q3, 2012 (after the approval in EU 
and the pricing in France). 
For Algeria and Tunisia scenario 2 has to be applied. 
For Morocco, the prerequisite of the availability of the French price is not the case but the 
European approval including the availability of an EU CPP is needed to apply for a 
registration. Therefore also for Morocco scenario 2 applies. 
 
5.4.4.3 77B"Master Dossier" 
For Monotuximab it is recommended to implement a so-called “Master Dossier Concept”. 
The Master Dossier represents the most comprehensive information available on the product 
from a regulatory point of view. Ideally the first created Master Dossier is the submitted 
dossier in at least one key market, e.g. EU and/or USA. The Master Dossier consists of the 
complete structure and content of Modules 2, 3, 4, and 5 according to NtA. The Master 
Dossier is the basis of information to be used to generate the international Master Dossier for 
the non-ICH-countries. 
After creation of the first Master Dossier (called Master 1 Dossier (M1 dossier)) which is the 
dossier submitted to EU and/or USA for the initial MAA of Monotuximab an updated Master 
Dossier will be created after the approval in EU and/or USA. This updated dossier is called 
Master 2 Dossier (M2 dossier). As the Master Dossier concept should be kept for the whole 
lifecycle of the product all updates and changed documentation submitted by VARs (e.g. 
applications for new indications) or REN to the EU and/or USA are included into the Master 
Dossier after approval in EU and/or USA. Such changes create an updated new version of 
the Master Dossier (next Master Dossier is then Master 3 (M3) Dossier). 
Based on the full (complete) M1 and M2 dossiers containing all sections as submitted/ 
approved in EU/USA, so called international Master Dossiers (M1 int. and M2 int.) are 
created. These international Master Dossiers also contain Module 2, 3, 4 and 5. Compared 
to the ICH dossier, the highly confidential documents concerning DS section of Module 3 are 
shortened due to confidentiality reasons and IP issues. Therefore an international version of 
the DS section of Module 3 is created containing abbreviated documents compared to the 
ICH dossier as the highly confidential information is deleted. The other documents of Module 
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2 and the complete Modules 4 and 5 are copied from the full ICH dossier and no documents 
are taken out for the international Master Dossier.  
Additionally to Module 2 to 5, also some general sections of Module 1 (administrative 
information) like 1.4 Information about the Expert (Curriculum Vitae (CV) + expert signature 
pages), 1.6 Environmental Risk Assessment or 1.8 Information relating to Pharmacovigilance 
is recommend to be included in the Master Dossiers M1, M2 and M1 int. and M2 int. since it 
shall not be country specific. 
 
5.4.4.4 78BSummary Table Concerning the Regulatory Strategy for 
the Marketing Authorization for the Different Countries 
In the XAPPENDIX 20 X a table summarizing the above described regulatory strategy for the 
different countries is provided. Within this table the registration scenario which is applicable, 
the dossier, which will be used for each country, the approx. timelines for sending out the 
dossier (assumed that all documents, studies, etc. for the countries are available) and the 
marketing priority (showing the market importance of the product within the different 
countries) is included. The table has the purpose to provide a short and compact overview on 
the regulatory strategy for MAA for ICH and non-ICH-countries. 
 
5.5 21BSummary and Discussion 
It is very important that the global development of a new substance (NBEs as well as NCEs) 
is based on the available ICH requirements as the ICH region is still the most important 
region for medicinal products based on market potential. In addition the growing markets like 
China, Brazil, Russia, India and ASEAN should be also kept in mind and the guidelines for 
these countries should be also carefully checked and be included in the global development 
program. If only the ICH requirements are included in the global development plan it might 
happen that additional studies like stability studies or preclinical studies or clinical studies 
needs to be created in order to be able to register the products in these non-ICH countries. 
To be able to make a global development efficient and within quite short timelines a kind of 
global plan/route map including the main aspects of quality, preclinical and clinical strategy 
should be created. It is clear that all route maps/plans should be updated accordingly based 
on the status of development (please refer to XAPPENDIX 18 X).The whole regulatory 
development has to be done according to ICH guidelines and requirements in order to be 
able to get MAs in ICH region as well as in many non-ICH-countries as a lot of non-ICH 
countries following ICH requirements. In addition some national regulations and guidelines 
may be taken into consideration (e.g. stability requirements for ASEAN countries or some LA 
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guidelines regarding stability for climatic zone III and IVA/IVB) in order to capture all needed 
requirements to be able to get MAs in all countries worldwide. 
Within the CMC development plan the CMC development strategy is described which 
includes the objective of the CMC development program as well as the development 
strategy. 
It is important to have the final formulation which is intended for submission of MAA ready 
before starting the Phase III trials. All guidelines and regulations with regard to stability 
requirements should be taken into consideration in order to be able to roll-out the MAA with 
all requested data to all countries worldwide as fast as possible. At the end of the plan there 
should be a decision tree to be able to decide for go/no go based on results of the proposed 
study program and short explanation for go/no go criteria should be provided. 
This decision tree contains also so called “Decision points”. One of these points is the 
decision to start the nonclinical development based on the results and the compound 
identified so far. If the results are promising the decision will be positive and the nonclinical 
development will be started. Based on experiences normally at the beginning of CMC 
development there are 100 compounds from which maybe 15-20 compounds (15-20%) will 
pass this first decision point and will go into nonclinical development. 
As mentioned before the final formulation of DP should be available before starting Phase III 
trials in order to perform the pivotal Phase III studies with the final formulation which will be 
then also submitted to apply for the MA. In case changes at the formulation during Phase III 
clinical studies are necessary these changes should be discussed with the authorities before 
submitting the changes in an IND amendment (USA) or CTA amendment (EU) to the 
authority. 
 
In addition the following considerations should be taken into account during development of a 
new compound (NBE or NCE): 
• Biomarker: 
• Biomarker should be included in clinical development phases 
• Clinical issues and recommendations: 
• Perform Phase III studies according to ICH requirements (like randomized, 
uncontrolled, double-blind,…) 
• For some diseases registrations based on Phase II studies are possible (like for cancer 
indications) 
• In some countries for all diseases and indications mandatorily Phase III data needed 
(e.g. Brazil, Turkey) for getting a registration 
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• Standard treatment for a disease might differ in the countries - therefore the 
comparison arm to the treatment arm has to be carefully selected 
• Some countries request local clinical trials like Vietnam, Taiwan, South Korea, China 
and Russia or they request participation in global trials with enough patients from their 
population 
• Pediatric studies (pediatric regulation - PIP/waiver) 
• Recommendation to perform two pivotal Phase III studies  
• Recommendation to include also Russia in global trials 
• Recommendation to include China in global trials with at least 200 patients (better 300 
patients) in treatment arm 
• Alternatively let China participates in global trial with less than 200 patients and do in 
addition a pan-Asian study with JP, China, Singapore Taiwan, South Korea, Vietnam 
and Hong Kong (as Vietnam, Taiwan and South Korea also request local clinical trials) 
• CMC issues: 
• Stability data climatic zone III (30°C/35 % rh) and IV (IVA and IVB (30°C/75 % rh)) 
• Requirements for two or more DS or DP manufacturers  
• Administrative issues: 
• CPP availability 
• For most of the countries EU approval is prerequisite for submission and/or approval in 
the country 
 
To provide a comprehensive overview of the requirements in the different regions worldwide 
for a new MAA please refer to requirements tables in XAPPENDIX 21 X. 
 
During the last years the requirements for developing new medicinal products becomes more 
and more complex. Since some years it is e.g. mandatory to present also pediatric studies in 
EU and USA and also some other countries. These additional studies cost additional time 
and money for the companies. For some indications which do not occur in children it is 
possible to apply for a waiver in EU to avoid making studies in children. But for indications 
which have an incidence in children it is mandatory to make clinical trials in children before 
submitting the MAA. Also discussions whether to perform special clinical studies in elderly 
people are still ongoing and it has to be seen whether also such studies will become 
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mandatory in future. Additionally there are more and more requirements to develop more 
patient tailored medicines which are more specific for special patient groups. One option to 
fulfill this goal is the usage of biomarkers. "A biomarker (or a biological marker) is a 
substance which is used as an indicator for a biological status. A biomarker is characterized 
as it objectively measures and evaluates as an indicator for normal biological processes, 
pathogenic processes or pharmacologic responses to a therapeutic intervention. It is used in 
many scientific fields. For example in the medicinal field, a biomarker can be a substance 
whose detection indicates a particular disease state, for example, the presence of an 
antibody may indicate an infection. To make it more specific, a biomarker may indicate a 
change in expression or state of a protein that correlates with the risk or progression of a 
disease, or with the susceptibility of the disease to a given treatment. It can be also a 
substance that is introduced into an organism as a means to examine organ function or other 
aspects of health".60 
Therefore for newly developed medicinal products the authority is very keen on results on 
biomarkers to make the therapy more patient tailored. In many medicinal indications no 
approval will be possible any more without showing results on biomarkers. Therefore it is 
mandatory for the companies to include biomarkers into their development program for new 
medicinal products. 
It is also very important to know that in some countries Phase II studies in general - 
independent of the indication of the medicinal product - are not sufficient for getting an 
approval for a MA. Therefore companies have to carefully plan their development concept 
and have to think whether to set up Phase III studies very early even in indications like 
cancer as a prerequisite to be able to get an approval in some countries like Brazil or Turkey. 
Otherwise the MA submission has to be postponed until the results of the Phase III trial are 
available. Also the comparison between the newly developed compound and the standard 
therapy might differ in the different countries. Therefore also the comparison arm to the 
treatment arm has to be carefully selected. 
It is also recommended to perform two pivotal Phase III trials in one indication as the 
tendency can be observed that DRAs grant MA not always on results of one Phase III trial 
anymore. There is a risk for not getting a MA, especially if the results of the one pivotal 
Phase III trial are not outstanding.  
Additionally some countries request mandatorily local clinical trials, e.g. in JP, Taiwan, South 
Korea, Vietnam, China or Russia or at least participation in global trials with enough patients. 
Enough patients in China e.g. mean that at least 200 patients minimum (better 300 patients) 
have to participate in the treatment arm! These numbers are mostly too high to be able to 
include so many patients of one population into a global trial (as there are also requirements 
                                                
60 http://en.wikipedia.org/wiki/Biomarker - dated 25.08.2010 
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how many Caucasian patients, etc. have to be included), therefore it is often not feasible to 
cover all requirements of the different countries by one global trial. As a consequence it is 
advisable to make in addition to the global trial so called regional trials, e.g. in Asia, or local 
trials in specific countries. As some Asian countries request a minimum number of patients 
participating in clinical trials it is possible to make a regional trial in Asian countries (so called 
pan-Asian study with JP, China, Singapore Taiwan, South Korea, Vietnam and Hong Kong) 
to fulfill all requests regarding clinical trials and to avoid making local clinical trials in the 
single countries. 
Not only the clinical aspects needs to be carefully evaluated for the global development there 
are also some CMC and administrative issues which needs to be taken into consideration. At 
least the requirements for stability data for climatic zone III (30°C/35 % rh) and IV (30°C/75 
% rh) have to be considered and have to be fulfilled to be able to apply for a MA in countries 
which request stability data for climatic zone III and/or IV (e.g. Brazil). Without having these 
data a registration might be impossible or only possible with a very limited shelf-life as the 
available stability data for climatic zone I and II are not sufficient for these countries. Also in 
many countries it is not possible to have two or more manufacturers for DS or DP registered 
(e.g. in Taiwan, Brazil or Vietnam). These facts need to be taken also into consideration 
during the development. 
Regarding administrative issues it is still today for many countries a prerequisite that 
companies have approval in EU and/or US before submitting a MA in the country. The CPP 
is a document showing that the product is approved in the country issuing the CPP and that 
the company is regularly inspected and is working according to GMP. The CPP is requested 
in many countries with submission of MA or at least during the evaluation process of the MA. 
Many countries until today will not grant a MA without the availability of a CPP. Countries 
where currently no CPP is needed for the approval of a MA are e.g. CH, AUS, Canada, 
South Korea and Russia. 
In addition to the requirements for the dossier which needs to be submitted for getting a MA 
a lot of other aspects need to be carefully evaluated before and during the global 
development of a new compound. There are the marketing issues which are quite important 
to be kept in mind. It is important that marketing will evaluate quite early during the global 
development the market potential for the new compound in the indications which are under 
development by doing some market researches. A detailed marketing strategy for all 
indications under development needs to be developed for the new compound including the 
positioning against comparators. Also the observation and evaluation of competitors has to 
be done by marketing. Pricing is also an important issue for establishing the marketing 
strategy therefore the market research is very important to be able to evaluate which price 
can be established for the new medicinal product in which country. Pricing is a very sensitive 
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issue as in many countries there are price limitations due to the governments. In additional 
the reimbursement issues need to be early evaluated whether the new medicinal product can 
be reimbursed in the different countries and which requirements need to be fulfilled to get the 
medicinal product reimbursed. It can be also anticipated that for future developments the 
proof of quality, safety and efficacy may not be sufficient but in addition the company has to 
proof also the cost benefit ratio for a new medicinal product by making some studies. 
Medicinal products which have shown a positive cost benefit ratio will be reimbursed.  
Besides the marketing aspects also a financial analysis has to be done including sales 
forecasts and net present value as well as the expected net present value. On the other hand 
also the research and development resources and costs, sales and marketing resources and 
costs and cost of goods have to be evaluated in order to calculate the approximately profit for 
the new medicinal product.  
Also the IP situation is very important to be checked and evaluated. Normally if a new 
compound is under development the companies ask for a patent protection. The patent 
protection is valid for 20 years after its approval. As normally the global development of a 
new compound takes between 8 - 12 years the companies have only 8 - 12 years time left to 
earn money with the newly developed medicinal product. Therefore there is the possibility to 
apply in addition to the patent for a so called supplementary protection certificate (SPC) 
which can provide after patent expiry additional protection for maximum 5 years. So in total 
the company which develops a new compound can have patent protection and SPC 
protection in total for maximum 25 years. After expiry of these protections generic companies 
can come to the market. 
In addition to patent protection in many countries there is also the possibility to get a data 
exclusivity. This means that if the applicant applies for a MA in this country the submitted 
dossier is protected for a certain time against generic companies. During the time of data 
exclusivity no generic company can make reference to the data of the originator company. In 
EU these data exclusivity period is 10 years, in US 5 years from day of approval of the MA. 
As normally the data exclusivity expires earlier than the patent it is possible for generic 
companies to submit after the expiry of data exclusivity (often also 2 years in advance of 
expiry of data exclusivity) and before patent expiry for the MA of the drug. The authorities will 
also grant the MA even the patent protection is still active. The generic company has then to 
wait for patent expiry before marketing its product, otherwise the patent holder can take legal 
steps against the generic company. 
As in some countries the data exclusivity does not exist and the confidentiality of the 
submitted data are also sometimes not guaranteed the applicant has to think very carefully in 
which countries the MA dossier will be submitted and how many data will be presented to the 
authority. Besides that, the IP rights (like patent protection) are not yet established in all 
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countries worldwide. So companies developing new compounds have to think quite early in 
development in which countries they would like to get MAs and in which countries they can 
and would like to apply for patents. As a patent has to be applied in each single country, 
which costs time and money for the company, the company has to think very carefully in 
which countries a patent protection is really useful and necessary. 
 
So in summary, the companies developing new innovative medicinal products have to think 
about a lot of different issues during their development phases. 
The changing environment for making global development of new products needs to be 
taken into consideration. Due to the political situation in many countries e.g. reforms of the 
health care systems (as many countries have to save money for their health care system) it 
becomes more and more difficult for the researching pharmaceutical companies to make 
global developments. In general, everybody would like to have new and innovative medicinal 
products better than the available drugs and especially for life threatening diseases but often 
people and the systems are not in favor to pay for these innovations. In many countries 
therefore the prices for new medicines are limited which means that companies have to think 
twice whether to introduce a new medicinal product into this market. Also the different 
markets are depending from each other - which means if a company would accept a certain 
price in one country (which is often lower than the price companies want to have for the 
medicinal product), other countries (e.g. neighbor countries) are looking for this price and 
make often an additional reduction of this price in their countries. E.g. the countries in ME 
region (like Saudi Arabia) ask for the reference prices in 30 countries (including EU 
countries, all neighbor countries in ME region) and based on the lowest price in these 
countries they will fix the price mostly again lower than the lowest price in the 30 requested 
countries. From a country perspective this makes sense in order to save money but for 
researching companies it unfortunately often leads to a situation that a drug will not be 
marketed in these countries as the price is too low to be rentable for the companies. As the 
development of a new medicinal products cost a lot of money and the patent protection of 
new medicinal products are limited (20 years patent protections plus 5 years protection 
through SPC) the companies need to have reinvested their development costs during these 
time. Therefore it is quite logical that new medicinal products are quite expensive and that 
the companies are not in favor to except all prices which countries offers them for their 
medicine. Therefore the tendency that certain drugs are not available in certain countries 
anymore because of price issues will probably increase during the next years. It has to be 
seen how governments in the countries and pharmaceutical companies will act and react on 
this issue which at the end goes to the expense of patients. 
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In principle the global submissions of an NBE or an NCE does not differ much regarding the 
submission strategy. In the past the development for NBEs and NCEs are mainly focused on 
EU and USA and consequently also the first submissions were prepared and done in EU and 
USA. Afterwards the other countries like JP, SEA, EE, LA, ME/AFR were covered. In future 
this will change certainly as pharmaceutical companies have recognized that also markets 
like JP, China or Russia become more and more importance. So in future the global 
submissions for NBEs or NCEs will not be focused first on EU and USA anymore but will also 
included countries like JP, China or Russia.  
As mentioned before the main differences between the development and consequently also 
for the global submission strategy between an NBE and an NCE lie within the CMC part. 
Critical topics for NCEs are e.g. the definition of the starting materials or the analysis and 
characterization of the impurities. The critical topics regarding NBEs are the characterization 
and the manufacturing process. It is really strongly recommended to discuss such topics in 
advance with the DRAs. Another issue which often comes up during the submission of the 
MAA dossier in the different countries is the QC testing of the DS and DP. In many countries 
it is mandatorily requested to make at least a QC testing of the DP during or after the 
evaluation of the dossier. The evaluation of the dossier and the outcome of the QC testing is 
the basis for granting the MA in these countries. In case QC testing is requested the 
applicant has to provide DP, DS and if available also the impurities and/or degradation 
products of DP. The request for QC testing for NCEs is normally no issue for the applicants 
as the materials, equipment and expertise needed for performing the QC testing is mainly 
available at the DRAs and only the samples have to be provided. Sometimes - in case 
material and/or equipment are not available at the DRA laboratory - also material and/or 
equipment like HPLC columns are requested from the applicant. The applicant then provides 
the requested material and/or equipment and the DRA performs the QC testing. For NBEs 
the QC testing is often more complicated as some special materials and/or equipment are 
needed, e.g. for the testing of the biological activity often cells are needed. Besides the 
samples then also the missing materials like cells are requested from the applicant. As 
mentioned above the provision of samples should be also no issue for an NCE. But the 
provision of materials like cells is sometimes an issue as the cells are often patent protected 
(but not in all countries as patents don’t exist in all countries or the applicant has not applied 
for the patent in all countries). One option to overcome these difficulties is the possibility to 
provide the cells accompanied with a confidentiality agreement which the DRA will sign and 
send back to the applicant. Within this confidentiality agreement the DRA guarantees that the 
cells are only used for the QC testing and are kept confidential. In many countries where no 
patent protection is available or not done by the applicant the DRAs are willing to sign such 
an agreement and to guarantee that the cells are only used for the QC testing.  
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After the QC testing is done and the evaluation of the dossier is finalized the MAA is granted. 
Should there be difficulties in performing the QC testing for an NBE or an NCE one possibility 
could be to invite the DRA to the laboratories of the applicant to demonstrate the QC testing. 
Besides the differences in the CMC part there might be also a difference in the submission 
strategy regarding the sequence of submissions (e.g. in which countries the first submissions 
are made and the sequence of countries where the MAA will be submitted). Based on the 
expertise of the DRAs on NBEs or NCEs and on the indications for which the NBE or NCE is 
developed it might differ in which countries the first MAAs will be submitted. It is advisable to 
submit the MAA first in countries with a great experience and expertise on NBEs or NCEs as 
well as a great expertise in the developed indications to be able to get a registration quite 
fast. Dependent in which countries the first registrations are granted this might support the 
registration process also in other countries. 
In summary it can be said that the only differences which can be seen regarding the 
submission strategy are regarding aspects in the CMC part and regarding the sequence of 
submissions (in which country to submit when the MAA dossier), otherwise there are not 
really differences in the submission strategy for an NBE or an NCE. 
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6 5BConclusion and Outlook 
This chapter describes the recommendation for development of a global regulatory strategy 
and provides a recommendation which regulatory procedure to use for which product. The 
recommendations are given based on my own experience in pharmaceutical industry for 
several years. 
 
6.1 22BRecommendation which Regulatory Procedure to use for 
which Product 
There are several regulatory aspects which have to be taken into account to decide which 
procedure (in case there are several regulatory procedures available in the countries) – 
should be used to apply for a MA in EU, USA, CADREAC, Singapore, China and Brazil. 
In principle it is dependent on the kind of medicinal product which should be registered in the 
country. The different registration procedures have often well defined prerequisites under 
which circumstances which type of registration procedure can be used (please refer to the 
table " Comparison of different registration procedures in the different countries and pro/con 
arguments for each procedure" in chapter X4 X/page 90ff.) - so it is mostly not possible for the 
applicants to choose by themselves the type of registration procedure. 
The accelerated procedures are in some countries only possible for MAAs of NCEs and not 
for NBEs due to the complexity of NBEs. In most countries fast track procedures are only 
applicable for serious or life-threatening diseases which have potential to address unmet 
medical need or for life-saving drugs or only for orphan drugs.  
E.g. in EU for several kind of products the CP is mandatory so there is no choice of 
procedure (refer to section X3.2.2 X and section X4 X), the same is also valid for other countries like 
CADREAC, China or USA. In Singapore it is dependent whether the medicinal product 
should be authorized before approval in the reference countries (like AUS, Canada, EU or 
USA) or whether to wait for submission until MA is granted in reference countries. In China 
there is also the possibility to apply for the MA before approval of the medicinal product in 
any country of the world via the special review procedure (see section X3.6.3 X and section X4 X). 
For using the accelerated procedures in the countries, there exists often very strict guidelines 
when and how to use these procedures.  
The "normal" registration procedures are applicable for all kind of products and can be used 
by the applicant for all kind of MAAs. 
Therefore it is advisable that the applicant evaluates very carefully before submission of an 
MAA which type of registration procedure can be used in which country for which type of 
product. In case of doubt or open questions it is advisable that the applicant may ask for a 
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consultation meeting with the authority of the concerned country. After the registration 
procedures are chosen for each country the applicant can submit the MAA. 
The different registration procedures in the countries have the identical main goal which is to 
protect human health and to make available new medicinal products as soon as possible. To 
evaluate the quality, safety and efficacy of the medicinal products is mandatory for getting 
approvals of the medicinal products. 
To sum up, aspects like flexibility of the applicant/MAH, duration of the MA procedure, 
evaluation procedure of the dossier, date for submission of MAA, lifecycle of a product, 
harmonization of dossier and labeling documents (SPC and PIL), costs of the procedure and 
of course the product itself should be considered for the decision which procedure to be used 
for the MAA of a certain product in the different countries. 
 
6.2 23BRecommendations for the Development of a Global 
Regulatory Strategy 
In general, different regulations and procedures regarding the application for a new MA exist 
in the different countries worldwide. The main goal of all regulatory regulations and 
procedures in the countries are to protect human health by following them and to describe in 
details how to approve new safe medicinal products. Each medicinal product (NBE and 
NCEs) has to show highest quality, safety and efficacy. 
The extent and the level of the requirements depend on the potential risk of harmful effects 
on human beings, animals and environment. 
During the development of a new product (NBE or NCE) it is therefore mandatory to know all 
these regulations and requirements especially of the key markets where a submission of the 
dossier for the new product will be done after development. To identify the key markets for a 
new product the marketing divisions of a company will evaluate during the development 
phases the market potential of the new product (NBE and NCE) under development. Based 
on this market research the whole global development program will be established with the 
goal to get registration as fast as possible in the key markets. Within the global development 
program all aspects concerning quality, safety and efficacy based on the current available 
legislations (regulations, directives and guidelines) have to be incorporated. It is advisable to 
create a global development team. This global development team should consist at least of 
representatives from the following functions: one representative from CMC, one 
representative from nonclinical (maybe one from toxicology and one from pharmacology), 
one representative from clinical, one representative from regulatory affairs and one 
representative from marketing. In addition the team should be led from a global development 
team leader and should have also one project manager as member for all project 
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coordinating work. The adequate time point for creation of such a global development team 
is after finalization of Phase 0 - before starting with clinical trials. 
It is emphasized that it is strongly recommended to include a representative from regulatory 
affairs in the global development team beginning latest after Phase 0 (latest after the 
nonclinical development is done). For the whole further development of a new compound the 
regulatory advice should be provided especially with regard to guidelines, regulations, etc. 
This is true for the CMC development as well as for the clinical development. The regulatory 
affairs representative can provide advice how to set up a clinical trial with regard to current 
regulation and guidelines to ensure that the clinical trial is performed according to the current 
regulations and guidelines. Otherwise there is the risk that the authority won't accept the trial 
if it is not performed according to current regulations and guidelines. This risk normally no 
company would like to take as especially the clinical development is quite expensive during 
the development of a new compound. 
In general it is advisable that the global team is the decision making board for the new 
product under development. For the most important decisions which are mostly also the most 
cost intensive decisions (like go on from Phase II to Phase III) it is mandatory that the global 
team will make a recommendation based on the available data and the upper management 
will decide finally. 
 
During the last years the requirements for developing new medicinal products becomes more 
and more complex. Since some years it is e.g. mandatory to present also pediatric studies in 
EU and USA and also in some other countries. These additional studies cost additional time 
and money for the companies. For some indications which are not available in children it is 
possible to apply for a waiver in EU to avoid making studies in children. But for indications 
which are also available in children it is mandatory to make clinical trials in children before 
submitting the MAA. Also discussions whether special clinical studies in the elderly are still 
ongoing and it has to be seen whether also such studies become mandatory in future.  
The highest goal for the development of new compounds for sure is the safety of the patients 
and also the proof of efficacy of the new medicinal product. For these goals the companies 
are surely willing to invest a lot of money to develop new innovative safe and efficient 
medicinal product. On the other hand the companies also need to have a return of 
investment (they should earn at least the money they invested in the development of the 
product). If in future companies have to recognize that there is no return of investment any 
more due to health economic issues like price reductions there might come the day where 
companies are not willing to develop new medicinal products any more as the development 
of new products costs more money that it brings back. Therefore the politicians in the 
different countries should evaluate very carefully the health care system before doing some 
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reforms which at the end might be a disadvantage for the patients because of the non 
availability of innovative drugs any more. 
Regarding this issue especially the changing environment for making global development of 
new products needs to be taken into consideration. Due to the political situation in many 
countries e.g. reforms of the health care systems it becomes more and more difficult for 
researching pharmaceutical companies to make global development. In principle everybody 
would like to have new and innovative medicinal products especially against life threatening 
diseases but often the people and the systems are not in favor to pay for these innovations. 
In many countries therefore the prices for new medicines are limited which means that 
companies have to think twice whether to introduce a new medicinal product into this market. 
As the development of a new medicinal products cost a lot of money and the patent 
protection of new medicinal products are limited (20 years patent protections plus 5 years 
protection through supplementary protection certificate (SPC)) companies should have 
reinvested their development costs during these protected time. Therefore it is quite logical 
that new medicinal products are quite expensive.  
 
All discussed issues and recommendations should be taken into consideration for future 
developments.  
In the past the focus in development lies clearly on the ICH region, mainly EU and USA. 
Companies make the global development based on these two markets (EU and USA). The 
development for other countries often started after the initial approval in EU and/or USA. This 
led often to a situation that approval in countries outside ICH can be achieved only years 
after the initial approvals in EU and USA as additional studies (like special stability studies, 
pharmacodynamic (PD) and/or pharmacokinetic (PK) studies or clinical studies) are needed 
for these countries. As countries outside ICH will become more and more important from 
their market potential companies are interested to receive approvals in these countries as 
early as possible. Therefore the global development of a new product should not be focused 
any more only on EU and USA in the first step. Countries like China, Russia, Brazil or India 
should be included in the global development quite early to be able to make parallel 
submissions or at least to submit as soon as an approval in EU and/or US is achieved.  
Based on the already discussed issues it can be anticipated that it will get more difficult to 
get new medicinal products approved in future. The requirements to get a medicinal product 
approved increase compared to some years ago and it might happen that the requirements 
will increase further. During the last years the tendency can be observed that more patient 
tailored drugs are requested by authorities compared to products approved in very broad 
indications. Companies are requested to develop patient tailored drugs. This might be not so 
beneficial from a company perspective as the number of patients which can be treated with 
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one medicinal product which is patient tailored might be smaller. Nevertheless, this is the 
direction agencies might follow in future. Therefore topics like biomarkers or other specific 
markers to identify patient tailored drugs will become more and more important in future. It is 
advisable for companies to include biomarkers or other specific marker in their development 
program of a new compound as otherwise authorities might not grant the submitted MA. In 
order to be sure what authorities want it is recommended to make scientific meetings with the 
authorities to discuss and agree on the clinical development program especially with regard 
to setting of clinical trials, endpoints and biomarkers/specific markers. 
Due to the higher requirements for developing new compounds also the development time 
and costs might increase. Therefore companies are interested to get high prices for new 
medicinal products in order to get their return on investment during the running patent period 
and data exclusivity period back to be able to invest the earned money in the development of 
other new compounds. 
Also other aspects like health economic aspects will become more and more important. 
Currently in many countries companies are free in setting the prices for new medicinal 
products which are normally quite high. If the medicinal product is reimbursed in a country 
the health care system has to pay the high price for the medicinal product. As many health 
care systems are not able to pay so many money anymore in future it is most likely that 
governments will limit prices for new medicinal products in many countries in order to relieve 
the health care systems. It can be also anticipated that for future developments the proof of 
quality, safety and efficacy may not be sufficient but in addition the company has to proof 
also the cost benefit ratio for a new medicinal product by making some studies. Medicinal 
products which have shown a positive cost benefit ratio will be reimbursed. This might lead to 
the situation that companies will not register and marketed new medicinal products in all 
countries in future as the price offered to get for the new medicinal product might be too low. 
This is a bad situation for patients as they might not be able to receive new drugs in future 
although the need for innovative new medicinal products will exceed especially due to the 
excess of age in the population. 
In conclusion the requirements to get a drug registered and reimbursed will increase and 
consequently the development costs for companies will increase, too. It has to be awaited 
how government will build up the health care systems in future and how requirements will 
change. One possible solution to deal with the increase costs for development and the 
increasing requirements might be that pharmaceutical companies will merge and will develop 
new innovative medicinal products together and share the development costs. This will be 
especially attractive for small and medium-sized companies. Also companies might think 
about the location of their development centers in order to optimize the development. It is 
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recommended that companies will have only one or two global development centers where 
the global development for all new compounds is done.  
Companies can also think about an "award" for fast and goal oriented development of new 
drugs. This might be an additional motivation for co-workers to work more efficient and to 
fasten the development of new drugs. 
Pharmaceutical companies should be in close contact with authorities in order to be able to 
fulfill all requirements needed to get a new medicinal product approved and marketed. 
Companies should be also in close contacts with governments and health care systems in 
order to fulfill their requirements and in order to be able to influence them with regard to 
decisions on health care systems. 
Authorities and governments should offer pharmaceutical companies some incentives in 
order to advance the development of new innovative drugs. 
As the requirements increase for getting new drugs registered, authorities might offer an 
incentive for companies developing new innovative drugs in future. Such incentives could be 
e.g. a longer data exclusivity period (as protection against generic companies), market 
exclusivity for some additional years or reduction of registration costs. 
Besides all increasing barriers for getting new products approved and marketed, it is of 
utmost importance that the development of new innovative medicinal product will be 
continued to offer patients best medicinal supply. 
Therefore it seems to be logical that pharmaceutical companies, authorities and 
governments have to work together and find solutions that the development of new 
innovative drugs will be attractive and efficient for all sites in future. 
 
 
 155
7 6BPreliminary Publications and Presentations 
Hörner A. "Describe the CADREAC-procedure for a product which was authorized via mutual 
recognition procedure in the EU and compare the CADREAC-procedure with the national 
procedure in one CADREAC country (e.g. Romania)", Wissenschaftliche Prüfungsarbeit zur 
Erlangung des Titels „Master of Drug Regulatory Affairs“ der Mathematisch-
Naturwissenschaftlichen Fakultät der Rheinischen Friedrich-Wilhelms-Universität Bonn, May 
2005; available from http://www.dgra.de/studiengang/master_thesis/hoerner.php and 
http://www.dgra.de/studiengang/pdf/master_hoerner_a.pdf, accessed August 6, 2010 
 
Hörner A. "Analysis of requirements for a new marketing authorization application for new 
chemical entities and new biological entities" Doktoranden-Vortragstag. 
Bonn: Rheinische Friedrich-Wilhelms-Universität Bonn, April 04, 2008; available from 
http://home.arcor.de/janna-schweim/8-Hoerner.pdf, accessed August 6, 2010 
 
Hörner A. "General requirements for a new marketing authorization application with focus on 
ASEAN"  Doktoranden-Vortragstag Bonn: Rheinische Friedrich-Wilhelms-Universität Bonn, 
April 25, 2009; available from http://www.harald-g-schweim.de/Hoerner-2009.pdf; Internet; 
accessed August 6, 2010 
 
Herrmann A. "General information, drug development and requirements for a new marketing 
authorization application for new chemical entities and new biological entities in China" 
Doktoranden-Vortragstag. 
Bonn: Rheinische Friedrich-Wilhelms-Universität Bonn, May 29, 2010; available from 
http://www.harald-schweim.de/09-Herrmann-2010.pdf Internet; accessed August 6, 2010. 
 
Herrmann A., Schweim H.G. "The Benefits of Joining nCADREAC" in Regulatory Affairs 
Journal (RAJ) Pharma, August 2010, P-485-487 
 
 
 156
8 7BCurriculum vitae 
Not contained in this version 
 
 
 157
 
 
 158
 
 
 
 
 
 
 159
9 8BAppendices 
 
APPENDIX 1 CTD TABLE OF CONTENTS 
The table of contents (ToCs) of Module 2 – 5 of the ICH CTD dossier is enclosed as 
an attachment: 
♦ Module 2: CTD Summaries 
Module 2.1 CTD ToCs (Module 2 – 5) 
Module 2.2 Introduction 
Module 2.3 Quality Overall Summary (QOS) 
Module 2.4 Nonclinical Overview (NCO) 
Module 2.5 Clinical Overview (CO) 
Module 2.6 Nonclinical Summary 
Module 2.7 Clinical Summary 
♦ Module 3: Quality - Chemical-pharmaceutical and biological information 
for chemical active substances and biological medicinal product 
3.1 Module 3 ToC 
3.2 Body of data  
3.2.S Drug substance (DS) 
3.2.S.1 General Information 
3.2.S.1.1 Nomenclature 
3.2.S.1.2 Structure 
3.2.S.1.3 General properties 
3.2.S.2 Manufacture 
3.2.S.2.1 Manufacturer(s) 
3.2.S.2.2 Description of manufacturing process and process controls  
3.2.S.2.3 Control of materials  
3.2.S.2.4 Controls of critical steps and intermediates (Biotech) 
3.2.S.2.5 Process validation and or evaluation 
3.2.S.2.6 Manufacturing process development  
3.2.S.3 Characterization ~xr26i 
3.2.S.3.1 Elucidation of structure and other characteristics ~xr27i 
3.2.S.3.2 Impurities ~xr28i 
3.2.S.4 Control of drug substance ~xr29i 
3.2.S.4.1 Specification ~xr30i 
3.2.S.4.2 Analytical procedures ~xr31i 
3.2.S.4.3 Validation of analytical procedures ~xr32i 
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3.2.S.4.4 Batch analyses ~xr33i 
3.2.S.4.5 Justification of specifications ~xr34i 
3.2.S.5 Reference standards of materials ~xr35i 
3.2.S.6 Container closure system ~xr36i 
3.2.S.7 Stability ~xr37i 
3.2.S.7.1 Stability summary and conclusions ~xr38i 
3.2.S.7.2 Post-approval stability protocol and stability commitment ~xr39i 
3.2.S.7.3 Stability data ~xr40i 
 
3.2.P Drug product (DP) ~xr41i 
3.2.P.1 Description and composition of the drug product 
3.2.P.2 Pharmaceutical development ~xr43i 
3.2.P.3 Manufacture ~xr44i 
3.2.P.3.1 Manufacturer(s) ~xr45i 
3.2.P.3.2 Batch formula ~xr46i 
3.2.P.3.3 Description of manufacturing process and process controls ~xr47i 
3.2.P.3.4 Controls of critical steps and intermediates ~xr48i 
3.2.P.3.5 Process validation and or evaluation ~xr49i 
3.2.P.4 Control of excipients ~xr50i 
3.2.P.4.1 Specifications ~xr51i 
3.2.P.4.2 Analytical procedures ~xr52i 
3.2.P.4.3 Validation of analytical procedures ~xr53i 
3.2.P.4.4 Justification of specifications ~xr54i 
3.2.P.4.5 Excipients of human or animal origin ~xr55i 
3.2.P.4.6 Novel excipients ~xr56i 
3.2.P.5 Control of drug product ~xr57i 
3.2.P.5.1 Specifications ~xr58i 
3.2.P.5.2 Analytical procedures ~xr59i 
3.2.P.5.3 Validation of analytical procedures ~xr60i 
3.2.P.5.4 Batch analyses ~xr61i 
3.2.P.5.5 Characterization of impurities ~xr62i 
3.2.P.5.6 Justification of specifications ~xr63i 
3.2.P.6 Reference standards or materials ~xr64i 
3.2.P.7 Container closure system 
3.2.P.8 Stability ~xr66i 
3.2.P.8.1 Stability summary and conclusion ~xr67i 
3.2.P.8.2 Post-approval stability protocol and stability commitment ~xr68i 
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3.2.P.8.3 Stability data ~x 
r69i 
3.2.A Appendices ~xr70i 
3.2.A.1 Facilities and equipmentxr73i 
3.2.A.2 Adventitious agents safety evaluation ~xr74i~xr75i 
3.2.A.3 Novel excipients 
3.2.R Regional information ~xr76i 
3.2.R.1 Batch records 
3.2.R.2 Process validation scheme for the drug product 
3.2.R.3 Medical device 
3.2.R.4 Medicinal products containing or using in the manufacturing process  
materials of animal and/or human origin 
 
3.3 Literature references 
 
♦ Module 4: Nonclinical Study Reports 
4.1 ToCs of Module 4 
4.2 Study Reports 
4.2.1 Pharmacology 
4.2.1.1 Primary Pharmacodynamics 
4.2.1.2 Secondary Pharmacodynamics 
4.2.1.3 Safety Pharmacology 
4.2.1.4 Pharmacodynamic Drug Interactions 
4.2.2 Pharmacokinetics 
4.2.2.1 Analytical Methods and Validation Reports (if separate reports are 
available) 
4.2.2.2 Absorption 
4.2.2.3 Distribution 
4.2.2.4 Metabolism 
4.2.2.5 Excretion 
4.2.2.6 Pharmacokinetic Drug Interactions (nonclinical) 
4.2.2.7 Other Pharmacokinetic Studies 
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4.2.3 Toxicology 
4.2.3.1 Single-Dose Toxicity (in order by species, by route) 
4.2.3.2 Repeat-Dose Toxicity (in order by species, by route, by duration; 
including supportive toxicokinetics evaluations) 
4.2.3.3 Genotoxicity 
4.2.3.3.1 In vitro 
4.2.3.3.2 In vivo (including supportive toxicokinetics evaluations) 
4.2.3.4 Carcinogenicity (including supportive toxicokinetics evaluations) 
4.2.3.4.1 Long-term studies (in order by species; including range finding 
studies that cannot appropriately be included under 
repeat-dose toxicity or pharmacokinetics) 
4.2.3.4.2 Short- or medium-term studies (including range-finding 
studies that cannot appropriately be included under repeat dose 
toxicity or pharmacokinetics) 
4.2.3.4.3 Other studies 
4.2.3.5 Reproductive and Developmental Toxicity (including range-finding 
studies and supportive toxicokinetics evaluations) (If modified study designs 
are used, the following sub-headings should be modified accordingly.) 
4.2.3.5.1 Fertility and early embryonic development 
4.2.3.5.2 Embryo-fetal development 
4.2.3.5.3 Prenatal and postnatal development, including maternal function 
4.2.3.5.4 Studies in which the offspring (juvenile animals) are dosed and/or 
further evaluated. 
4.2.3.6 Local Tolerance 
4.2.3.7 Other Toxicity Studies (if available) 
4.2.3.7.1 Antigenicity 
4.2.3.7.2 Immunotoxicity 
4.2.3.7.3 Mechanistic studies (if not included elsewhere) 
4.2.3.7.4 Dependence 
4.2.3.7.5 Metabolites 
4.2.3.7.6 Impurities 
4.2.3.7.7 Other 
 
4.3 Literature references 
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♦ Module 5: Clinical Study Reports 
5.1 ToCs of Module 5 
5.2 Tabular Listing of All Clinical Studies 
5.3 Clinical Study Reports 
5.3.1 Reports of Biopharmaceutic Studies 
5.3.1.1 Bioavailability (BA) Study Reports 
5.3.1.2 Comparative BA and Bioequivalence (BE) Study Reports 
5.3.1.3 In vitro-In vivo Correlation Study Reports 
5.3.1.4 Reports of Bioanalytical and Analytical Methods for Human Studies 
5.3.2 Reports of Studies Pertinent to Pharmacokinetics using Human 
Biomaterials 
5.3.2.1 Plasma Protein Binding Study Reports 
5.3.2.2 Reports of Hepatic Metabolism and Drug Interaction Studies 
5.3.2.3 Reports of Studies Using Other Human Biomaterials 
5.3.3 Reports of Human Pharmacokinetic (PK) Studies 
5.3.3.1 Healthy Subject PK and Initial Tolerability Study Reports 
5.3.3.2 Patient PK and Initial Tolerability Study Reports 
5.3.3.3 Intrinsic Factor PK Study Reports 
5.3.3.4 Extrinsic Factor PK Study Reports 
5.3.3.5 Population PK Study Reports 
5.3.4 Reports of Human Pharmacodynamic (PD) Studies 
5.3.4.1 Healthy Subject PD and PK/PD Study Reports 
5.3.4.2 Patient PD and PK/PD Study Reports 
5.3.5 Reports of Efficacy and Safety Studies 
5.3.5.1 Study Reports of Controlled Clinical Studies Pertinent to the Claimed 
Indication 
5.3.5.2 Study Reports of Uncontrolled Clinical Studies 
5.3.5.3 Reports of Analyses of Data from More Than One Study 
5.3.5.4 Other Clinical Study Reports 
5.3.6 Reports of Post-Marketing Experience  
5.3.7 Case Report Forms and Individual Patient Listings 
 
5.4 Literature References 
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APPENDIX 2 CTD TABLE OF CONTENT FOR EU MODULE 1 
♦ Module 1: Administrative Information and Prescribing Information 
Table of Content 
1.0 Cover Letter 
1.1 Comprehensive Table of Contents 
1.2 Application Form 
1.3 Product Information 
1.3.1 Summary of product characteristics (SPC), Labeling and Package 
Leaflet (PIL) 
1.3.2 Mock-up 
1.3.3 Specimen 
1.3.4 Consultation with Target Patient Groups 
1.3.5 Product Information already approved in the Member States 
1.3.6 Braille 
1.4 Information about the Experts 
1.4.1 Quality 
1.4.2 Non-Clinical 
1.4.3 Clinical 
1.5 Specific Requirements for Different Types of Applications 
1.5.1 Information for Bibliographical Applications 
1.5.2 Information for Generic, ‘Hybrid’ or Bio-similar Applications 
1.5.3 (Extended) Data/Market Exclusivity 
1.5.4 Exceptional Circumstances 
1.5.5 Conditional Marketing Authorisation 
1.6 Environmental Risk Assessment 
1.6.1 Non-GMO 
1.6.2 GMO 
1.7 Information relating to Orphan Market Exclusivity 
1.7.1 Similarity 
1.7.2 Market Exclusivity 
1.8 Information relating to Pharmacovigilance 
1.8.1 Pharmacovigilance System 
1.8.2 Risk-management System 
1.9 Information relating to Clinical Trials 
Responses to Questions 
Additional Data 
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APPENDIX 3 DIFFERENCES NBE AND NCE WITH REGARD TO MODULE 2 AND 3 
For detailed information please refer to the attached tableX12 
 NCE NBE 
Module 2 
Section: 2.3.S.3 
Characterization 
(name, manufacturer) 
A summary of the interpretation of evidence of 
structure and isomerism, as described in 
3.2.S.3.1, should be included. 
When a drug substance is chiral, it should be 
specified whether specific stereoisomers or a 
mixture of stereoisomers have been used in 
the nonclinical and clinical studies, and 
information should be given as to the 
stereoisomer of the drug substance that is to 
be used in the final product intended for 
marketing. 
For NCE and Biotech: 
The QOS should summarize the data on 
potential and actual impurities arising from the 
synthesis, manufacture and/or degradation, 
and should summarize the basis for setting the 
acceptance criteria for individual and total 
impurities. The QOS should also summarize 
the impurity levels in batches of the drug 
substance used in the non-clinical studies, in 
the clinical trials, and in typical batches 
manufactured by the proposed commercial 
process. The QOS should state how the 
proposed impurity limits are qualified. 
A tabulated summary of the data provided in 
3.2.S.3.2, with graphical representation, where 
appropriate should be included. 
For Biotech: 
A description of the desired product and product-related 
substances and a summary of general properties, 
characteristic features and characterization data (for 
example, primary and higher order structure and 
biological activity), as described in 3.2.S.3.1, should be 
included. 
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Module 3 
3.2.S.1.2 Structure 
(name, manufacturer) 
 
NCE: 
The structural formula, including relative and 
absolute stereochemistry, the molecular formula, 
and the relative molecular mass should be 
provided. 
Reference CPMP-Guidelines: “Chemistry of the 
New Active Substance” and 
“Chemistry of the Active Substance” 
Biotech: 
The schematic amino acid sequence indicating glycosylation 
sites or other posttranslational modifications and relative 
molecular mass should be provided, as appropriate. 
 
Reference CPMP Guidelines: “Chemistry of the New Active 
Substance” and “Chemistry of 
the Active Substance” 
 
Module 3 
3.2.S.2.2 Description of 
Manufacturing Process 
and Process Controls 
(name, manufacturer) 
 
NCE: 
A flow diagram of the synthetic process(es) 
should be provided that includes molecular 
formulae, weights, yield ranges, chemical 
structures of starting materials, intermediates, 
reagents and drug substance reflecting 
stereochemistry, and identifies operating 
conditions and solvents. 
A sequential procedural narrative of the 
manufacturing process should be submitted. The 
narrative should include, for example, quantities 
of raw materials, solvents, catalysts and reagents 
reflecting the representative batch scale for 
commercial manufacture, identification of critical 
steps, process controls, equipment and operating 
conditions (e.g., temperature, pressure, pH, 
time). 
Alternate processes should be explained and 
described with the same level of detail as the 
primary process. Reprocessing steps should be 
Biotech: 
Information should be provided on the manufacturing 
process, which typically starts with a vial(s) of the cell bank, 
and includes cell culture, harvest(s), purification and 
modification reactions, filling, storage and shipping 
conditions. Batch(es) and scale definition.  
An explanation of the batch numbering system, including 
information regarding any pooling of harvests or 
intermediates and batch size or scale should be provided. 
Cell culture and harvest. 
A flow diagram should be provided that illustrates the 
manufacturing route from the original inoculum (e.g. cells 
contained in one or more vials(s) of the Working Cell Bank 
up to the last harvesting operation. The diagram should 
include all steps (i.e., unit operations) and intermediates. 
Relevant information for each stage, such as population 
doubling levels, cell concentration, volumes, pH, cultivation 
times, holding times, and temperature, should be included. 
Critical steps and critical intermediates for which 
specifications are established (as mentioned in 3.2.S.2.4) 
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 NCE NBE 
identified and justified. Any data to support this 
justification should be either referenced or filed in 
3.2.S.2.5. 
 
should be identified. 
A description of each process step in the flow diagram 
should be provided. 
Information should be included on, for example, scale; 
culture media and other additives (details provided in 
3.2.S.2.3); major equipment (details provided in 3.2.A.1); 
and process controls, including in-process tests and 
operational parameters, process steps, equipment and 
intermediates with acceptance criteria (details provided in 
3.2.S.2.4). Information on procedures used to transfer 
material between steps, equipment, areas, and buildings, as 
appropriate, and shipping and storage conditions should be 
provided. (Details on shipping and storage provided in 
3.2.S.2.4.). 
Purification and modification reactions 
A flow diagram should be provided that illustrates the 
purification steps (i.e., unit operations) from the crude 
harvest(s) up to the step preceding filling of the drug 
substance. All steps and intermediates and relevant 
information for each stage (e.g., volumes, pH, critical 
processing time, holding times, temperatures and elution 
profiles and selection of fraction, storage of intermediate, if 
applicable) should be included. Critical steps for which 
specifications are established as mentioned in 3.2.S.2.4 
should be identified. 
A description of each process step (as identified in the flow 
diagram) should be provided. The description should include 
information on, for example, scale, buffers and other 
reagents (details provided in 3.2.S.2.3, major equipment 
(details provided in 3.2.A.1), and materials. For materials 
such as membranes and chromatography resins, 
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information for conditions of use and reuse also should be 
provided. (Equipment details in 3.2.A.1; validation studies 
for the reuse and regeneration of columns and membranes 
in 3.2.S.2.5.) The description should include process 
controls (including in-process tests and operational 
parameters) with acceptance criteria for process steps, 
equipment and intermediates. (Details in 3.2.S.2.4.). 
Reprocessing procedures with criteria for reprocessing of 
any intermediate or the drug substance should be 
described. (Details should be given in 3.2.S.2.5.). 
Information on procedures used to transfer material between 
steps, equipment, areas, and buildings, as appropriate, and 
shipping and storage conditions should be provided (details 
on shipping and storage provided in 3.2.S.2.4.). 
Filling, storage and transportation (shipping) 
A description of the filling procedure for the drug substance, 
process controls (including in-process tests and operational 
parameters), and acceptance criteria should be provided. 
(Details in 3.2.S.2.4.) The container closure system(s) used 
for storage of the drug substance (details in 3.2.S.6.) and 
storage and shipping conditions for the drug substance 
should be described. 
Module 3 
3.2.S.2.3 Control of 
Materials (name, 
manufacturer) 
 
NCEs and Biotech: 
Materials used in the manufacture of the drug 
substance (e.g., raw materials, starting materials, 
solvents, reagents, catalysts) should be listed 
identifying where each material is used in the 
process. Information on the quality and control of 
these materials should be provided. Information 
demonstrating that materials (including 
biologically-sourced materials, e.g., media 
Biotech: 
Materials used in the manufacture of the drug substance 
(e.g., raw materials, starting materials, solvents, reagents, 
catalysts) should be listed identifying where each material is 
used in the process. Information on the quality and control of 
these materials should be provided. Information 
demonstrating that materials (including biologically-sourced 
materials, e.g., media components, monoclonal antibodies, 
enzymes) meet standards appropriate for their intended use 
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components, monoclonal antibodies, enzymes) 
meet standards appropriate for their intended use 
(including the clearance or control of adventitious 
agents) should be provided, as appropriate. For 
biologically-sourced materials, this can include 
information regarding the source, manufacture, 
and characterization. (Details in 3.2.A.2 for both 
NCE and Biotech) 
 
(including the clearance or control of adventitious agents) 
should be provided, as appropriate. For biologically-sourced 
materials, this can include information regarding the source, 
manufacture, and characterization. (Details in 3.2.A.2 for 
both NCE and Biotech) 
 
Additional for Biotech: 
Control of Source and Starting Materials of Biological Origin 
Summaries of viral safety information for biologically-
sourced materials should be provided. (Details in 3.2.A.2.) 
Source, history, and generation of the cell substrate 
Information on the source of the cell substrate and analysis 
of the expression construct used to genetically modify cells 
and incorporated in the initial cell clone used to develop the 
Master Cell Bank should be provided as described in 
CPMPICH Guidelines Q5B and Q5D. 
Cell banking system, characterization, and testing 
Information on the cell banking system, quality control 
activities, and cell line stability during production and 
storage (including procedures used to generate the Master 
and Working Cell Bank(s)) should be provided as described 
in CPMP-ICH 
Guidelines Q5B and Q5D. 
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Module 3 
3.2.S.2.5 Process 
Validation and/or 
Evaluation (name, 
manufacturer) 
 
Process validation and/or evaluation studies for 
aseptic processing and sterilization should be 
included. 
 
Process validation and/or evaluation studies for aseptic 
processing and sterilization should be included. 
 
Biotech: 
Sufficient information should be provided on validation and 
evaluation studies to demonstrate that the manufacturing 
process (including reprocessing steps) is suitable for its 
intended purpose and to substantiate selection of critical 
process controls (operational parameters and in-process 
tests) and their limits for critical manufacturing steps (e.g., 
cell culture, harvesting, purification, and modification). 
The plan for conducting the study should be described and 
the results, analysis and conclusions from the executed 
study(ies) should be provided. The analytical procedures 
and corresponding validation should be cross-referenced 
(e.g., 3.2.S.2.4, 3.2.S.4.3) or provided as part of justifying 
the selection of critical process controls and acceptance 
criteria. 
For manufacturing steps intended to remove or inactivate 
viral contaminants, the information from evaluation studies 
should be provided in 3.2.A.2. 
Module 3 
3.2.S.2.6 Manufacturing 
Process Development 
(name, manufacturer) 
 
NCE: 
A description and discussion should be provided 
of the significant changes made to 
the manufacturing process and/or manufacturing 
site of the drug substance used in producing 
nonclinical, clinical, scale-up, pilot, and, if 
available, production scale 
batches. 
Biotech: 
The developmental history of the manufacturing process, as 
described in 3.2.S.2.2, should be provided. The description 
of change(s) made to the manufacture of drug substance 
batches used in support of the marketing application (e.g., 
nonclinical or clinical studies) should include, for example, 
changes to the process or to critical equipment. The reason 
for the change should be explained. Relevant information on 
drug substance batches manufactured during development, 
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Reference should be made to the drug substance 
data provided in section 3.2.S.4.4. 
Reference CPMP-ICH Guideline: “Impurities 
testing guideline: impurities in new drug 
substances 
such as the batch number, manufacturing scale, and use 
(e.g., stability, nonclinical, reference material) in relation to 
the change, should be provided. 
The significance of the change should be assessed by 
evaluating its potential to impact the quality of the drug 
substance (and/or intermediate, if appropriate). For 
manufacturing changes that are considered significant, data 
from comparative analytical testing on relevant drug 
substance batches should be provided to determine the 
impact on quality of the drug substance (see Q6B for 
additional guidance). A discussion of the data, including a 
justification for selection of the tests and assessment of 
results, should be included. Testing used to assess the 
impact of manufacturing changes on the drug substance(s) 
and the corresponding drug product(s) can also include 
nonclinical and clinical studies. Cross-reference to the 
location of these studies in other modules of the submission 
should be included. 
Reference should be made to the drug substance data 
provided in section 3.2.S.4.4. 
Module 3 
3.2.S.3 Characterization 
(name, manufacturer) 
3.2.S.3.1 Elucidation of 
Structure and other 
Characteristics (name, 
manufacturer) 
NCE: 
Confirmation of structure based on e.g., synthetic 
route and spectral analyses should be provided. 
Information such as the potential for isomerism, 
the identification of  stereochemistry, or the 
potential for forming polymorphs should also be 
included. 
Biotech: 
For desired product and product-related substances, details 
should be provided on primary, secondary and higher-order 
structure, post-translational forms (e.g., glycoforms), 
biological activity, purity, and immunochemical properties, 
when relevant. 
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Module 3 
3.2.A APPENDICES 
3.2.A.1 Facilities and 
Equipment (name, 
manufacturer) 
Biotech: 
 
 Biotech: 
A diagram should be provided illustrating the manufacturing 
flow including movement of raw materials, personnel, waste, 
and intermediate(s) in and out of the manufacturing areas. 
Information should be presented with respect to adjacent 
areas or rooms that may be of concern for maintaining 
integrity of the product. 
Information on all developmental or approved products 
manufactured or manipulated in the same areas as the 
applicant's product should be included. 
A summary description of product-contact equipment, and 
its use (dedicated or multi-use) should be provided. 
Information on preparation, cleaning, sterilization, and 
storage of specified equipment and materials should be 
included, as appropriate. 
Information should be included on procedures (e.g., 
cleaning and production scheduling) and design features of 
the facility (e.g., area classifications) to prevent 
contamination or cross-contamination of areas and 
equipment, where operations for the preparation of cell 
banks and product manufacturing are performed. 
Module 3 
3.2.A.2 Adventitious 
Agents Safety 
Evaluation (name, 
dosage form, 
manufacturer) 
 
 Information assessing the risk with respect to potential 
contamination with adventitious agents should be provided 
in this section. 
For non-viral adventitious agents: 
Detailed information should be provided on the avoidance 
and control of non-viral adventitious agents (e.g., 
transmissible spongiform encephalopathy agents, bacteria, 
mycoplasma, fungi). This information can include, for 
example, certification and/or testing of raw materials and 
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excipients, and control of the production process, as 
appropriate for the material, process and agent. 
Reference CPMP-ICH Guidelines: "Derivation and 
Characterization of Cell Substrates Used for Production of 
Biotechnological/ Biological Products", “Specifications: Test 
Procedures and Acceptance Criteria for Biotechnological/ 
Biological Products" 
Reference CPMP Guideline: "Minimizing the Risk of 
Transmitting animal Spongiform Encephalopathy Agents via 
Medicinal Products" 
For viral adventitious agents: 
Detailed information from viral safety evaluation studies 
should be provided in this section. Viral evaluation studies 
should demonstrate that the materials used in production 
are considered safe, and that the approaches used to test, 
evaluate, and eliminate the potential risks during 
manufacturing are suitable. 
Reference CPMP-ICH Guidelines: "Viral Safety Evaluation 
of Biotechnology Products Derived From Cell Lines of 
Human or Animal Origin", "Derivation and Characterization 
of Cell Substrates Used for Production of Biotechnological/ 
Biological Products", “Specifications: Test Procedures and 
Acceptance Criteria for Biotechnological/ Biological 
Products" Reference CPMP Guideline: " virus validation 
studies: the design, contribution and interpretation of studies 
validating the inactivation and removal of viruses” 
Materials of Biological Origin 
Information essential to evaluate the virological safety of 
materials of animal or human origin (e.g. biological fluids, 
tissue, organ, cell lines) should be provided. (See related 
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information in 3.2.S.2.3, and 3.2.P.4.5). For cell lines, 
information on the selection, testing, and safety assessment 
for potential viral contamination of the cells and viral 
qualification of cell banks should also be provided. (See 
related information in 3.2.S.2.3). 
Testing at appropriate stages of production The selection of 
virological tests that are conducted during manufacturing 
(e.g., cell substrate, unprocessed bulk or post viral 
clearance testing) should be justified. The type of test, 
sensitivity and specificity of the test, if applicable, and 
frequency of testing should be included. Test results to 
confirm, at an appropriate stage of manufacture, that the 
product is free from viral contamination should be provided. 
(See related information in 3.2.S.2.4 and 3.2.P.3.4). 
Viral Testing of Unprocessed Bulk 
In accordance with Q5A and Q6B, results for viral testing of 
unprocessed bulk should be included. 
 
Viral Clearance Studies 
In accordance with Q5A, the rationale and action plan for 
assessing viral clearance and the results and evaluation of 
the viral clearance studies should be provided. Data can 
include those that demonstrate the validity of the scaled-
down model compared to the commercial scale process; the 
adequacy of viral inactivation or removal procedures for 
manufacturing equipment and materials; and manufacturing 
steps that are capable of removing or inactivating viruses. 
(See related information in 3.2.S.2.5 and 3.2.P.3.5). 
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APPENDIX 4 TABLE OF CONTENTS FOR AN NDA IN USA 
 
Besides the usual CTD sections which are requested for all ICH regions the 
following additional documents are requested for an NDA or BLA in USA X19X: 
 
A. Module 1 - Administrative and Prescribing Information 
Module 1 should contain all administrative documents (e.g., application forms, 
claims of categorical exclusion and certifications), and labeling, including the 
documents described below, as needed (Applicants often choose to submit a cover 
letter with their submissions. If you plan to include a cover letter, it should be placed 
at the beginning of Module 1.)  
Documents should be organized in the order listed below. Generally, all of the 
documents in Module 1 can be provided in a single volume. Environmental 
assessments should be submitted separately. 
1. FDA form 356h 
The first document in Module 1 should be FDA form 356h. 
2. Comprehensive table of contents 
The next document in Module 1 should be the comprehensive table of contents for 
the entire submission. Each NDA and ANDA submission is required to have a 
comprehensive table of contents or index for the entire submission as described in 
21 CFR 314.50 and 314.94. The comprehensive table of contents significantly 
enhances the usefulness of the document. It should include a complete list of all 
documents provided in the submission by module. 
In the table of contents, you should identify the location of each document by 
referring to the volume numbers that contain the relevant documents and any tab 
identifiers. In general, the name for the tab identifier should be the name of the 
document (e.g., patent certification, financial disclosure) or section heading 
according to the CTD format (e.g., 3.2.P.4.2). If the full name of the document is too 
long for the tab identifiers, you should substitute an alternative name that adequately 
identifies the document. You should not use page numbers in the table of contents 
to refer to documents, but use tab identifiers as described above. 
3. Administrative documents 
a. Administrative documents 
You should provide the appropriate administrative documents with the submission. 
Examples of administrative documents are listed below. See 21 CFR 314.50, 
314.94, and 601.2 for details on the administrative documents needed for specific 
submissions. FDA form 356h lists most of the administrative documents to be 
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included in Module 1. The order of such documents should be consistent with that in 
FDA Form 356h. 
• Patent information on any patent that claims the drug, if applicable 
• Patent certifications (not for BLA) 
• Debarment certification 
• Field copy certification (not for BLA) 
• User fee cover sheet 
• Financial disclosure information 
Letters of authorization for reference to other applications or drug master files 
• Waiver requests 
• Environmental assessment or request for categorical exclusion 
• Statements of claimed exclusivity and associated certifications 
Since these documents are small, you should place them in the same volume, 
separated by tab identifiers. If you submit an environmental assessment, you should 
provide it as a separate volume. 
b. Prescribing information 
You should include all copies of the labels and all labeling for the product in Module 
1. The type of labeling provided depends on the submission. Examples of 
prescribing information include container and package labels as well as package 
inserts, draft labeling, patient leaflets, information sheets, and required Medication 
Guides. You should separate each sample of labeling by tab identifiers. 
c. Annotated labeling text 
For the NDA, you should provide a copy of the proposed labeling text with 
annotations directing reviewers to the information in the summaries and other 
modules that support each statement in the labeling, as described in 21 CFR 
314.50(c)(2)(i). The annotated labeling text should include the content of the labeling 
described under 21 CFR 201.57 and all text, tables, and figures used in the package 
insert. 
d. Labeling comparison 
For the ANDA, you should provide the comparison of labeling that is described in 21 
CFR 314.94(a)(8). 
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B. Module 2 – Common Technical Document Summaries 
Module 2 should include the summary documents. You should provide the 
documents for this module in the order described below. 
1. Overall CTD table of contents 
For the first document in this module, you should provide a comprehensive table of 
contents listing all of the documents provided in the submission for modules 2 
through 5. 
2. Introduction to the summary documents 
You should provide the introduction to the summary described in the guidance 
document M4: Organization of the CTD as a one page document. 
3. Overviews and summaries 
Module 2 should contain the following additional documents as described in the 
appropriate guidance documents (M4Q: The CTD -Quality, M4S: The CTD - Safety, 
M4E: The CTD – Efficacy): 
• Quality overall summary (2.3, Module 2, section 3) 
• Non clinical overview (2.4) 
• Clinical overview (2.5) 
• Nonclinical summary (2.6) 
• Clinical summary (2.7) 
The nonclinical summary and the clinical summary should be provided in separate 
volumes for ease of use by reviewers. 
C. Module 3 - Quality 
Module 3 should include information on the drug or biological substance and product 
that should be provided in the order described below. See Appendix A for additional 
recommendations on the content and organization of module 3. 
1. Module 3 table of contents 
The first document in this module should be a table of contents listing all of the 
documents provided for module 3. See the guidance document M4Q: The CTD 
Quality for the headings and order to be used in the table of contents, including 
numbering of section headings. 
2. Body of data 
Each individual subsection related to the drug or biological substance and product 
should be provided as an individual document either bound separately or divided by 
tab identifiers, depending on the size of the subsection. The documents should be 
presented in the order in which they are listed in the table of contents. 
3. Literature References 
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Each literature reference should be provided as an individual document, separated 
from the others by tab identifiers. 
D. Module 4 - Nonclinical Study Reports 
Module 4 should contain the nonclinical study reports and related information. You 
should provide the documents for this module in the order described below. 
1. Module 4 table of contents 
The first document in this module should be a table of contents listing all of the 
documents provided for module 4. See the guidance to industry M4S: The CTD – 
Safety for the headings and order to be used in the table of contents, including 
numbering of section headings. 
2. Study reports and related information 
You should provide each study report and each related document as an individual 
document, separated from the other documents by binders or tab identifiers. These 
documents should be presented in the order in which they are listed in the table of 
contents. 
3. Literature References 
Each literature reference should be provided as an individual document, separated 
from the others by tab dividers. 
E. Module 5 - Clinical Study Reports 
Module 5 should contain clinical study reports and related information. You should 
provide the documents for this module in the order described below. 
1. Module 5 table of contents 
The first document in this module should be a table of contents listing all of the 
documents provided in Module 5. See the guidance to industry M4E: The CTD – 
Efficacy for the headings and order to be used in the table of contents, including 
numbering of section headings. 
2. Study reports and related information 
You should provide each study report and each related document, such as tabular 
listings of all clinical studies, as an individual document separated from the other 
documents by binders or tab dividers. We recommend that tab identifiers be 
provided for each appendix in a study report. These documents should be presented 
in the order in which they are listed in the table of contents. 
The submission of a separate Integrated Summary of Efficacy (ISE) and/or 
Integrated Summary of Safety (ISS) is not required when the information provided 
can be incorporated into the CTD summaries and overview. When the ISS or ISE is 
submitted, it should be included in Module 5.3.5.3, Meta-Analyses. The applicant 
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should raise any questions concerning the ISS and ISE with FDA staff prior to 
submission of the application. 
You should include any case report forms (CRF) as separate documents. The case 
report forms should be organized by study. 
The individual patient listings or case report tabulations (CRT) should include all of 
the clinical data collected in each study, organized by domain of data (e.g., adverse 
event, laboratory, physical examination). Each domain of data should be provided 
as a separate document. As with the CRFs, the CRTs should be organized by study. 
3. Literature References 
Each literature reference should be provided as an individual document separated 
from the others by tab identifiers. 
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APPENDIX 5 TABLE OF COMPARISON OF MECHANISMS TO HASTEN PRODUCT AVAILABILITY IN USA 
Comparison of Mechanisms to Hasten Product Availability22: 
 Accelerated review Priority review Fast track 
Authority 1992 Rule: 21 CFR 314 and 601 (In 
1997, Federal Food, Drug, and 
Cosmetic Act (FFDCA) 506(b).) 
1996 Agency Procedure: 
CDER Manual of Policies and 
Procedures 
(MAPP) 6020.3; and 
CBER Manual of Standard Operating 
Procedures and Policies (SOPP) 8405 
1997 Statute: 
FFDCA 506(a). 
 
Procedure [Not specified; presumably 
manufacturer would request and FDA 
would determine whether to grant.] 
Clinical team leader of FDA review 
team, upon receipt of application, 
makes recommendation. 
 
Any time before marketing 
approval, manufacturer 
requests designation; FDA 
grants if criteria are met. 
Quality criteria Serious or life-threatening illness not applicable (n.a.) Serious or life-threatening 
condition 
Potential to address unmet 
medical need 
Major advance in treatment or treatment 
where no adequate therapy exists 
Potential to address unmet 
medical need 
Adequate and well-controlled studies 
supporting use of surrogate outcome 
n.a. 
Benefit during development Adjusted trial outcome requirements n.a. Close communication with 
FDA 
Benefit during review n.a.  Additional attention; expedited review Rolling review 
Post approval requirements Studies to extend results from 
surrogate to clinical outcome. 
n.a. 
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APPENDIX 6 TABLE OF SPECIFIC NATIONAL REQUIREMENTS OF NCADREAC DRAS CONCERNED  
 
Country Scope of 
the 
procedure
Timing 
of sub-
mission 
Expected 
handling net 
time 
Language 
of dossier
No. of copies 
to be 
submitted 
Electronic submission Need of samples 
and/or substances 
Fees Date of 
implemen-
tation 
Bulgaria 
 
Points 3.1, 
3.2. and 3.3 
of principles
Variant  I 6 months, after 
receiving the 
complete 
documentation 
English  
Bulgarian 
1 copy 
 
4  copies of 
SPC (in 
Bulgarian 
language) 
 
4  copies of 
PIL (in 
Bulgarian 
language) 
 
4  copies of 
labeling (in 
Bulgarian 
language) 
 
CD-ROM, together with 
paper documentation of 
identical content;  
After approval SPC and 
PIL (final approved 
version) in the Bulgarian 
language on a 3,5 inch 
floppy diskette using 
Word  for Windows 
2 samples of the 
medicinal product 
presented in the outer 
packaging;  
reference substance (if 
referred to in the testing 
procedure) 
MA (original medicinal product): 
Bulgarian Drug Agency (BDA) fee: 2532 
BGN levs  
Ministry of Health (MoH) fee: 3 800 BGN 
levs 
 
MA (original medicinal product – for II, III, 
IV etc pharmaceutical form):  
BDA fee: 1884 BGN levs  
MoH fee: 950 BGN levs 
 
MA (original medicinal product – for 
different quantity of active substance 
(strength)):  
BDA fee: 1256 BGN levs  
MoH fee: 420 BGN levs 
 
MA (generic medicinal product, included 
in Pharmacopoeia): 
Bulgarian Drug Agency (BDA) fee: 1909 
BGN leva  
Ministry of Health (MoH) fee: 1700 BGN 
leva 
 
MA (generic medicinal product included 
in Pharmacopoeia – for II, III, IV etc 
pharmaceutical form):  
BDA fee: 1432 BGN leva  
MoH fee: 425 BGN leva 
 
MA (generic medicinal product included 
in Pharmacopoeia – for different quantity 
of active substance (strength)): 
BDA fee: 955 BGN leva  
MoH fee: 420 BGN leva 
MA (generic medicinal product, non-
date of 
publishing 
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Country Scope of 
the 
procedure
Timing 
of sub-
mission 
Expected 
handling net 
time 
Language 
of dossier
No. of copies 
to be 
submitted 
Electronic submission Need of samples 
and/or substances 
Fees Date of 
implemen-
tation 
included in Pharmacopoeia): 
Bulgarian Drug Agency (BDA) fee: 2110 
BGN leva  
Ministry of Health (MoH) fee: 1700 BGN 
leva 
 
MA (generic medicinal product non-
included in Pharmacopoeia – for II, III, IV 
etc pharmaceutical form):  
BDA fee: 1583 BGN leva  
MoH fee: 425 BGN leva 
 
MA (generic medicinal product non-
included in Pharmacopoeia – for different 
quantity of active substance (strength)): 
BDA fee: 1055 BGN leva  
MoH fee: 420 BGN leva 
 
VARs (in Bulgaria VARs are not 
divided to type IA and type IB yet): 
-type I:  
BDA fee: 75 BGN levs 
MoH fee: 100 BGN levs 
(there are exceptions from MoH fee) 
 
-type II:  
BDA fee: 202 BGN levs 
MoH fee: 100 BGN levs 
(in case of new indication MoH fee: 300 
BGN levs) 
REN procedure: 
 
original medicinal product: 
Bulgarian Drug Agency (BDA) fee: 1266 
BGN levs  
Ministry of Health (MoH) fee: 3040 BGN 
levs 
 
original medicinal product – for II, III, IV 
etc pharmaceutical for):  
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Country Scope of 
the 
procedure
Timing 
of sub-
mission 
Expected 
handling net 
time 
Language 
of dossier
No. of copies 
to be 
submitted 
Electronic submission Need of samples 
and/or substances 
Fees Date of 
implemen-
tation 
BDA fee: 942 BGN levs  
MoH fee: 760 BGN levs 
 
original medicinal product – for different 
quantity of active substance (strength):  
BDA fee: 628 BGN levs  
MoH fee: 336 BGN levs 
 
generic medicinal product, included in 
Pharmacopoeia: 
Bulgarian Drug Agency (BDA) fee: 954.5 
BGN levs  
Ministry of Health (MoH) fee: 1360 BGN 
levs 
 
MA (generic medicinal product included 
in Pharmacopoeia – for II, III, IV etc 
pharmaceutical form):  
BDA fee: 716 BGN levs  
MoH fee: 340 BGN levs 
 
generic medicinal product included in 
Pharmacopoeia – for different quantity of 
active substance (strength): 
BDA fee: 477.5 BGN levs  
MoH fee: 336 BGN levs 
 
generic medicinal product, non-included 
in Pharmacopoeia: 
Bulgarian Drug Agency (BDA) fee: 1055 
BGN levs 
Ministry of Health (MoH) fee: 1360 BGN 
levs 
 
generic medicinal product non-included 
in Pharmacopoeia – for II, III, IV etc 
pharmaceutical form:  
BDA fee: 769 BGN levs  
MoH fee: 340 BGN levs 
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Country Scope of 
the 
procedure
Timing 
of sub-
mission 
Expected 
handling net 
time 
Language 
of dossier
No. of copies 
to be 
submitted 
Electronic submission Need of samples 
and/or substances 
Fees Date of 
implemen-
tation 
generic medicinal product non-included 
in Pharmacopoeia – for different quantity 
of active substance (strength): 
BDA fee: 527.5 BGN levs  
MoH fee: 336 BGN levs 
 
 
THERE ARE FIXED EXCHANGE 
RATES OF Euro against the Bulgarian 
Lev (1 Euro is appr. 1.95583 LEV 
(BGNN)) 
Croatia 
 
Point 3.1 Variant I 6 months, after 
receiving the 
complete 
documentation 
English, 
Croatian 
1 copy Modules 1-3 in paper, 
modules 4 and 5 on CD-
ROM, SPC, PIL and 
labeling in paper version 
 2 samples + reference 
substance 
MA: 2.800 € 
VARs: type I: 240 € ,  
type II 900€,  
Transfer of MA: 240 €   
date of 
publishing 
Romania Points 3.1 
and 3.3 of 
principles 
Variant  I 6 months, after 
receiving the 
complete 
documentation 
English 
Romanian 
1 copy possible submission of the 
dossier in Word, pdf, rtf, 
jpg and tiff format,   CD-
ROM, together with paper 
documentation of identical 
content;  
SPC and PIL (final 
approved version) in the 
Romanian language on a 
3,5 inch floppy diskette 
using Word  for Windows 
2 samples of the 
medicinal product 
presented in the outer 
packaging;  
reference substance (if 
referred to in the testing 
procedure) 
MA:  
- new active substance/biological 
products 2105 € 
- known  active substance with BE 
studies 1420 € 
- known  active substance without BE 
studies 1055 € 
- combination in  fixed doses 1840 € 
- well established use (WEU) 1540 € 
 
VARs: 
-type IA: 210 € 
-type IB: 330 € 
-type II: 460 € 
 
Transfer of MA 300 € 
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APPENDIX 7 INFORMATION SHARING LETTER 
Text in italics should be replaced by the data specific to individual submissions. 
 
Name of the product:  
Mutual Recognition Procedure No.:  
  
Approval of Information Sharing between the DRA of the Reference Member State and 
the nCADREAC DRA 
 
The Marketing Authorisation Holder (Drug Master File Holder) in the Reference Member 
State hereby notifies to the DRA of the Reference Member State of the submission of an 
application for the marketing authorisation of the following medicinal product to the 
nCADREAC DRA:  
 
name of the medicinal product, dosage form, strength, package size/s 
(differences in brand name, if any) 
proposed marketing authorisation holder in the country of the nCADREAC DRA  
 
The Marketing Authorisation Holder (Drug Master File Holder) in the Reference Member 
State agrees that the DRA of the Reference Member State may make available to the 
nCADREAC DRA any information concerning the quality, safety and efficacy of the above 
product. The extent of this information shall not exceed that which is made available to EU 
Member States. In the case that variant II of this simplified procedure is used, the Marketing 
Authorisation Holder (Drug Master File Holder) in the Reference Member State agrees with 
the participation of the nCADREAC expert in the break out session.  
The information will be used by the nCADREAC DRA in accordance with applicable laws and 
regulations for the marketing authorisation and safe use of medicinal products in the country 
of the nCADREAC DRA.  
This Declaration is made as of the date first written below and remains valid for the period 
during which the product is authorised in the Member States of the EU and the country of the 
nCADREAC DRA respectively.   
The copy of this declaration is sent to the nCADREAC DRA. 
 
Date:                   Signature of the Marketing Authorisation Holder  
                                      (Drug Master File Holder) 
                                     First name, family name:  
                                     Address:   
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APPENDIX 8 REPORT ON THE REPORT  ON  THE  MARKETING  
AUTHORISATION  GRANTED BY  THE  NCADREAC  DRA  
CONCERNED OF  THE  MEDICINAL PRODUCT  SUBJECTED  
TO  THE MUTUAL RECOGNITION  PROCEDURE  IN  THE  EU 
Text in italics should be replaced by the data specific to individual submissions. 
nCADREAC DRA 
TO: DRA of the Reference Member State  
 
REPORT  ON  THE  MARKETING  AUTHORISATION  GRANTED BY  THE  nCADREAC  
DRA  CONCERNED OF  THE  MEDICINAL PRODUCT  SUBJECTED  TO  THE  MUTUAL 
RECOGNITION  PROCEDURE  IN  THE  EU 
 
Name of the product in the RMS, pharmaceutical form/s, strength/s relevant to this report 
INN or common name of the active ingredient/s 
MRP number/s of the product 
Name of the MA holder in the RMS  
□ Report on acceptance/REN of the MRP MA  
□ Report on disagreement with the MRP MA*  
□ Report on refusal of VAR*  
□ Report on retrospective inclusion of the product in the simplified nCADREAC system   
□ Request to RMS*  
Name of the product in the nCADREAC DRA's country concerned 
National Marketing authorisation number/s 
Date of issue of national marketing authorisation decision 
Name of the marketing authorisation holder in the nCADREAC DRA's country concerned  
Authorised dosage forms, strengths, package sizes in nCADREAC DRA's country concerned 
  
Modifications of SPC and PIL (specifying differences, except different name of the product, 
MA holder, national MA number)  
Modifications of labelling (specifying differences, except different name of the product, MA 
holder, national MA number)  
 
Explanatory notes*:  
Enclosures: 
 
Date                       Signature of the person responsible within the nCADREAC DRA 
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APPENDIX 9 TABLE OF CONTENTS FOR ACTD 
 
Part I: Table of Contents (ToC), Administrative Data and Product Information 
The part I contains at the beginning an overall ToC of the whole ACTD which 
provided overall information of the dossier. After the ToC the administrative 
documents are contained. Administrative data can vary from country to country 
based on local requirements. Typical administrative data are application forms, 
CPPs, label, package inserts, etc. At the last section of part I the product information 
including prescribing information, pharmacological class, mode of action, adverse 
drug reactions,… is contained. 
It is divided in the following sections: 
• Section A: Introduction 
• Section B: Overall ASEAN CTD ToC 
• Section C: Documents required for registration (e.g. application forms, CPP, 
labeling, Product Data Sheet, prescribing information) 
 
Part II: Quality Document 
This part contains the QOS followed by the quality documents (DS and DP). The 
quality control documents should be described as much as possible. 
It is divided in the following sections: 
• Section A: ToCs 
• Section B: QOS 
• Section C: Body of Data 
 
Part III: Nonclinical Document 
This part begins with the nonclinical overview, followed by the nonclinical written 
summaries and the nonclinical tabulated summaries. The study reports may not be 
required for NCEs and biotechnological products if the original product is already 
authorized in the reference countries. An authority should ask for the necessary 
documents in case of a request for specific study reports. 
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It is divided in the following sections: 
• Section A: ToCs 
• Section B: NCO 
• Section C: Nonclinical Written and Tabulated Summaries 
1. ToCs 
2. Pharmacology 
3. Pharmacokinetics 
4. Toxicology 
• Section D: Nonclinical Stud Reports 
1. ToCs 
2. Pharmacology 
3. Pharmacokinetics 
4. Toxicology 
 
Part IV: Clinical Document 
This part contains the clinical overview and the clinical summary. The study reports 
may not be required for NCEs and biotechnological products if the original product is 
already authorized in the reference countries. An authority should ask for the 
necessary documents in case of a request for specific study reports. 
It is divided in the following sections: 
• Section A: ToCs 
• Section B: CO 
• Section C: Clinical Summary 
1. Summary of Biopharmaceutics and Associated Analytical Methods 
2. Summary of Clinical Pharmacology Studies 
3. Summary of Clinical Efficacy 
4. Summary of Clinical Safety 
5. Synopses of Individual Studies 
• Section D: Tabular Listing of All Clinical Studies 
• Section E: Clinical Study Reports 
• Section F: List of Key Literature References 
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APPENDIX 10 DOSSIER REQUIREMENTS FOR QUALITY PART OF THE DOSSIER FOR ASEAN COUNTRIES  
 
No. Parameter Components Requirements 
   NCE Biotech 
S DRUG SUBSTANCE    
S1 General information    
 1.1. Nomenclature Information from S1 X X 
 1.2. Structure 1) Structural formula, including relative and absolute stereochemistry, the molecular 
formula, and the relative molecular mass 
2) Schematic amino acid sequence indicating glycosylation sites or other 
posttranslational modifications and relative molecular mass as appropriate 
X X 
 1.3. General Properties Physico-chemical characteristics and other relevant properties including biological 
activity for biotech 
X X 
S2 Manufacturer    
 2.1. Manufacturer(s) Name and address of the manufacturer(s) X X 
 2.2. Description of the 
manufacturing process 
and process control 
1) The description of the drug substance manufacturing process and process control 
that represents the applicant’s commitment for the manufacture of the drug substances. 
2) Information on the manufacturing process, which typically starts with a vial(s) of the 
cell bank, and includes cell culture, harvest(s), purification and modification reaction, 
filling, storage and shipping conditions 
X X 
 
X 
 
 2.3. Control of materials 1) Starting materials, solvents, reagents, catalysts, and any other materials used in the 
manufacture of the drug substance indicating where each material is used in the 
process. Tests and acceptance criteria of these materials. 
2) Control of source and starting materials of biological origin 
3) Source, history and generation of cell substrate 
4) Cell bank system, characterization and testing 
X X 
 
X 
 
X 
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No. Parameter Components Requirements 
5) Viral safety evaluation X 
X 
 2.4. Controls of critical 
steps and intermediates 
1) Critical steps: Test and acceptance criteria with justification 
Including experimental data, performed at critical steps of the manufacturing process to 
ensure that the process is controlled 
2) Intermediates: Specifications and analytical procedure, if any, for intermediates 
isolated during the process 
3) Stability data supporting storage conditions 
X 
 
 
X 
X 
 
 
X 
X 
 2.5. Process validation 
and/or evaluation 
Process validation and/or evaluation studies for aseptic processing and sterilization X X 
 2.6. Manufacturing 
process development 
1) Description and discussion of significant changes made to the manufacturing process 
and/or manufacturing site of the drug substance used in producing non-clinical, clinical, 
scale-up, pilot and if available, production scale batches 
2) The development history of the manufacturing process as described in S.2.2. 
X X 
 
X 
S3 Characterization    
 3.1. Elucidation of 
structure and other 
characteristics 
1) Confirmation of structure based on e.g. synthetic route and spectral analyses 
2) Details on primary, secondary and higher-order structure and information on 
biological activity, purity and immunochemical properties (when relevant) 
X  
X 
 3.2. Impurities Summary of impurities monitored or tested for during and after manufacture of drug 
substance 
X X 
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No. Parameter Components Requirements 
S4 Control of drug 
substance 
   
 4.1. Specifications 1) Detailed specification, tests and acceptance criteria 
2) Specify source, including as appropriate species of animal, type of microorganism, 
etc. 
X X 
X 
 4.2. Analytical 
procedures 
The analytical procedures used for testing of drug substance X X 
 4.3. Validation of 
analytical procedures 
Analytical validation information, including experimental data for the analytical 
procedures used for testing of drug substance 
X X 
 4.4. Batch analysis Description of batches and results of the analysis to establish the specifications X X 
 4.5. Justification of 
specification 
Justification for drug substance specifications X X 
S5 Reference standards or 
materials 
Information on the reference standards or reference materials used for testing of the 
drug substance 
X X 
S6 Container Closure 
System 
Description of the container closure systems X X 
S7 Stability Stability report X X 
P DRUG PRODUCT    
P1 Description and 
Composition 
1) Description 
2) Composition 
Name, quantity stated in metric weight or measures, function and quality standard 
reference 
X 
X 
X 
X 
P2 Pharmaceutical 
Development 
   
 2.1. Information on 
development studies 
Data on the development studies conducted to establish that the dosage form, 
formulation, manufacturing process, container closure system, microbiological attributes 
X X 
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No. Parameter Components Requirements 
and usage instruction are appropriate for the purpose specified in the application 
 2.2. Components of the 
drug product 
Active ingredient 
• Justification of the comparability of the active ingredient with excipients listed in P1 
• In case of combination products, justification of comparability of active ingredients 
with each other 
Excipients 
• Justification for the choice of excipients listed in P1, which may influence the drug 
product performance 
 
X 
 
 
 
X 
 
X 
 
 
 
X 
 2.3. Finished product Formulation Development 
• A brief summary describing the development of the finished product (taking into 
consideration the proposed route of administration and usage of NCE and Biotech) 
Overages 
• Justification for any overage in the formulation(s) described in P1 
Physiochemical and biological properties 
• Parameters relevant to the performance of the finished product, e.g. pH, dissolution 
X 
 
 
X 
 
 
X 
X 
 
 
X 
 
 
X 
 2.4. Manufacturing 
process development 
1) Selection and optimization of the manufacturing process 
2) Differences between the manufacturing process(es) used to produce pivotal clinical 
batches and the process described in P.3.2., if applicable 
X 
X 
X 
X 
 2.5 Container Closure 
System 
Suitability of the container closure system used for the storage, transportation (shipping) 
and used for finished product 
X X 
 2.6. Microbiological 
Attributes 
Microbiological attributes of the dosage form, where appropriate X X 
 2.7. Compatibility Compatibility of the finished product with reconstitution diluent(s) or dosage devices X X 
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No. Parameter Components Requirements 
P 3 Manufacture    
 3.1. Batch formula Name and quantities of all ingredients X X 
 3.2. Manufacturing 
process and process 
control 
Description of manufacturing process and process control X X 
 3.3. Control of critical 
steps and intermediates 
Test and acceptance criteria X X 
 3.4. Process validation 
and/or evaluation 
Description, documentation and results of the validation and/or evaluation studies for 
critical steps or critical assays used in the manufacturing process  
 
X X 
P4 Control of excipients    
 4.1. Specifications Specifications for excipients X X 
 4.2. Analytical 
procedures 
Analytical procedures used for testing excipients where appropriate X X 
 4.3. Excipient of human 
or animal origin 
Information regarding sources and/or adventitious agents X X 
 4.4. Novel excipients For excipient(s) used the first time in a finished product or by a new route of 
administration, full details of manufacture, characterization and controls, with cross 
reference to supporting safety data (non-clinical or clinical) 
X X 
P5 Control of drug product    
 5.1. Specifications Specifications for the finished product X X 
 5.2. Analytical 
procedures 
Analytical procedures used for testing the finished product X X 
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No. Parameter Components Requirements 
 5.3. Validation of 
analytical procedures 
Analytical validation information, including experimental data for the analytical 
procedures used for testing of the finished product 
Non compendial method 
X 
 
X 
X 
 
X 
 5.4. Batch analysis Description and test results of all relevant batches X X 
 5.5. Characterization of 
impurities 
Information on characterization of impurities X X 
 5.6. Justification of 
specification 
Justification for the proposed finished product specification(s) X X 
P6 Reference standard or 
materials 
Information on the reference standards or reference materials used for testing of the 
finished product 
X X 
P7 Container Closure 
System 
Specification and control of primary and secondary packaging material, type of 
packaging and the package size, details of packaging inclusion (e.g. desiccant, etc.) 
X X 
P8 Stability Stability report: data demonstrating that product is stable through its proposed shelf life 
Commitment on post approval stability monitoring 
X X 
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APPENDIX 11 DOSSIER REQUIREMENTS FOR AN NCE IN CHINA 
 
II Application Dossier Items 
 A Summary  
1) Name of the drugs. 
2) Certified Documents. 
3) Objectives and basis for R & D. 
4) Summary of main study work. 
5) Draft of packaging insert, note to the draft, and latest literature. 
6) Design of packaging and labeling. 
 
B Pharmaceutical data 
7) Summary of Pharmaceutical Study, 
8) Research information and relevant literature of the production process of 
the drug substance, research information and relevant literature of 
formula and process of the preparations. 
9) Study information and relevant literature for the chemical structure and 
components determination. 
10) Study information and literature for quality specification. 
11) Draft of quality specification and notes, and providing reference standard. 
12) Test report of drug sample. 
13) The source, test report and quality specification of drug substance and 
excipient. 
14) Stability study and relevant literature. 
15) Selection basis and quality specification of immediate packing material 
and container. 
 
C Pharmacology and toxicology study information. 
16) Summary of pharmacology and toxicology study. 
17) Primary pharmacodynamics study and literature. 
18) General Pharmacology study and literature. 
19) Acute/single dose toxicity study and literature. 
20) Repeated dose toxicity study and literature. 
21) Special safety study and literature of hypersensitive (topical, systemic 
and photo-toxicity), hemolytic and topical irritative (blood vessel, skin, 
mucous membrane, and muscle) reaction related to topical and systemic 
use of the drugs. 
22) Study and relevant literature on Pharmacodynamics, toxicity and 
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pharmacokinetics change caused by the interactions amongst multiple 
components in the combination products. 
23) Study and literature of mutagenicity test. 
24) Study and literature of reproductive toxicity. 
25) Study and literature of carcinogenicity test. 
26) Study and literature of drug dependence. 
27) Study and literature of pre-clinical pharmacokinetics. 
 
D Clinical Study Information 
28) Summary of global clinical study information. 
29) Clinical study protocol. 
30) Investigator’s Brochure. 
31) Draft of Informed Consent Form, approval of the Ethics Committee. 
32) Clinical study report. 
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APPENDIX 12 TABLE OF APPLICATION INFORMATION ITEM FOR CHINA 
 
In
fo
rm
at
io
n 
ca
te
go
ry
 
in
fo
rm
at
io
n 
ite
m
 Registration category and information item requirement 
1 2 3 4 5 6 
Su
m
m
ar
y 
in
fo
rm
at
io
n 1 + + + + + + 
2 + + + + + + 
3 + + + + + + 
4 + + + + + + 
5 + + + + + + 
6 + + + + + + 
Ph
ar
m
ac
eu
tic
al
 In
fo
rm
at
io
n 
7 + + + + + + 
8 + *4 + + *4 *4 
9 + + + + + + 
10 + + + + + + 
11 + + + + + + 
12 + + + + + + 
13 + + + + + + 
14 + + + + + + 
15 + + + + + + 
 1 2 3 4 5 6 
Ph
ar
m
ac
ol
og
y 
an
d 
to
xi
co
lo
gy
  
16 + + + + + + 
17 + *14 ± *16 － － 
18 + *14 ± *16 － － 
19 + *14 ± *16 － － 
20 + *14 ± *16 － － 
21 *17 *17 *17 *17 *17 *17 
22 *11 － － － － － 
23 + ± ± ± － － 
24 + ± ± ± － － 
25 *6 － *6 *6 － － 
26 *7 － － － － － 
27 + *18 *18 + *18 － 
C
lin
ic
al
 
St
ud
y 
in
fo
rm
a t
i
28 + + + + + + 
29 + + + + + △ 
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In
fo
rm
at
io
n 
ca
te
go
ry
 
in
fo
rm
at
io
n 
ite
m
 Registration category and information item requirement 
1 2 3 4 5 6 
30 + + + + + △ 
31 + + + + + △ 
32 + + + + + △ 
 
Notes:  
1. + Denote the information must be submitted, 
2. ± Denote literature can be used instead of test information, 
3. − Denote the information may be exempted, 
4. ∗ Denote the information shall be submitted according to the requirement, ∗6 refer 
to note 6. 
5. △denote that the provisions 4 of “V , Requirement For Clinical Study” shall apply. 
6. literature refers to literature and / or summary of literature of all Pharmacology 
and toxicology study information of the drug in the application (including 
pharmacodynamic, mechanism of action, general pharmacology and toxicology 
and pharmacokinetics)” 
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APPENDIX 13 DOSSIER REQUIREMENTS FOR AN NBE IN CHINA 
 
 A Summary information  
1) Name of the drugs. 
2) Certified Documents. 
3) Objectives and basis for the application. 
4) Summary and evaluation of main research results. 
5) Sample draft of insert sheet, notes to the draft, and literature. 
6) Sample design for packing, label. 
 
 B Pharmaceutical Study Information  
7) Summary of Pharmaceutical Study Information. 
8) Research information of the raw material used for production. 
i) Research information about the sourcing, collection, and quality control of 
the animal or plant tissues or cells, unprocessed blood plasma. 
ii) Research information about the sourcing, collection (or selection) process, 
and determining of cells used for production. 
iii) Information about the establishment, determination, and storage of the 
strains banks, as well as the stability of transfer of culture. 
iv) Research information about the sourcing, quality control of other raw 
materials used for production. 
9) Research information about the production process of the raw materials or the 
unprocessed fluids. 
10) Research information of the formula and process of the preparations, source 
and quality standards of the supplementives, as well as the relevant 
literatures. 
11) Experiment information and literature of the quality study of the products, 
including the preparing and standardizing of the Standard Material or 
Controls, as well as the comparison information with those similar product 
already marketed at domestic or overseas. 
12) Record of manufacturing and testing of the sample products to be used for 
application of clinical study. 
13) Draft of the manufacture and test standards, with notes to the draft and 
verification information of the test method. 
14) Preliminary research information about the stability. 
15) Basis for selection and quality standards of immediate packing material and 
container. 
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 C Pharmacology and Toxicology Study Information  
16) Summary about the pharmacology and toxicology study information. 
17) Experiments information and literature of pharmacodynamic. 
18)  Experiments information and literature of regular pharmacology study. 
19)   Experiments information and literature of acute toxicity. 
20)  Experiments information and literature of long term toxicity. 
21) Experiments information and literature of animal pharmacokinetics. 
22) Experimental data and literature of mutations test. 
23) Experimental data and literature of reproductive toxicity. 
24) Experimental data and literature of carcinogenicity test. 
25) Research information and literature of immunotoxicity and / or immunogenicity. 
26) Experiments information and literature on major special safety test information 
related to topical and systemic use of the drugs, such as hemolysis and 
topical (blood vessel, skin, mucous membrane, endometium, tunica and 
muscle) irritation. 
27) Experiments information and literature of the efficacy, toxicity and 
pharmacokinetics caused by the interactions between multiple components in 
the combination products. 
28) Experiment information and literature of drug dependence. 
 
 D Clinical Study Information  
29) Summary of clinical study at domestic and overseas. 
30) Clinical study plan and protocol. 
31) Investigator’s Brochure. 
32)  Sample draft of Informed Consent Form, approval of the ethics committee. 
33)  Summary report of the clinical study. 
 
 201
 E Others  
34) Brief summary of the pre-clinical study. 
35) Experiments and study information and summary of the production process 
improvement, quality perfection, the pharmacology and toxicology study and 
other works conducted during the clinical study. 
36) Amendments and basis to amend of the approved manufacturing and testing 
standards. 
37) Research and study information of the stability test. 
38) Manufacturing and testing records of the 3 consecutive batches of trial 
products. 
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APPENDIX 14 TABLE OF APPLICATION INFORMATION ITEMS FOR CHINA 
 
A Table of Application Information Items for therapeutic biological products, (Information Items 1-15, 29-38) 
 
Info Cat. Info Item 
Registration category and requirement for information 
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 
Summary 
Information 
1 + + 
R
e
f
e
r
 
t
o
 
T
e
c
h
n
i
c
a
l
 
g
u
i
d
a
n
c
e
 
R
e
f
e
r
 
t
o
 
T
e
c
h
n
i
c
a
l
 
g
u
i
d
a
n
c
e
 
+ + + + + + + + + + + 
2 + + + + + + + + + + + + + 
3 + + + + + + + + + + + + + 
4 + + + + + + + + + + + + + 
5 + + + + + + + + + + + + + 
6 + + + + + + + + + + + + + 
p
h
a
r
m
a
c
e
u
t
i
c
a
l
 
7 + + + + + + + + + － + － + 
8 + + + － + + + + + － － － + 
9 + + + － + + + + + － － － + 
10 + + + + + + + + + － + － + 
11 + + + + + + + + + － + － + 
12 + + + + + + + + + － + － + 
13 + + + + + + + + + － + － + 
14 + + + + + + + + + － + － + 
15 + + + + + + + + + － + － + 
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Info Cat. Info Item 
Registration category and requirement for information 
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 
CT Info 
29 + + + + + + + + + + + + + 
30 + + + + + + + + + + + + + 
31 + + + + + + + + + + + + + 
32 + + + + + + + + + + + + + 
33 + + + + + + + + + + + + + 
other 
34 + + + + + + + + + + + + + 
35 + + + + + + + + + + + + + 
36 + + + + + + + + + － + － + 
37 + + + + + + + + + － + － + 
38 + + + + + + + + + － + － + 
 
Notes: 
1. + denote the information must be submitted, 
2. － denote the information may be exempted, 
3. ± denote the information required or not required based on the particular case. 
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B Table of Application Information Items for pharmacology and toxicology information for therapeutic biological product 
(Information Items 14-29) 
 
Cat. Item
Registration category and requirement for information 
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 
P
h
a
r
m
a
c
o
l
o
g
y
 
&
 
T
o
x
i
c
o
l
o
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y
 
16 + + 
R
e
f
e
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R
e
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e
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o
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i
d
a
n
c
e
 
+ + + + + + + + + + + 
17 + + + + + + + + + + + + + 
18 + + + + + + + + + + + + + 
19 + + + + + + + + + + + + ± 
20 + + + + + + + + + + + + + 
21 + + ± ± ± － + ± + + ± + ± 
22 ± ± ± ± ± － ± ± ± ± － ± － 
23 ± ± ± ± ± － ± ± ± ± － ± － 
24 ± ± ± ± ± － ± ± ± ± － ± － 
25 + + + + + － + + + + － + ± 
26 + + + + + － + + + + + + ± 
27 － － － + － － － － － － － － － 
28 ± ± ± － － － ± － － ± － － － 
 
Notes: 
4. + denote the information must be submitted, 
5. － denote the information may be exempted, 
6. ± denote the information required or not required based on the particular case.” 
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Requirements regarding clinical studies: 
 
Item Phase Sample Size 
Import Chemical Drug PK 8 - 12 
 Phase III ≥ 100 patients 
Biological Drug Phase I 20 (testing group) 
 Phase II 100 (testing group) 
 Phase III 300 (testing group) 
 
Common MNC Practice for biological oncology product: 
¾ Very few company goes through Phase I to III entirely 
¾ The estimation of local study cases No. is based on experiences, specific indications, and could be discussed with local authority. 
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Smart Strategy Analysis: 
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Strategy scenario analysis (high prevalence disease/indications): 
¾ Best practice of registration case No. in China 
 
Registration requirement NCE NBE  
 New drug or new indication New drug (not yet approved in 
China) 
New indication (drug had 
been approved in China) 
Case No. in pivotal study 
(testing group) 
≥ 100 cases ≥ 200 cases ≥ 150 cases 
Chinese PK data ≥ 8 - 12 cases ≥ 20 cases ≥ 20 cases 
 
¾ Remark: 
o If the filing package contains more than one indication for NDA submission, the case No. in each indication can be decreased 
o PK data can be the PK profile from Phase III study 
 
Strategy scenario analysis (rare or low incident disease/indications): 
Situation Regulatory Strategy 
Orphan drug and rare diseases/indications Clinical Trial Waiver application 
Relatively low incident rate or late stage of diseases Small scale local registration study or small cases No. in 
global study (local study: open, single arm, PK profile in 
certain No. of patients) 
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Key factors to achieve simultaneous regulatory approval: 
¾ Integrate China into global regulatory plan (ideally after proof of concept) 
¾ Involve China into global pivotal study and align appropriate Chinese patient number for registration 
¾ Initiate Asia trial (bridging study) with main purpose for China registration and in parallel due to scientific issues (different epidemiology 
or etiology among different regions) 
¾ Involve China medical & regulatory people at the early stage of drug development
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APPENDIX 15 ADMINISTRATIVE DOCUMENTS ARE REQUIRED FOR NEW MEDICINAL PRODUCTS WHICH ARE IMPORTED 
TO BRAZIL 
 
Requirement New medicinal products (NCEs) Biological products 
(NBEs) 
Petition formularies X X 
Receipt of payment of the respective fee or exemption document 
when applicable 
X X (additionally declaration of 
the size of the company) 
Copy of the operative license  
 
X X (additionally copy of the 
operating authorization of 
the company 
Copy of the register of the technical responsible professional at 
the professional council 
X X 
Copy of the protocol of the notification of the pilot batches 
manufacturing dossier (for products manufactured in Brazil) 
X  
Copy of operating authorization and of the special operating 
authorization, if applicable 
X  
Information of the registration status of the product worldwide X X 
CPP 
• Proof of the registration of the finished 
biological/chemical medicinal product in the 
manufacturing country or in another country  
• Proof of the commercialization of the product in the 
manufacturing country 
• Attachment the approved package insert 
X X 
Letter of authorization (Power of Attorney) X X 
GMP certificates: X X 
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Requirement New medicinal products (NCEs) Biological products 
(NBEs) 
• issued by ANVISA or copy of the protocol of the 
inspection request for local manufacturer 
• issued by ANVISA for the production line of the 
manufacturer in Brazil (for products imported as bulk 
or in primary package into Brazil) 
• issued by the CAs in the country of manufacture 
(notarized copy is required) of bulk product, as 
product in the primary package or as finished 
biological/chemical medicinal product 
Manufacturing authorizations 
• for all manufacturing sites involved in the DS and DP 
manufacturing process 
X X 
Authorization for the use of trademark X X 
Information about the manufacturing stage of imported products: 
finished product, bulk or in primary packaging 
X X 
Statement regarding the Batch code interpretation X X 
Bar code for all marketing presentations  X 
Document indicating: name and address of the manufacturers of: 
the biological active ingredient; the biological medicinal product in 
bulk; the biological medicinal product in the respective primary 
package; the finished biological medicinal product. Name and 
address of the manufacturer that issued the release certificate of 
the finished biological medicinal products batches 
 X 
Copy of the documents that determines the product specifications 
for a finished biological medicinal product 
 X 
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APPENDIX 16 DOSSIER REQUIREMENTS (PHARMACEUTICAL/CHEMICAL/BIOLOGICAL, PRECLINICAL AND CLINICAL 
DOCUMENTATION) FOR BRAZIL 
 
Requirements New medicinal 
products (NCEs) 
Biological products 
(NBEs) 
Package insert (general information about the product including information about 
pharmaceutical form, formula, routes of administration, indications and 
contraindications, adverse reactions and others) 
X X 
Mock-ups of the packaging materials X X 
Production and quality control report containing information about the formula; 
summary of the manufacturing process; report on quality control with 
physicochemical, biological and microbiologic controls; analytical methods; 
information about the reference standards used and other detailed information: 
• Amount of the components of the formula specified by their respective 
technical names Brazilian Common Denomination (DCB), DCI, INN or 
CAS, following the regulations in force 
• Amount and role of each component in the formula expressed in the 
metric system or standard unit 
• Inform the function of each component in the formula 
• Maximum and minimum industrial batch size 
• Description of the manufacturing process of the API and finished product 
and of the equipment used 
• Description of the manufacturing process of the medicinal product in bulk 
• In process control methods 
• Criteria for batches identification 
• Codification used by the manufacturer to identify the batches of the 
finished biological medicinal products 
X 
 
 
X 
X 
 
X 
X 
 
X 
 
X 
X 
X 
X 
 
X 
 
 
X 
X 
 
X 
X 
 
X 
 
X 
X 
X 
X 
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Requirements New medicinal 
products (NCEs) 
Biological products 
(NBEs) 
• Storage conditions and procedures used during transportation of the API; 
of the biological medicinal product in bulk; of the biological medicinal 
product in the primary package; of the finished biological medicinal 
product and respective storage conditions 
• Transport validation report of the product in the primary package and as 
finished biological medicinal product. 
• In case of thermolabil products add a declaration of the manufacturer 
that the transport complies with the cold chain requirements 
• Report on the viral inactivation process and the respective validation. For 
blood products. 
• Report on the sorology quality control process and reactive C protein, 
carried out with the plasma and respective validation. For blood products 
(*) Brazilian pharmacopoeia or other international codes accepted by the ANVISA 
(Resolution-RDC 79 of 11-Apr-2003 and Resolution RDC 169 of 21-Aug-2006 
X 
 
X 
 
 
X 
 
X 
 
X 
 
X 
 
API 
• Technical information: structure formula; molecular formula; molecular 
weight; synonymous; physical form; burning point; solubility; specific 
optical rotation; organoleptic properties; possible isomers; 
polymorphism; salt/base ratio; IR spectrum; other identification 
parameters used by the API manufacturer 
• Description of the manufacturing process of the API and of the 
equipment used 
• Detailed quality control report including physico- chemical, biological and 
microbiological analysis carried out with the API 
• Analytical methods and respective limits and reference standards used 
by the manufacturer 
X X 
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Requirements New medicinal 
products (NCEs) 
Biological products 
(NBEs) 
• stability studies 
• list of solvents 
• list of residual solvents 
• respective concentrations 
Manufacturing batch records of DP X X 
Quality control of raw materials 
• Detailed description of the specifications 
• Identification and quantification analytical methods of the formula 
components and of the major contaminants 
• For drops, the routine analytical tests and specifications for the device 
• Notes: reference values have to be described on official compendiums 
accepted by the ANVISA; in house methods have to be validated for the 
active ingredient. Translation is only required if the original language is 
not English or Spanish 
X X 
Quality control of the finished product 
• Detailed analytical methods; specifications and respective bibliographic 
references; graphic representations of the dissolution profile, when 
applicable 
• Detailed quality control report including physico- chemical, biological and 
microbiological analysis carried out with the finished biological/chemical 
medicinal product 
• For imported biological medicinal products, analytical methods used by 
the importer 
X 
 
 
 
X 
 
X 
X 
 
 
 
X 
 
X 
Certificates of analysis (CoAs) of DS and DP X X 
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Requirements New medicinal 
products (NCEs) 
Biological products 
(NBEs) 
Physical; chemical; biological and microbiological quality control methods to be 
carried out by the importer 
X X 
Stability study 
• Description of the stability studies of the finished biological/chemical 
medicinal product to support the proposed expiry period 
• Stability studies should be carried out with at least 3 batches of the 
product in the same strength; pharmaceutical form; primary package and 
ambient conditions. 
• Studies results shall be presented in tables containing the physico-
chemical; microbiological and chemical analysis; manufacturing date 
and batches codification identification 
• ANVISA accepts stability tests carried out based on the MCS and WHO 
criteria. EMA; ICH and FDA guidelines will be accepted as references. 
• Accelerated stability study results of three batches and results of the 
ongoing long term studies 
• Note: Accelerated: 40± 2°C/75 ±5%RH (storage temp.:15°C -30°C); 
Accelerated: 25±2ºC/60±5% RH (storage temp.:2°C - 8°C) 
• Please see Resolution RE 01/05 for detailed guidelines 
• For medicinal products imported in bulks: 
o expiry period must take into consideration the maximum 
storage period until primary packaging 
• For medicinal products imported in bulk or in the primary package: 
o follow up stability studies have to be carried out in Brazil 
X X 
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Requirements New medicinal 
products (NCEs) 
Biological products 
(NBEs) 
BSE information 
• Resolution RDC 305/02 : accomplishment with the restrictions for 
products containing raw materials subject the current legislation referred 
to the BSE 
X X 
Packaging materials specifications X X 
Complementary information: 
• Inform the inscription of the substance or the basic formula components 
in formularies; pharmacopeias; standardizing official publications or any 
recognized scientific publication. 
• Bibliography 
• Advantages of the formula with the respective clinical rationale 
• Products in association of one or more substances have to add evidence 
of safety ,efficacy and benefits of the Association 
 X 
Pharmacodynamics 
• Mechanism of action 
• Dosage and administration 
• Rationale for the recommended dosage 
• Therapeutic index, when applicable 
X X 
Pharmacokinetics (for each API of the formulation) 
• pKa 
• biological half-life 
• Absorption 
• Distribution 
X X 
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Requirements New medicinal 
products (NCEs) 
Biological products 
(NBEs) 
• Biotransformation 
• Excretion/elimination 
Pharmacovigilance data including Phase IV clinical studies results X X 
Preclinical report 
• Acute and sub acute toxicity, chronic, reproductive toxicity, mutagenicity, 
oncogenic potential 
X X 
Clinical studies: safety and efficacy 
• Phase I, II, III; Phase IV studies when applicable 
• Clinical studies being carried out in Brazil, have to include information 
about the status and who is responsible for. 
• The applicant may present clinical studies that demonstrate 
‘noninferiority” as a demonstration of the therapeutic indication and 
safety. 
• For new medicinal products associations and two or more marketing 
presentations in one package for concomitant or sequential use: 
rationale about the benefits of the combination and, when applicable, 
results of: comparative relative bioavailability among the API’s in 
combination and each of the API’s of the formula; clinical trials for each 
therapeutic indication to prove the additive or synergic effect of the 
combination with no increase of the risks involved. Depending on the 
case, when appropriate technical or ethical rationale is available, the 
clinical studies may be substituted or complemented by other alternative 
studies. 
• New therapeutic indication of a medicinal product already approved for 
marketing in Brazil for another company in the same strength and 
pharmaceutical form: Phase II clinical trials results 
X 
X 
X 
 
X 
 
 
X 
 
 
 
 
 
X 
 
 
X 
X 
X 
 
X 
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Requirements New medicinal 
products (NCEs) 
Biological products 
(NBEs) 
• New strength; new pharmaceutical form; route of administration of a 
medicinal product already approved for marketing in Brazil for another 
company: Phases II and III. These studies may be replaced by relative 
bioavailability studies when in a therapeutic renage already approved for 
the product 
X 
Price report 
• Provide price of the medicinal product in countries where it is marketed. 
In case the product is not marketed abroad, present price proposal 
• Note: Although there is no reimbursement in Brazil, the registration 
approval of a new medicinal product will not be granted without a price 
proposal of the applicant. 
X X 
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APPENDIX 17 ROUTE MAP FOR CREATION OF A CTD DOSSIER FOR MAA 
 
Route 
Map_Submission Mast 
 
Author First Draft 
[date]
Final Draft 
[date]
Submission-
ready document 
[date]
M1 Dossier
Dossier ID Number
M1
Version No.
Comments Lifecycle 
Attributes
1.0.55 VAR Type II Clinical Cover Letter EMEA Sep 2008 S
1 Module 1
1.1 Comprehensive table of contents
1.0.1 MAA Cover letter
1.2 Application form incl. Annexes
1.2.1 Application Form MAA
1.3 Product Information
1.3.1 Summary of product characteristics, labelling and package leaflet
1.3.1 SPC, Labelling and Package Leaflet
1.3.2 Mock-ups
1.3.3 Specimen
1.3.4 Consultation with Target Patient Groups
1.3.5 Product Information already approved in the Member States
1.3.6 Braille
1.4 Information about the Experts
1.4.1 Information about the expert - quality
1.4.2 Nonclinical
1.4.2 Information about the expert - nonclinical
1.4.3 Clinical
1.4.3 Information about the expert - clinical
1.5 Specific requirements for different types of application 
1.5.1 Information for bibliographical applications  
1.5.2 Information for Generic, "Hybrid" or Bio-similar Applications  
1.5.3 (Extended) Data/market Exclusivity  
1.5.4 Exceptional Circumstances  
1.5.5 Conditional Marketing Authorisation  
1.6 Environmental Risk Assessment  
1.6 Environmental Risk Assessment
1.6.1 Non-GMO
1.6.2 GMO 
1.7 Information relating to Orphan Market Exclusivitiy
1.7.1 Similarity  
1.7.2 Market Exclusivity  
1.8 Information relating to Pharmacovigilance
1.8.1 Pharmacovigilance System
1.8.2 Risk-management System
1.9 Information relating to Clinical Trials
1.9 Information relating to Clinical Trials
Additional data
Manufacturing Authorisation of manufacturer
QP Declaration of manufacturer
Responses to Questions
CTD Structure 
MODULE 1
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Author First Draft 
[date]
Final Draft 
[date]
Submission-
ready document 
[date]
M1 Dossier
Dossier ID Number
M1
Version No.
Comments Lifecycle 
Attributes
S
2 Module 2
2.1 CTD table of contents (Module 2-5)
2.2 Introduction
2.3 Quality Overall Summary
2.3.1 Introduction
2.3.S Drug Substance
2.3.P Drug Product
2.3.A Appendices
2.3.R Regional Information
2.4 Nonclinical overview
2.4 Nonclinical overview
2.5 Clinical overview
2.5 Clinical Overview
Annex 1 CIOMS Forms Arrest
Annex 2 CIOMS line listing Arrest
Annex 3 CIOMS Forms Infarction and Ischemia
Annex 4 CIOMS line listing Infarction and Ischemia
Annex 5 CIOMS Forms PE
Annex 6 CIOMS line listing PE
2.6 Nonclinical Summary 
2.6.1 Introduction
2.6.2 Pharmacology Written Summary
2.6.3 Pharmacology Tabulated Summary
2.6.4 Pharmacokinetics Written Summary
2.6.5 Pharmacokinetics Tabulated Summary
2.6.6 Toxicology Written Summary
2.6.7 Toxicology Tabulated Summary
2.7 Clinical Summary
2.7.1 Summary of Biopharmaceutic Studies and Associated Analytical Methods
2.7.2 Summary of Clinical Pharmacology Studies
2.7.3 Summary of Clinical Efficacy
2.7.4 Summary of Clinical Safety
2.7.5 Literature-References
2.7.6 Synopses of Individual Studies
CTD Structure 
Module 2
220
Author First Draft 
[date]
Final 
Draft 
[date]
Submissio
n-ready 
document 
[date]
M1 
Dossier
Dossier 
ID 
Number
M1
Version 
No.
Comments Lifecycle 
Attributes
S
3 Module 3 Quality
3.1 Table of contents
3.2 Body of data
3.2.S Drug Substance
3.2.S.1 General information
3.2.S.1.1 Nomenclature
3.2.S.1.2 Structure
3.2.S.1.3 General properties
3.2.S.2 Manufacture
3.2.S.2.1 Manufacturer(s)
3.2.S.2.2 Description of manufacturing process and process controls
3.2.S.2.3 Control of materials
3.2.S.2.4 Controls of critical steps and intermediates
3.2.S.2.5 Process validation and/or evaluation
3.2.S.2.6 Manufacturing process development
3.2.S.3 Characterization
3.2.S.3.1 Elucidation of structure and other characteristics
3.2.S.3.2 Impurities
3.2.S.4 Control of drug substance
3.2.S.4.1 Specification
3.2.S.4.2 Analytical procedures
3.2.S.4.3 Validation of analytical procedures
3.2.S.4.4 Batch analyses
3.2.S.4.5 Justification of specification
3.2.S.5 Reference standards or materials
3.2.S.5 Reference standards or materials
3.2.S.6 Container closure system
3.2.S.6 Container closure system
3.2.S.7 Stability
3.2.S.7.1 Stability summary and conclusions
3.2.S.7.2 Post-approval stability protocol and stability commitment
3.2.S.7.3 Stability data
3.2.P Drug product
3.2.P.1 Description and composition of the drug product
3.2.P.2 Pharmaceutical development
3.2.P.3 Manufacture
3.2.P.3.1 Manufacturer(s)
3.2.P.3.2 Batch formula
3.2.P.3.3 Description of manufacturing process and process controls
3.2.P.3.4 Control of critical steps (Description) and intermediates
CTD Structure 
MODULE 3
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Author First Draft 
[date]
Final 
Draft 
[date]
Submissio
n-ready 
document 
[date]
M1 
Dossier
Dossier 
ID 
Number
M1
Version 
No.
Comments Lifecycle 
AttributesCTD Structure 
MODULE 3
3.2.P.3.5 Process validation and/or evaluation
3.2.P.4 Control of excipients
3.2.P.4.1 Specifications
3.2.P.4.2 Analytical procedures
3.2.P.4.3 Validation of analytical procedures
3.2.P.4.4 Justification of specification
3.2.P.4.5 Excipients of human or animal origin
3.2.P.4.6 Novel excipients
3.2.P.5 Control of drug product
3.2.P.5.1 Specification(s)
3.2.P.5.2 Analytical procedures
3.2.P.5.3 Validation of analytical procedures
3.2.P.5.4 Batch analyses
3.2.P.5.5 Characterization of impurities
3.2.P.5.6 Justification of specification
3.2.P.6 Reference standards or materials
3.2.P.6 Reference standards or materials
3.2.P.7 Container closure system
3.2.P.7 Container closure system
3.2.P.8 Drug product stability
3.2.P.8.1 Stability summary and conclusion
3.2.P.8.2 Post-approval stability protocol and stability commitment
3.2.P.8.3 Stability data
3.2.A Appendices
3.2.A.1 Facilities and equipment
3.2.A.2 Adventitious safety evaluation 
3.2.A.3 Novel excipients
3.2.R Regional information
3.2.R.1 Batch records 
3.2.R.2 Process validation scheme for Drug Product
3.2.R.3 Medical Device
3.2.R.4 Materials of animal origin incl. Table A,B and C
3 Literature references
3.3.1.x
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Study 
Number
Author First Draft 
[date]
Final Draft 
[date]
Submission-
ready document 
[date]
M1 Dossier
Dossier ID Number
M1
Version No.
Comments Lifecycle 
Attributes
S
4 Module 4 Nonclinical study reports
4.1 Table of contents
4.2 Study reports
4.2.1 Pharmacology
4.2.1.1 Primary Pharmacodynamics
4.2.1.1.x Study reports
4.2.1.2 Secondary Pharmacodynamics
4.2.1.2.x Study reports
4.2.1.3 Safety Pharmacology
4.2.1.3.x Study reports
4.2.1.4 Pharmacodynamic Drug Interactions 
4.2.1.4.x Study reports
4.2.2 Pharmacokinetics 
4.2.2.1 Analytical methods and validations reports 
4.2.2.1.x Study reports
4.2.2.2 Absorption 
4.2.2.2.x Study reports
4.2.2.3 Distribution 
4.2.2.3.x Study reports
4.2.2.4 Metabolism 
4.2.2.4.x Study reports
4.2.2.5 Excretion 
4.2.2.5.x Study reports
4.2.2.6 Pharmacokinetic drug interactions 
4.2.2.6.x Study reports
4.2.2.7 Other pharmacokinetic studies
4.2.2.7.x Study reports
4.2.3 Toxicology
4.2.3.1 Single-dose toxicity
4.2.3.1.x Study reports
4.2.3.2 Repeated-dose toxicity
4.2.3.2.x Study reports
4.2.3.3.1 In vitro
4.2.3.3.1.x Study reports
4.2.3.3.2 In vivo
4.2.3.3.2.x Study reports
4.2.3.4 Carcinogenicity 
4.2.3.4.X Study reports
4.2.3.4.1 Long-term studies 
4.2.3.4.1.x Study reports
4.2.3.4.2 Short- or medium-term studies 
4.2.3.4.2.x Study reports
4.2.3.4.3 Other studies 
4.2.3.4.3.x Study reports
4.2.3.5 Reproductive and developmental toxicity v
4.2.3.5.1 Fertility and early embryonic development 
4.2.3.5.1.x Study reports
4.2.3.5.2 Embryo-fetal development 
4.2.3.5.2.x Study reports
4.2.3.5.3 Prenatal and postnatal development 
4.2.3.5.3.x Study reports
4.2.3.5.4 Studies in which the offspring (juvenile animals) are dosed 
and/or further evaluated 
4.2.3.5.4.x Study reports
CTD Structure 
MODULE 4
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Study 
Number
Author First Draft 
[date]
Final Draft 
[date]
Submission-
ready document 
[date]
M1 Dossier
Dossier ID Number
M1
Version No.
Comments Lifecycle 
AttributesCTD Structure 
MODULE 4
4.2.3.6 Local tolerance
4.2.3.6.x Study reports
4.2.3.7 Other toxicity studies (if available)
4.2.3.7.1 Antigenicity
4.2.3.7.1.x Study reports
4.2.3.7.2 Immunotoxicity 
4.2.3.7.2.x Study reports
4.2.3.7.3 Mechanistic studies 
4.2.3.7.3x Study reports
4.2.3.7.4 Dependence 
4.2.3.7.4.x Study reports
4.2.3.7.5 Metabolites 
4.2.3.7.5.x Study reports
4.2.3.7.6 Impurities 
4.2.3.7.6.x Study reports
4.2.3.7.7 Other
4.2.3.7.7.x Study reports
4.3 Literature references
4.3.x
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Study Number Author First Draft 
[date]
Final Draft 
[date]
Submission-
ready document 
[date]
M1 Dossier
Dossier ID Number
M1
Version No.
Comments Lifecycle 
Attributes
S
5 Clinical Study Report
5.1 Table of contents for clinical study reports
5.2 Tabular Listing of all Clinical Studies
5.3 Clinical study reports
5.3.1 Reports of biopharmaceutic studies 
5.3.1.x Study reports
5.3.1.1 Bioavailability study reports 
5.3.1.1.x Study reports
5.3.1.2 Comparative bioavailability and bioequivalence  study reports 
5.3.1.2.x Study reports
5.3.1.3 In vitro-In vivo correlation study reports 
5.3.1.3.x Study reports
5.3.1.4 Reports of Bioanalytical and Analytical Methods
5.3.1.4.x Study reports
5.3.2 Reports of Studies Pertinent to Pharmacokinetics using Human Biomaterials
5.3.2.x Study reports
5.3.2.1 Plasma Protein Binding Study Reports 
5.3.2.1.x Study reports
5.3.2.2 Reports of Hepatic Metabolism and Drug Interaction Studies 
5.3.2.2.x Study reports
5.3.2.3 Reports of Studies Using Other Human Biomaterials 
5.3.2.3. x Study reports
5.3.3 Reports of Human Pharmacokinetic (PK) Studies
5.3.3.x Study reports
5.3.3.1 Healthy Subject PK and Initial Tolerability Study Reports 
5.3.3.1.x Study reports
5.3.3.2 Patient PK and Initial Tolerability Study Reports
5.3.3.2.x Study reports
5.3.3.3 Intrinsic Factor PK Study Reports 
5.3.3.3.x Study reports
5.3.3.4 Extrinsic Factor PK Study Reports 
5.3.3.4.x Study reports
5.3.3.5 Population PK Study Reports 
5.3.3.5.x Study reports
5.3.4 Reports of Human Pharmacodynamic (PD) Studies 
5.3.4.x Study reports
5.3.4.1 Healthy Subject PD and PK/PD Study Reports 
5.3.4.1.x Study reports
5.3.4.2 Patient PD and PK/PD Study Reports
5.3.4.2.x Study reports
5.3.5 Reports of Efficacy and Safety Studies
5.3.5.1 Study Reports of controlled Clinical Studies Pertinent to the Claimed 
Indication
5.3.5.1.x Study reports
5.3.5.2 Study Reports of Uncontrolled Clinical Studies
5.3.5.2.x Study reports
5.3.5.3 Reports of Analyses of Data from More Than One Study
5.3.5.3.x Study reports
5.3.5.4 Other Study Reports
5.3.5.4.x Study reports
5.3.6 Reports of Postmarketing Experience - not applicable
5.3.6.x Periodic Safety Update Report
5.3.7 Case Report Forms and Individual Patient Listings, When Submitted 
5.3.7.x Study reports
5.4 Literature references
5.4.x
CTD Structure 
MODULE 5
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APPENDIX 18 AN EXAMPLE FOR A GLOBAL PLAN: 
 
Target: Monoclonal antibody which is EGFR targeting 
INN: Monotuximab 
Indications under development and stage of development: 
Hodgkin lymphoma: Phase III clinical trial is ongoing  
Squamous cancer of the head and neck (SCCHN): Phase II clinical trials ongoing 
Breast cancer: Phase I clinical trials are ongoing 
 
Example for a ToC: 
Table of Content 
List of Abbreviations 
Executive Summary 
Major changes since last global plan version (only applicable for updates of a global plan) 
1 Decision(s) required 
2 Product Vision 
2.1 Compound Description 
2.2 Vision 
3 Product Objectives 
3.1 Target Product Profile or Target Product Claims 
3.2 Short, medium & long term objectives 
4 Analysis of the situation 
4.1 Data Summary (aspects common to all indications under development) 
4.1.1 Brief Assessment of Intellectual Property Situation 
4.1.2 Contractual Obligations with External Partners (only if applicable) 
4.1.3 Manufacturing and supply summary 
4.1.4 Non clinical summary 
4.1.5 Regulatory summary 
4.1.6 SWOT analysis 
4.2 Data Summary (indication-specific aspects) 
4.2.1 Hodgkin lymphoma 
Clinical summary 
Summary of competitive situation 
4.2.2  Squamous cancer of the head and neck (SCCHN) 
Clinical summary 
Summary of competitive situation 
4.2.3  Breast cancer 
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Clinical summary 
Summary of competitive situation 
5 Development Options considered for the current investment decision 
5.1 Summary of Options considered 
5.2. Hodgkin lymphoma 
5.2.1 Summary/rationale of this option 
5.2.2 Decision Tree and go/no go Criteria 
5.2.3 Timelines, Resources, Costs and Sales 
5.2.4 Evaluation of the options 
5.3. SCCHN 
5.3.1 Summary/rationale of SCCHN 
5.3.2 Decision Tree and go/no go Criteria 
5.3.3 Timelines, Resources, Costs and Sales 
5.3.4 Evaluation of the options 
Critical Success Factors 
5.4. Breast cancer 
5.4.1 Summary/rationale of this option 
5.4.2 Decision Tree and go/no go Criteria 
5.4.3 Timelines, Resources, Costs and Sales 
5.4.4 Evaluation of the options 
5.5. Indication IV (combination therapy) (only if applicable) 
6 Details of/Strategy for recommended/endorsed option(s) 
6.1 Recommendation 
6.2 Rationale for Option SCCHN (Hodgkin lymphoma and/or Breast Cancer) 
6.3 Scope of Work for Hodgkin lymphoma 
6.3.1 Non clinical development strategy 
6.3.2 Clinical development strategy 
6.3.3 Regulatory development strategy 
6.3.4 Commercial development strategy 
6.3.5 Manufacturing and supply strategy 
6.3.6 Key milestones 
6.3.7 Critical Path Aspects 
6.3.8 Criteria for passing next development point 
6.4 Scope of Work for SCCHN 
6.4.1 Non clinical development strategy 
6.4.2 Clinical development strategy 
6.4.3 Regulatory development strategy 
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6.4.4 Commercial development strategy 
6.4.5 Manufacturing and supply strategy 
6.4.6 Key milestones 
6.4.7 Critical Path Aspects 
6.4.8 Criteria for passing next development point  
6.5 Scope of Work for Breast cancer 
6.5.1 Non clinical development strategy 
6.5.2 Clinical development strategy 
6.5.3 Regulatory development strategy 
6.5.4 Commercial development strategy 
6.5.5 Manufacturing and supply strategy 
6.5.6 Key milestones 
6.5.7 Critical Path Aspects 
6.5.8 Criteria for passing next development point 
7 Key Risks and Opportunities 
7.1 Threats & Opportunities – Probability and impact 
7.2 Action plans to minimize risks/maximize key opportunities 
8 Financial Analysis 
8.1 Key Assumptions and Sales Forecast 
8.2 Research and Development resources and costs 
8.3 Sales and Marketing resources and costs 
8.4 Cost of Goods 
8.5 Net present value & expected net present value 
9 Communication plan 
10 List of supporting documents 
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APPENDIX 19 AVAILABLE GUIDELINES AND REGULATIONS 
 
Quality guidelines 
 
ICH documents 
• ICH M4 Quality:  
Quality overall Summary and CTD Quality Rev 1 
• ICH Q 1 A (R2):  
Stability Testing of New Drug Substances and Products 
• ICH Q 1 B: 
Photostability Testing of New Active Substances and Medicinal products 
• ICH Q 1 E: 
Evaluation of Stability Data 
• ICH Q 2 A: 
Validation of Analytical Methods: Definitions and Terminology 
• ICH Q 2 B: 
Validation of Analytical Procedures: Methodology 
• ICH Q 3 A (R):  
Impurities Testing: Impurities in New Drug Substances 
• ICH Q 3 B (R):  
Impurities in New Medicinal Products 
• ICH Q 3 C: 
Impurities: Residual Solvents 
• ICH Q 6 A: 
Specifications: Test procedures and Acceptance Criteria for New Drug Substances and 
New Drug Products: Chemical Substances 
• ICH Q 7 A: 
Good Manufacturing Practice for Active Pharmaceutical Ingredients  
 
EU documents 
• CPMP/QWP/130/96, Rev 1:  
Guideline on the Chemistry of New Active Substances 
• CPMP/QWP/158/01 Rev:  
NfG on Quality of Water for Pharmaceutical Use 
• CPMP/QWP/072/96:  
NfG on Start of Shelf-Life of the Finished Dosage Form 
• CPMP/QWP/155/96:  
NfG on Development Pharmaceutics 
• CPMP/QWP/054/98:  
Annex to NfG on Development Pharmaceutics (CPMP/QWP/155/96):  
Decision Trees for Selection of Sterilisation Methods. 
• CPMP/QWP/130/96, Rev 1:  
Guideline on the Chemistry of New Active Substances 
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• CPMP/QWP/848/96:  
NfG on Process Validation  
• CPMP/QWP/2054/03:  
Annex II to NfG on Process Validation:  
Non-Standard Processes 
• CPMP/QWP/159/96:  
NfG on Maximum Shelf-Life for Sterile Products after First Opening or following 
Reconstitution 
• CPMP/QWP/486/95:  
NfG on Manufacture of the Finished Dosage Form 
• CPMP/QWP/419/03:  
NfG on Excipients, Antioxidants and Antimicrobial Preservatives in the Dossier for 
Application for Marketing Authorisation of a Medicinal Product 
• CPMP/QWP/4539/03:  
Guideline on Plastic Primary Packaging Materials 
• CPMP/QWP/297/97 Rev. 1:  
NfG on Summary of Requirements for Active Substances in Part II of the Dossier 
• CPMP/SWP/QWP/4446/00:  
NfG on Specification Limits for Residues of Metal Catalysts 
• EMEA/410/01 Rev. 2:  
NfG on Minimizing the Risk of Transmitting Animal Spongiform Encephalopathy Agents 
via Human and Veterinary Medicinal Products 
 
FDA documents 
• Container Closure Systems for Packaging Human Drugs and Biologics 
• Environmental Assessment of Human Drug and Biologics Applications 
• Format and Content of the Chemistry, Manufacturing and Controls Section of an 
Application  
• INDs for Phase 2 and 3 Studies; Chemistry, Manufacturing, and Controls Information 
• NDAs: Impurities in Drug Substances 
• Submission Documentation for Sterilization Process Validation in Applications for Human 
and Veterinary Drug Products. 
• Submission of Chemistry, Manufacturing and Controls Information for Synthetic Peptide 
Substances 
• Submitting Documentation for the Manufacturing of and Controls for Drug Products 
• Submitting Documentation for the Stability of Human Drugs and Biologics 
• Submitting Samples and Analytical Data for Methods Validation 
• Submitting Supporting Documentation in Drug Applications for the Manufacture of Drug 
Substances 
• Submitting Supporting Documentation in Drug Applications for the Manufacture of Drug 
Products 
• Drug Product: Chemistry, Manufacturing, and Controls Information (Draft) 
• Drug Substance: Chemistry, Manufacturing, and Controls Information (Draft) 
• Stability Testing of Drug Substances and Drug Products (Draft) 
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• Manufacture, Processing or Holding of Active Pharmaceutical Ingredients (Draft) 
• Sterile Drug Products Produced by Aseptic Processing – Current Good Manufacturing 
Practice 
• Preparation of Investigational New Drug Products (Human and Animal)  
 
 
 
Non-clinical guidelines 
ICH documents 
• ICH M4 Safety:  
Nonclinical Summaries and Organisation of Module 4 
• ICH M 3:  
Non-Clinical Safety Studies for the Conduct of Human Clinical Trials for Pharmaceuticals 
• ICH S 1 A:  
Need for Long-term Rodent Carcinogenicity Studies of Pharmaceuticals 
• ICH S 1 B:  
Testing for Carcinogenicity of Pharmaceuticals 
• ICH S 1 C: 
Dose Selection for Carcinogenicity Study of Pharmaceuticals. 
• ICH S 2 A:  
Genotoxicity: Guidance on Specific Aspects of Regulatory Genotoxicity Tests for 
Pharmaceuticals 
• ICH S 2 B:  
Genotoxicity: A Standard Battery for Genotoxicity Testing of Pharmaceuticals 
• ICH S 3 A:  
Toxicokinetics: A Guidance for Assessing Systemic Exposure in Toxicology Studies 
• ICH S 3 B:  
Pharmacokinetics: Guidance for Repeated Dose Tissue Distribution Studies 
• ICH S 4 A:  
Duration of Chronic Toxicity Testing in Animals 
• ICH S 5 A:  
Reproductive Toxicology: Detection of Toxicity to Reproduction for Medicinal Products 
• ICH S 5 B:  
Reproductive Toxicology: Toxicity on Male Fertility 
• ICH S 7 A:  
Safety Pharmacology Studies for Human Pharmaceuticals 
• ICH S 7 B:  
Safety Pharmacology Studies for assessing the potential for Delayed Ventricular 
Repolarization (QT Interval Prolongation) by Human Pharmaceuticals 
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EU documents 
• CPMP/SWP/1042/99 corr.:  
NfG on Repeated Dose Toxicity 
• CPMP/SWP/2145/00:  
NfG on Non-Clinical Local Tolerance Testing of Medicinal Products 
• CPMP/986/96:  
PtC in the Assessment of the Potential for QT Interval Prolongation by Non-
cardiovascular Medicinal Products 
• CPMP/SWP/4447/00:  
NfG on Environmental Risk Assessment on Medicinal Products for Human Use 
• CPMP/SWP/5199/02:  
Position Paper on the Limits of Genotoxic Impurities 
• EudraLex 3BS11A:  
Note for Pharmacokinetics and metabolic studies in the safety evaluation of new 
medicinal products in animals 
• EudraLex Vol. 3C  
Note for guidance on pharmacokinetic studies in man 
• EudraLex 3CC29A  
Investigation of chiral active substances 
• EudraLex Vol. 4  
Good manufacturing practices - Annex 13 (Manufacture of Investigational Medicinal 
Products) 
 
FDA documents 
• Carcinogenicity Study Protocol Submissions 
• Format and Content of the Nonclinical Pharmacology/Toxicology Section of an 
Application 
• Immunotoxicology Evaluation of Investigational New Drugs 
• Photosafety Testing 
• Single Dose Acute Toxicity Testing for Pharmaceuticals - Revised 
• Integration of Study Results to Access Concerns About Human Reproductive and 
Developmental Toxicities 
• Nonclinical Studies for Development of Pharmaceutical Excipients 
• Statistical Aspects of the Design, Analysis, and Interpretation of Chronic Rodent 
Carcinogenicity Studies of Pharmaceuticals 
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Clinical guidelines 
ICH documents 
• ICH M4 Efficacy:  
Clinical Overview, Clinical Summary, Sample Tables for Clinical Summary and Module V 
• ICH E 2 A:  
Good Clinical Safety Data Management: Definitions and Standards for Expedited 
Reporting 
• ICH E 3:  
Structure and Content of Clinical Study Reports 
• ICH E 4:  
Dose Response Information to support Drug Registration 
• ICH E 6:  
Guideline for Good Clinical Practice 
• ICH E 8:  
General Considerations for Clinical Trials 
• ICH E 9:  
Statistical Principles for Clinical Trials 
• ICH E 10:  
Choice of Control Group and Related Issues for Clinical Trials 
• ICH E 14:  
The Clinical Evaluation of QT/QTs Interval Prolongation and Proarrhythmic Potential for 
Non-Antiarrhythmic drugs 
 
EU documents 
• CPMP/EWP/205/95 rev. 2 – corr.:  
NfG on Evaluation of Anticancer Medicinal Products in Man 
• CPMP/EWP/569/02:  
NfG on Evaluation of Anticancer Medicinal Products in Man: 
Addendum on Pediatric Oncology 
• CPMP/EWP/560/95  
NfG on the Investigation of Drug Interactions 
• CPMP/EWP/908/99:  
PtC on Multiplicity Issues in Clinical Trials 
• CPMP/EWP/2330/99:  
PtC on Application with 1.) Meta-analyses and 2.) One Pivotal study 
• CPMP/EWP/2863/99:  
PtC on Adjustment for baseline Covariates  
• CPMP/EWP/2747/00:  
NfG on Co-ordinating Investigator Signature of Clinical Study Reports 
• CPMP/EWP/2998/03:  
NfG on the Inclusion of Appendices to Clinical Study Reports in Marketing Authorisation 
Applications 
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FDA documents 
• Cancer Drug and Biological Products - Clinical Data in Marketing Applications 
• Providing Clinical Evidence of Effectiveness for Human Drug and Biological Products 
• Study and Evaluation of Gender Differences in the Clinical Evaluation of Drugs. 
• Study of Drugs Likely to be used in the Elderly. 
• Submission of Abbreviated Reports and Synopses in Support of Marketing Applications. 
• Available Therapy  
• Pediatric Oncology Studies in Response to a Written Request 
• Premarketing Risk Assessment (Draft) 
• Drug Metabolism/Drug Interaction Studies in the Drug Development Process: Studies In 
Vitro (Draft) 
• In Vivo Metabolism/Drug Interaction Studies - Study Design, Data Analysis, and 
Recommendations for Dosing and Labeling  
• Exposure-Response Relationships - Study Design, Data Analysis, and Regulatory 
Applications  
• Information Program on Clinical Trials for Serious or Life-Threatening Diseases and 
Conditions 
• Information Program on Clinical Trials for Serious or Life-Threatening Diseases: 
Establishment of a Data Bank 
• Fast Track Drug Development Programs: Designation, Development, and Application 
Review  
• Pharmacogenomic Data Submissions 
 
 235
APPENDIX 20 SUMMARY TABLE CONCERNING THE REGULATORY 
STRATEGY FOR THE MA FOR THE DIFFERENT COUNTRIES 
 
 
Planned 
sending 
date 
Planned 
submission 
date 
Country Area Marketing 
Priority 
Scenario Master 
Dossier 
Q1, 2011 Q1, 2011 EU EU 1  M1 
Q1, 2011 Q1, 2011 USA USA 1  M1 
Q1/Q2, 2011 Q1/Q2, 
2011 
Switzerland CH 2  M1 
Q1/Q2, 2011 Q1/Q2, 
2011 
Japan JP 1  M1 
Q3/2011  Australia SEA 1 1 M1 
Q3/2011  South Korea SEA 1 1 M1 
Q3/2011  Russia EE 1 1 M1int 
Q3/2011  South Africa  2 1 M1 
Q2/2012  Lebanon AF 1 2 M2 int. 
Q2/2012  Belarus EE 1 2 M2 int. 
Q2/2012  Israel EE 1 2 M2 
Q2/2012  Kazakhstan EE 1 2 M2 int. 
Q2/2012  Turkey EE 1 2 M2 int. 
Q2/2012  Ukraine EE 1 2 M2 int. 
Q2/2012  Argentina LA 1 2 M2 int. 
Q2/2012  Chile LA 1 2 M2 int. 
Q2/2012  Colombia LA 1 2 M2 int. 
Q2/2012  Mexico LA 1 2 M2 int. 
Q2/2012  Venezuela LA 1 2 M2 int. 
Q2/2012  Iran ME 1 2 M2 int. 
Q2/2012  Kuwait ME 1 2 M2 int. 
Q2/2012  Saudi Arabia ME 1 2 M2 int. 
Q2/2012  UAE ME 1 2 M2 int. 
Q2/2012  China SEA 1 2 M2 int. 
Q2/2012  India SEA 1 2 M2 int. 
Q2/2012  Singapore SEA 1 2 M2 int. 
Q2/2012  Taiwan SEA 1 2 M2 int. 
Q3,2012  Algeria AF 2 2 M2 int. 
Q3,2012  Morocco AF 2 2 M2 int. 
Q3,2012  Croatia EE 2 2 M2 int. 
Q3,2012  Montenegro EE 2 2 M2 int. 
Q3,2012  Serbia EE 2 2 M2 int. 
Q3,2012  Brazil LA 2 2 M2 int. 
Q3,2012  Costa Rica LA 2 2 M2 int. 
Q3,2012  Dom. Rep. LA 2 2 M2 int. 
Q3,2012  Ecuador LA 2 2 M2 int. 
Q3,2012  El Salvador LA 2 2 M2 int. 
Q3,2012  Guatemala LA 2 2 M2 int. 
Q3,2012  Honduras LA 2 2 M2 int. 
Q3,2012  Nicaragua LA 2 2 M2 int. 
Q3,2012  Panama LA 2 2 M2 int. 
Q3,2012  Peru LA 2 2 M2 int. 
Q3,2012  Uruguay LA 2 2 M2 int. 
Q3,2012  Bahrain ME 2 2 M2 int. 
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Planned 
sending 
date 
Planned 
submission 
date 
Country Area Marketing 
Priority 
Scenario Master 
Dossier 
Q3,2012  Egypt ME 2 2 M2 int. 
Q3,2012  Oman ME 2 2 M2 int. 
Q3,2012  Qatar ME 2 2 M2 int. 
Q3,2012  Hong Kong SEA 2 2 M2 int. 
Q3,2012  Indonesia SEA 2 2 M2 int. 
Q3,2012  Malaysia SEA 2 2 M2 int. 
Q3,2012  New Zealand SEA 2 2 M2 int. 
Q3,2012  Philippines SEA 2 2 M2 int. 
Q3,2012  Thailand SEA 2 2 M2 int. 
Q3,2012  Vietnam SEA 2 2 M2 int. 
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APPENDIX 21 REQUIREMENTS TABLES 
 
Requirements.xls
 
Requirements Asia
Country CPP US CPP EU Module 2 Module 3 
full
Module 3 
abbr.
Module 4 Module 5 SPC 
US/EU
PI Labeling Mock-ups Translations Regulatory 
status list
Samples 
demonstration/
analysis
No. of 
Samples
GMP 
legalized 
(notarized 
and 
legalized)
Supply 
agreement
Power of attorney to 
register, market and 
disribute 
(notarized?)
Trademark 
certificate
Declaration 
for cold 
chain
Price 
certificate
Plan 
master 
file
Other 
documents
Regulatory 
procedure e.g. fast 
track, orphan drug, 
priority review
Comments Approval 
Time 
(months)
Australia no no yes yes no yes yes US/EU yes yes yes no yes 12
China yes yes yes no yes yes yes US/EU yes yes yes yes yes analysis ? yes 18-24
Singapore no yes yes no yes no no US/EU yes yes yes no yes demonstration 2 yes two 
assessment 
reports of two 
benchmarking 
Authorities e.g. 
EMA and FDA
abridged evaluation 
within 2 months
Taiwan yes no yes no yes yes yes US/EU yes yes yes no yes 1 yes 12-18
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Requirements EEMEA
Country CPP US CPP EU Module 2 Module 3 
abbr.
Module 4 Module 5 Clinical data SPC 
US/EU
PI Labeling Mock-ups Translations Regulatory 
status list
Samples 
demonstration/
analysis
No. of 
Samples
GMP legalized 
(notarized and 
legalized)
Supply 
agreement
Power of 
attorney to 
register, market 
and disribute 
(notarized?)
Trademark 
certificate
Declaration 
for cold 
chain
Price 
certificate
Plan 
master 
file
Other documents Regulatory 
procedure e.g. fast 
track, orphan drug, 
priority review
Approval 
Time 
(months)
Croatia yes yes yes yes yes EU yes yes yes no yes analysis 5 yes no no no yes yes priority review 15
Turkey yes yes* yes yes yes yes Phase III data mandatorily 
needed
US/EU yes yes yes Module 2 and 
3
yes demonstration 1** yes no yes no yes yes yes  Public price of origin country, all 
registered country public price and 
their VAT rate, FOB price and DMF
for the compound
normal 24-36
239
Requirements Latin America
Country
CPP 
US
CPP 
EU
Module 2 Module 3 
full
Module 3 
abbr.
Module 4 Module 5 Clinical data SPC 
US/EU
PI Labeling Mock-ups Translations Regulatory 
status list
Samples 
demonstration/
analysis
No. of samples GMP 
legalized 
(notarized 
and 
legalized)
Supply 
agreement
Power of 
attorney to 
register, 
market and 
disribute 
(notarized?)
Trademark certificate Declaration for 
cold chain
Price certificate Plan master file Other documents Regulatory 
procedure e.g. fast 
track, orphan drug, 
priority review
Approval 
Time 
(months)
Brazil yes yes
yes no yes no no Phase III data mandatorily needed US/EU yes yes yes yes yes demonstration 1 necessary yes yes yes yes 1. inspection of manufacturer may 
be required; 2.Batch records of 
three batches; 3 flow chart of the 
manufacturing; 4. Site master 
file;5 - original PIL 12
Mexico yes yes
yes no yes no no Published clinical literature US/EU yes yes yes yes analysis 1 yes yes yes Stability study signed by the head 
of quality assurance, Certificate of 
Analysis of one batch of DS and 
three batches of DP incl. 
Chromatograms, batch records
10
240
Requirements non-ICH
Country CPP US CPP EU Module 2 Module 3 
full
Module 3 
abbr.
Module 4 Module 5 Clinical data SPC 
US/EU
PI Labeling Mock-ups Translations Regulatory 
status list
Samples 
demonstration/
analysis
No. of 
Samples
GMP legalized 
(notarized and 
legalized)
Supply 
agreement
Power of attorney to 
register, market and 
disribute 
(notarized?)
Trademark certificate Declaration for 
cold chain
Price certificate Plan master file Other documents Regulatory 
procedure e.g. fast 
track, orphan drug, 
priority review
Approval 
Time 
(months)
Croatia yes yes yes no yes yes EU yes yes yes no yes analysis 5 yes no no no yes yes Original EU dossier plus CHMP 
opinion, Commission decision, 
EU Assessment Reports, AtOs 
during the EU procedure, 
statements
priority review 15
Turkey yes yes* yes no yes yes yes Phase III data mandatorily needed US/EU yes yes yes Module 2 and 
3
demonstration 1** yes no yes no yes yes yes  Public price of origin country, all 
registered country public price 
and their VAT rate, FOB price 
and DMF for the compound
normal 24-36
Brazil yes yes
yes no yes no no Phase III data mandatorily needed US/EU yes yes yes yes yes demonstration 1 yes yes yes yes yes 1. inspection of manufacturer may 
be required; 2.Batch records of 
three batches; 3 flow chart of the 
manufacturing; 4. Site master 
file;5 - original PIL 12
Mexico yes yes
yes no yes no no Published clinical literature US/EU yes yes yes yes analysis 1 yes yes yes Stability study signed by the head 
of quality assurance, Certificate 
of Analysis of one batch of DS 
and three batches of DP incl. 
Chromatograms, batch records
10
Australia no no yes yes no yes yes US/EU yes yes yes no yes 12
China yes yes yes no yes yes yes US/EU yes yes yes yes yes analysis ? yes 18-24
Singapore no yes yes no yes yes yes US/EU yes yes yes no demonstration 2 yes two assessment reports of two 
benchmarking Authorities e.g. 
EMA and FDA
abridged evaluation 
within 2 months
Taiwan yes no yes no yes yes yes US/EU yes yes yes no 1 yes 12-18
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